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Cordyceps militaris is a family member of Cordyceps. Cordyceps sinensis 
has been reported to have a wide variety of biological functions. However, the 
biological activities of Cordyceps militaris are not well documented. In this study, 
biological activities such as anti-tumor and immunomodulatory activities of 
Cordyceps militaris were investigated. In our in vitro study, water extract of cultured 
fruiting bodies of Cordyceps militaris (WECM) inhibited the growth of human 
hepatocellular carcinoma HepG2 cells, multidrug resistant human hepatocellular 
carcinoma R-HepG2 cells, acute promyelocytic leukemia HL-60 and NB-4 cells as 
well as murine sarcoma SC-180 cells. Our in vivo study demonstrated that oral 
administration of WECM for 3 weeks can inhibit the growth of tumor SC-180 in 
BALB/c mice. WECM was also found to have immunostimulatory effect. It 
stimulated the proliferation of splenic lymphocytes in vitro. Besides, three weeks 
treatment of WECM stimulated the proliferation of T helper and cytotoxic T cells in 
BALB/c mice. Three weeks treatment of WECM did not induce heart tissue or 
liver damage in BALB/c mice as assessed by enzymatic assays of creatine kinase, 
lactate dehydrogenase, alanine transaminase and aspartate transaminase. 
Cordycepin is the chemical constituent isolated from Cordyceps militaris in 
1950. In this study, the anti-tumor activity of cordycepin was investigated by using 
different human tumor cell lines such as HepG2, R-HepG2, HL-60 and NB-4 cells. 
Cordycepin was found to inhibit the growth of HepG2, R-HepG2, HL-60 and NB-4 
cells respectively with the IC50 163 i^ M, 148 i^M, 149 |iM and 144 pM for 24 hours 
treatment. The underlying mechanisms of the anti-tumor activity of cordycepin on 
these cell lines were also investigated. 
The observations of morphological changes, DNA fragmentation and 
vii 
Abstract 
phosphatidylserine extemalization suggested that the anti-tumor activity of 
cordycepin on HL-60 and NB-4 cells was mediated by the induction of apoptosis. 
The cordycepin-induced apoptosis involved the increase of death receptor (Fas) 
expression, activation of caspase-8, collapse of mitochondrial membrane potential, 
release of cytochrome c and activation of caspase-9 and caspase-3. The release of 
cytochrome c involved the decreased expression of anti-apoptotic Bcl-2 and increased 
expression of pro-apoptotic Bax, Bcl-Xs and truncated Bid (tBid). 
Cell cycle analysis showed that the anti-tumor effect of cordycepin on 
HepG2 and R-HepG2 cells was mediated by the G2/M phase arrest of the cell cycle. 
The cell cycle arrest induced by cordycepin involved the decreased expression of cell 
cycle regulatory proteins such as cyclin A, cyclin B, cdc2 and the increased 
expression of cyclin dependent kinase inhibitor p21. The slight increase in p53 
levels in HepG2 and R-HepG2 cells after cordycepin treatment suggested that the 
G2/M phase arrest may be mediated by p53. DNA fragmentation was also observed 
in R-HepG2 cells after treated with cordycepin for 48 hours. This suggested that 
cordycepin also induces apoptosis in R-HepG2 cells. However, the molecular 





















濃度（ICsG)分別爲163 | i M � 1 4 8 i ^ M � 1 4 9 ^iM和144 ^iM�我們對蟲草素抑制 
這些腫瘤細胞的抗癌機理亦進行了硏究。 
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Chapter 1 Introduction 
1.1 Cordyceps 
Cordyceps sinensis, also known as Chinese caterpillar fungus or 
"DongChongXiaCao", is one of the most valuable Chinese medicinal herbs and used 
for hundreds of years. It is found primarily in cold areas at high altitude (3000 
meters or more) on the Qinghai-Tibetan plateau. Cordycpes sinensis is parasitic on 
the larvae of moth, especially the moth Hepialus armoricanus, which lives 6 inches 
underground. In late autumn, chemicals on the skin of the caterpillars interact with 
the fungal spores and release the fungal mycelia, which then infect the caterpillar and 
utilize nutrients from the caterpillar. By early summer of the following year, the 
fungal infestation kills the caterpillar and the fruiting body grows out from the head of 
caterpillar (Zhu et al,, 1998). Recently, over 350 of herb-worms have been reported 
worldwide and more than 58 types are found in China. Cordyceps militaris is 
another member ot Cordyceps family. Both the Cordyceps sinensis (Fig. 1.1 A) and 
Cordyceps militaris (Fig. I.IB) have medicinal value and are distributed widely in 
China. Because of the overpicking by people, the natural Cordyceps become rare 
and valuable. Biologist and medicinal professionals in China, Hong Kong and 
abroad such as Korea started to develop the cultivation of Cordyceps. Studies have 
indicated that the cultured Cordyceps have similar or even better chemical ingredients 
and pharmacological functions to that of the natural Cordyceps (Chen, 1985; Du, 
1986; Zhang, 1990). Table 1.1 lists the chemical constituents of natural Cordyceps. 
-
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Fig. 1.1 Photographs of (A) Cordyceps sinensis and (B) Cordyceps ndlUaris, 
(http://wwwxhina-herbsxom/cordycepsh.html) 
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Chapter 1 Introduction 
Table 1.1 Chemical constituents of natural Cordyceps. (Zhu et al, 1998) 
1. Protein, peptides, all essential amino acids and polyamines 
2. Saccharides and sugar derivatives (e.g. D-mannitol) 
3. Sterols such as ergosterol, delta-3 ergosterol，erogosterol peroxide, 3-sitosterol, 
daucosterol and campasterol 
4. Nucleosides such as adenine, uracil, uridine, guanosine, thymidine and 
deoxyuridine 
5. Fatty acids and other organic acids 
6. Vitamins 
7. Inorganics including: K, Na, Ca, Mg, Fe, Cu, Mn，Zn, Pi, Se, Al，Si, Ni, Sr，Ti，Cr, 
Ga，V，and Zr  
- 4 
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Chapter 1 Introduction 
1.1.1 Pharmacological Functions of Cordyceps 
Cordyceps exhibits a broad spectrum of biological and pharmacological 
functions such as anti-tumor activities, immunomodulatory activities, hepatic, 
cardiovascular and renal functions. 
1.1.1.1 Anti-tumor Activities 
A number of studies showed that Cordyceps have anti-tumor effects. Du 
et al. (1986) demonstrated that subcutaneous and peritoneal administration of natural 
Cordyceps sinensis and cultured Cordyceps mycelia inhibited the growth of Sarcoma 
180. Cordyceps militaris was also found to inhibit the growth of tumor and prolong 
the survival period of Swiss mice implanted with Sarcoma 180 and inhibit the growth 
and metastasis of Lewis pneumonic cancer in C57BL mice (Liu et aL, 1997). 
Warm water extract of Cordyceps sinensis (ECS) showed a growth « 
inhibitory effect on murine tumor cell lines such as Meth A fibrosarcoma (Meth A) 
and Ehrlich ascites carcinoma cells (EAC). ECS-treatment increased the survival 
period of the allogenic ICR mice inoculated with EAC. ECS-treatment also 
increased the survival period of the syngeneic BALB/c mice inoculated with Meth A. 
The anti-tumor effect of ECS in the allogeneic mice was reduced when the mice 
received whole body X-irradiation (5 Gy) before EAC implantation. This indicated 
that the anti-tumor effect of ECS was mediated through its immunomodulatory action 
(Yoshida etal., 1989). 
Study of Kuo et al. (1994) also demonstrated that the methanol extract of 
Cordyceps sinenesis fruiting bodies inhibited the growth of tumor cell lines, namely 
K562, Vero, Wish, Calu-1, and Raji tumor cells. It was suggested that the growth 
inhibition is due to the presence of low molecular weight tumor growth inhibitors, 
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Other than cordycepin and polysaccharides present in Cordyceps sinensis (Kuo et al., 
1994). 
A polysaccharide fraction of Cordyceps sinensis (PSCS) was found to inhibit 
the growth of leukemic U937 cells and induce them differentiating into mature 
monocyte/macrophages through stimulating the production of differentiation-inducing 
cytokines by mononuclear leukocytes (Chen et al., 1997b). 
Down-regulation of the major histocompatibility complex (MHC) antigens 
of certain tumors may result in an escape of immune surveillance. Methanol extract 
of fruiting bodies of Cordyceps sinensis was found to increase the expression of MHC 
class II antigens on human hepatoma cell line HA22T/VGH, with or without IFN-y 
induction. The increase of MHC class II antigens makes the host immune 
surveillance more effective against tumor cells with down-regulated MHC class II 
antigen expression (Chiu et al., 1998). 
Two anti-tumor sterol, namely 5a,8a-epidioxy-24(R)-methylcholesta-
6,22-dien-3 p-D-glucopyranoside and 5,6-epoxy-24(R)-methylcholesta-7,22-
dien-3p-ol were isolated from the methanolic extract of cultured mycelia of 
Cordyceps sinensis. The glycosylated form of ergosterol peroxide was found to have 
inhibitory effect on the proliferation of K562, Jurkat, WM-1341, HL-60, and 
RPMI-8226 tumor cell lines and the inhibitory effect was greater than its aglycone 
5a,8a-epidioxy-24(R)-methylcholesta-6,22-dien-3p-ol (Bok et al, 1999). 
The hot water extract of cultured fruiting bodies of Cordyceps sinensis 
(WECS) inhibited spontaneous liver metastasis of Lewis lung carcinoma (LLC) and 
B16 melanoma cells in syngeneic mice (C57BL/6CrSlc). The primary tumor weight 
of WECS (100 mg/kg)-administered mice was reduced to 80% of that of the control 
mice in the LLC-cell experiment and that of WECS (200 mg/kg)-administered mice 
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was reduced to 53% of that of the control mice in the B16-cell experiment. WECS 
also showed direct anti-tumor activity on LLC and B16 cells. 10 |ig/ml and 30 
jag/ml of WECS inhibited the number of LLC cells by 56% and 84%, 60% and 96% 
when compared with those of the control for 48 and 72 hours treatment, respectively. 
In the case of B16 cells, 10 |ig/ml and 30 |ig/ml decreased the cell numbers by 62% 
and 69%, 84% and 90% compared with those of the control for 48 and 72 hours 
treatment (Nakamura et al., 1999a). 
1.1.1.2 Immunomodulatory Activities 
Immunostimulatory functions of Cordyceps sinensis have been reported. 
Zhang et al. (1985) found that natural Cordyceps sinensis and its cultured mycelia can 
activate peritoneal macrophages. The alkaline phosphatase activity of the 
macrophages was also increased. The polysaccharide of Cordyceps sinensis also 
showed immunostimulating activity in mice. It activated the phagocytic activity of 
reticuloendothelial system and increased the phagocytic rate and index of mouse 
peritoneal macrophages. Besides, it promoted T lymphocyte transformation in vitro, 
elevated serum IgG levels in mice and antagonized splenic atrophy and leukocyte 
decrease induced by cortisone and cyclophosphamide (Zhang et al, 1985). Study of 
Chen et al. (1985) demonstrated that both natural Cordyceps sinensis and cultured 
mycelia of Cordyceps sinensis can increase the size of the spleen, decrease the size of 
the thymus and prevent atrophy of spleen and liver and hypertrophy of the thymus in 
mice induced by cyclophosphamide. Furthermore, the phagocytic function of 
Kupffer cell and the number of phagocytes were increased after treatment (Chen, 
1985): 
The effects of Cordyceps sinensis on murine T lymphocyte subsets have 
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been reported. A preparation of Cordyceps sinensis (Cs-Cr) increased the number of 
T helper cells and Lyt-l/Lyt-2 (T helper to T suppressor cell) ratio in peripheral blood 
and spleen of the treated mice. Besides, the spleen weight, phagocyte counts and 
phagocytic activity were elevated. In addition Cs-Cr protected T helper cells from 
the immunosuppressive effects of prednisolone acetate and cyclophosphamide. It 
was suggested that Cs-Cr is an immunoregulator of cellular immunity and may be 
potentially useful in immunodeficient or immunosuppressed patients (Chen et al, 
1991). 
The effects of Cordyceps sinensis on peripheral NK cells from healthy 
persons and leukemia patients have been studied. It was found that water extract of 
Cordyceps sinensis augmented NK cell activity and increased CD 16 expression in 
lymphocytes and the binding capacity to K562 (Liu et al, 1992). Study of Xu et al. 
(1992) showed that intraperitoneal (i.p.) injection of ethanol extract of Cordyceps 
sinensis (CS-II) augmented the NK activities of mouse in vitro and in vitro. Besides, 
the inhibition of mouse NK activity by cyclophosphamide was prevented following 
the administration of CS-II. In addition, the in vitro NK activity of human peripheral 
blood mononuclear cells (PBMs) was elevated by preincubation of PBMs with CS-II. 
Furthermore, the colony formation of B16 melanoman in mouse lung was reduced 
significantly by i.p. pretreatment of mice with CS-II. This study indicated that CS-II 
may be used as an immunopotentiating agent in treating cancer and immunodeficient 
patients. 
Apart from the immunostimulatory effects, the immunosuppressive effect of 
Cordyceps sinensis has also been reported. Two fractions of methanol extracts from 
fruiting bodies of Cordyceps sinensis (CS-36-39 and CS-48-51) was found to inhibit 
the blastogenesis response, NK cell activity and IL-2 production of human 
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mononuclear cells (HMNC) stimulated by phytohemagglutinin (PHA). TNF-a 
production in HMNC cultures was also blocked by CS-36-39 and CS-48-51 (Kuo et 
al,, 1996). 
1.1.1.3 Hepatic Functions 
Cordyceps sinensis was found to improve liver function. In a 3-month 
study of 33 patients with hepatitis B，cultured Cordycpes sinensis mycelia was 
reported to improve the liver function, promote negative transfer of HBsAg and 
markedly help to raise plasma albumin, lower y-globulin and to adjust body 
irnmunocompetence (Zhou et al” 1990). 
Hot water extract of cultured Cordycpes sinensis mycelia (Cs) administered 
to mice (200 mg/kg/day, p.o.) for 3 weeks caused a consistent increase in the ratio of 
ATP/inorganic phosphate, an indicator of high energy state of the liver. The 
intracellular pH of the Cs extract-treated mice was not significantly different from that 
of the control mice and no steatosis, necrosis, inflammation or fibrosis were observed 
in the liver specimens from Cs extract-treated mice (Manabe et al., 1996). 
Another study found that oral administration of water extracts of Cordyceps 
sinensis (WECS) activated Kupffer cells function in rats. In the experiment, test 
animals were administered daily with WECS (200 mg/kg, p.o.) for 25 days until the 
day before the colloidal carbon injection. The half-life of the colloidal carbon in the 
blood of WECS-treated rats was significantly shorter than that of the control rats. 
The stimulation of the Kupffer cells function was believed to be partially involved in 
the anti-metastatic action of WECS (Nakamura et al., 1999b). 
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1.1.1.4 Cardiovascular Functions 
Cordyceps sinensis have been found to have cardiovascular protective 
functions. Administration of ethanol extract of Cordyceps sinensis counteracted the 
arrhythmia induced by aconitine or BaCl� in rats and increased the tolerant dose of 
ouabain to produce the arrhythmias in guinea pigs. It also reduced the heart rate of 
anesthetic rats and decreased the contractility of isolated papillary muscle or atria in 
guinea pigs. However, it showed no effect on the automatic rhythmicity and the 
functional refractory period of the atria (Mei et al., 1989). 
Oxidized low-density lipoprotein (LDL) is considered to be an important 
factor in the development of atherosclerosis. Cordycpes sinesis was found to have 
antioxidant and anti-lipid peroxidation properties. The hot water extract of fruiting 
bodies of cultured Cordyceps sinensis showed a great oxygen free radical scavenging 
activity. When LDL was incubated with macrophages in the presence of CuCl2, the 
hot water extract showed a strong inhibitory effect against lipid peroxidation in the 
medium and consequent accumulation of cholesteryl ester in macrophages 
(Yamaguchi et al., 2000a). Another study showed that oral administration of water 
extracts of the fruiting bodies of cultured Cordyceps sinensis (WECS) for 12 weeks 
significantly suppressed the increased serum lipid peroxide level in a dose-dependent 
manner. WECS also suppressed the increased aortic cholesteryl ester level in a 
dose-dependent manner. It was suggested that WECS prevent cholesterol deposition 
in the aorta by inhibiting LDL oxidation mediated by free radical (Yamaguchi et al., 
2000b). 
1.1.1.5 Renal Functions 
Cordyceps sinensis also showed renal improvement functions. Cheng et al. 
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(1992) found that Cordyceps sinensis treatment (0.5g/kg, for 4 months) reduced blood 
urea nitrogen (BUN) and serum creatinine, improved anemia and decreased the 
mortality of chronic renal failure (CRF) rats. In addition, it significantly enhanced 
the transformation rates of splenic lymphocytes and promoted the rate of IL-2 
receptor production and expression of IL-2 in lymphocytes. It was suggested that a 
delay in the deterioration of renal functions is correlated with the functional 
improvement of cell-mediated immune system (Cheng, 1992). 
Some studies have indicated that Cordyceps sinensis reduces nephrotoxicity 
caused by aminoglycoside. In the study of Zhen et al. (1992)，simultaneous 
administration of Cordyceps sinensis with gentamycin in rats protected the proximal 
tubular cells from gentamycin-toxicity. After the establishment of kanamycin 
nephrotoxic acute renal failure (ARF), the use of Cordyceps sinensis caused an earlier 
recovery from ARF. Study of Li et al. (1996) demonstrated that Cordyceps sinensis 
administration reduced ‘ BUN, SCr, sodium excretion and urinary 
nephro-aminoglycosidase (NAGase) together with less severity of histopathological 
changes. Cordyceps sinensis also promoted an earlier recovery of renal oxygen 
consumption, insulin clearance and sodium absorption in isolated perfused kidney of 
intoxicated rat (Li et al., 1996). 
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1.2 Biological Activities of Cordycepin 
Various bioactive components are found in fungi of the genus Cordyceps. 
Cordycepin (3 '-deoxyadenosine) is one of the bioactive constituents isolated from 
Cordyceps militaris by Cuningham et al. in 1950. The biological activities of 
cordycepin include (a) inhibition of RNA synthesis, (b) disruption of microtubule 
network, (c) inhibition of nucleic acid methylation, (d) enhancement of cell 
differentiation, (e) anti-tumor activity and (f) anti-fungal activity. The structure of 
cordycepin was shown in Fig. 1.2. 
1.2.1 Inhibition of RNA Synthesis 
Study of Glazer (1976) showed that intraportal injection of cordycepin to 
partially hepatectomized rats inhibited nuclear rRNA and hnRNA in a dose-dependent 
manner. loannidis et al. (1999) also demonstrated that the addition of cordycepin to 
« 
HeLa 1C5 cells caused a dose-dependent decrease in c-myc mRNA levels. 
1.2.2 Disruption of Microtubule Network 
The effects of cordycepin on microtubule network have been reported. It 
was found that the amount of microtubular crystals formed after exposure of several 
different cell types to vinblastine sulfate is markedly reduced after pretreatment with 
cordycepin (Deitch & Sawicki, 1979). Zieve et al. (1987) showed that addition of 
cordycepin to the culture medium cells caused an arrest at the onset of mitosis and the 
depolymerization of spindle microtubules to small asters. After 4 hours treatment 
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1.2.3 Inhibition of Nucleic Acid Methylation 
Measurements of in vivo nucleic acid methylation showed that cordycepin 
caused a significant inhibition of 2 ‘-0-methyluridine, 2 ‘-0-methylcytidine, 
5-methyluridine and 5-methylcytidine accumulation in RNA and of 5-methylcytosine 
formation in DNA. It was believed that 3'deoxy analogues of S-adenosylmethionine 
and S-adenosylhomocysteine are responsible for the inhibition of nucleic acid 
methylation by cordycepin (Kredich, 1980). 
1.2.4 Enhancement of Cell Differentiation 
Study of Mathew et al. (1989) showed that the addition of cordycepin to 
HL-60 cells enhanced the l,25(OH)2 vitamin Ds-induced monocytic differentiation of 
HL-60. The phenotypic evidence of monocytic differentiation correlated with the 
increased levels of mRNA for c-fos and c-fms, which are known to be activated 
during differentiation of HL-60 cells. However, cordycepin alone did not induce 
differentiation. This indicated that cordycpein could enhance cell differentiation but 
not induce differentiation. 
1.2.5 Anti-tumor Activity 
Recent studies have shown that cordycepin is specifically cytotoxic to 
TdT-positive tumor cells, in the presence of adenosine deaminase (ADA) inhibitor. 
Study of Koc Qt al. (1996) showed that in the presence of ADA inhibitor, cordycpein 
caused profound cytotoxicity to a number of terminal deoxynucleotidyl transferase 
(TdT) positive tumor cell lines like NALM-6，HPB-ALL, MOLT-4, CEM, 8402， 
298-26, S-59, P388, FLE-1-4, at low concentration. Higher concentration was 
required to produce significant cytotoxic effects on TdT-negative cell lines. Kodama 
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et al. (2000) also demonstrated that cordycepin exerted prominent cytotoxic effects on 
TdT-positive leukemia cells such as NALM-6, MOLT-4, CEM, P288D1 and S49.1 
cells in the presence of ADA inhibitor. 
1.2.6 Anti-fungal Activity 
Apart from the anti-tumor activity, anti-fungal activity of cordycepin was 
reported. In the study of Sugar and McCaffrey (1998), cordycepin was found to 
prolong the survival rates of ICR mice infected with Candida albicans 64， 
fluconazole-resistant Candida albicans and fluconazole-resistant Candida krusei 
isolates, respectively. 
_ -





Fig. 1.2 Structure of cordycepin (3'deoxyadenosine). 
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1.3 Hepatocellular Carcinoma 
1.3.1 Incidence and Risk Factor of Hepatocellular Carcinoma 
Hepatocellular carcinoma (HCC) is one of the world's most common 
malignancies, causing almost one million deaths annually. There are marked 
geographical variations in the incidence of HCC with majority of cases arising in 
high-risk areas such as China, South-East Asia and Africa. The incidence exceeds 
30 cases/100,000/year in the East Asian region. HCC has become the second cancer 
killer in China since 1990s. The incidence in Western countries such as USA and 
Australia is rising (Akriviadis et al., 1998; Tang, 1998; Teo & Fock，2001; 
McCaughan et al, 2002). The major risk factors for HCC development are chronic 
hepatitis B vims (HBV) infection, chronic hepatitis C virus (HCV) infection and 
alcoholic cirrhosis. Other factors such as patient age, sex, duration, severity of liver 
disease and aflatoxin exposure also contribute to the relative risk of developing HCC 
(Akriviadis et cd., 1998; Teo & Fock，2001; El Serag, 2002; Nissen & Martin, 2002). 
1.3.2 Treatment of Hepatocellular Carcinoma 
1.3.2.1 Hepatic Resection 
In general, partial liver resection is the treatment of first choice, especially 
for early.tumor stages. It allows a good chance of long-term cure and 35% survival 
rate at 5 years is expected in patients resected for HCC. The two main variables that 
affect outcomes are size of the tumor and underlying liver disease. Most centers use 
a cut off of >5 cm in diameter of the tumor to exclude a patient from resection. 
Patients with poor hepatic function are not suitable for hepatic resection (Tang, 1998; 
Teo & Fock, 2001). In addition, patients with cirrhotic liver are not candidates for 
the hepatic resection, since cirrhotic liver has only residual function and a reduced 
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capacity for regeneration (McCaughan et al, 2002). The resection of HCC in a 
non-cirrhotic liver is relatively safe and straightforward. Unfortunately, in majority 
of the cases, tumor will recur after apparently successful resection. The risk of HCC 
recurrence is influenced by several factors such as the size of the tumor and the 
presence of vascular invasion (Johnson, 2002; McCaughan et al., 2002). 
1.3.2.2 Liver Transplantation 
When tumors are non-resectable because of anatomical restrictions (location, 
size or number of intrahepatic lesions) or functional impairment (underlying cirrhosis), 
liver transplantation may be an alternative (Akriviadis et al, 1998). In patients with 
HCC of <5 cm in diameter and with poor liver function, liver transplant is considered. 
Nowadays, liver transplantation is usually suitable for patients who have single tumor 
with 5 cm or less in diameter, no more than three tumor nodules and each 3 cm or less 
in diameter, no vascular invasion and no extrahepatic spread. If patients with large 
tumors are selected for transplantation, rapid HCC recurrence and patient death 
usually ensue. The major limitation for liver transplantation in the treatment of HCC 
is the availability of donor organs, since demand always exceeds the supply (Teo & 
Fock, 2001; McCaughan et al., 2002). 
1.3.2.3 Non-surgical Therapeutic Modalities for Hepatocellular Carcinoma 
(1) Systemic Chemotherapy 
Single-agent chemotherapy and combination chemotherapy have been 
claimed as effective in palliation of HCC. Among the chemotherapeutic agents, the 
anthracyclin derivative doxorubicin (adriamycin) was initially considered the most 
effective. However, the overall response rate to systemic administration of 
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doxorubicin is extremely poor (Akriviadis et aL, 1998). Study of Lai et al. (1988) 
found that doxorubicin induced tumor regression of 25% to 50% in 5% of patients and 
of over 50% in only 3.3% of patients. The median survival rate of the doxorubicin 
group and the group receiving no anti-tumor therapy was 10.6 weeks and 7.5 weeks, 
respectively. Four out of eight patients who received less than 500 mg/m of 
doxorubicin developed cardiotoxicity (Lai et al” 1988). Another study by Lai et al. 
(1989) showed that the median survival rate and tumor regression of patients on 
doxorubicin was lower than that of recombinant alpha 2 interferon (rIFN). Besides, 
doxorubicin caused fatal complications due to cardiotoxicity and neutropenia in 25% 
of patients (Lai et al., 1989). The use of other chemotherapeutic agents, such as 
epirubicin and cisplatin, and combination therapies using doxorubicin and 
5-fluorouracil given systemically, or even through intra-arterial injection, have not 
improved the median survival rates significantly. The risk of adverse events 
including cardiac and bone marrow toxicity and activation of the multidrug resistance 
gene, weighs against the potential benefits following systemic administration of 
anthracyclins and hardly justifies their use. Currently, there is no indication for 
systemic chemotherapy in patients with HCC until more efficacious and less toxic 
drugs become available (Akriviadis et al., 1998). 
(2) Hormonal Therapy 
Tamoxifen as monotherapy in the treatment of HCC is ineffective. 
Several studies have shown that there is no correlation between the expression of 
estrogen receptors and the effect of tamoxifen treatment. Megestrol as another 
hormonal therapy agent has more positive results especially in improving the quality 
of life. Octreotide can be given in cases of impaired liver function and can lead to 
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disease stabilization in about one third of patients. Side effects with hormonal 
treatment are rare and mild (Treiber, 2001). 
(3) Immunotherapy 
Interferon-a (IFN-a)，interleukin-2 (IL-2)，lymphokine-activated killer 
(LAK)/IL-2 and tumor-infiltrating lymphocyte are preparations that have been used. 
However, the response is not yet satisfactory (Tang, 1998). Immunotherapy using 
recombinant IFN-a was used in Hong Kong and was shown to have improvement in 
survival status (Lai et al, 1989). 
(4) Transcatheter Arterial Chemoembolization (TACE) 
Chemoembolization is considered when percutaneous approaches are not 
feasible because of the site or size of the tumor or the presence of contraindications, 
or to control tumor growth prior to transplantation or surgical resection. 
Chemotherapeutic agent, such as mitomycin, adriamycin and cisplatinum mixed with 
lipoidal, is delivered directly to the tumor via the feeding vessels. Embolization is 
then performed with insertion of a material such as gelfoam. The aim is to induce 
tumor necrosis. The procedure is contraindicated in the presence of portal vein 
thrombosis or poor hepatic reserve. Major complications include hepatic infarction 
leading to liver failure and ischaemic cholecystitis. Since the long-term survival is 
dismal, TACE is generally accepted as palliative rather than curative (Teo & Fock， 
2001; McCaughan et al., 2002). 
(5) Percutaneous Ethanol Injection (PEI) 
PEI is a relatively simple procedure in which absolute alcohol is injected 
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into an HCC focus, usually less than 5 cm in size, using a specialized, CT-guided, 
multiporous fine needle. Treatment may be repeated several times, sometimes on 
consecutive days (Akriviadis et aL, 1998; McCaughan et al” 2002). The effect of 
treatment is to induce cellular dehydration, coagulative necrosis and vascular 
thrombosis in and around the lesion. After treatment，many patients experience pain 
and a low-grade fever. Severe complications such as hepatic infarction, 
intraperitoneal haemorrhage, needle-tract implantation, liver abscess and haemobilia 
may occur (McCaughan et al., 2002). 
1.3.3 Human Hepatocellular Carcinoma Cell Lines 
1.3.3.1 Human Hepatocellular Carcinoma Cell Line HepG2 
HepG2 is a human hepatocellular carcinoma cell line derived from a 
15-year-old Caucasian male. HepG2 cells are epithelial in shape. The cells express 
3-hydroxy-3-methylglutaryi-CoA reductase and hepatic triglyceride lipase activities 
(Busch et aL, 1990) and demonstrate decreased expression of apoA-1 mRNA and 
increased expression of catalase mRNA in response to gramoxone (oxidative stress) 
(Cuthbert et al, 1997). 
1.3.3.2 Multidrug Resistant Human Hepatocellular Carcinoma Cell Line 
R-HepG2 
The multidrug resistant cell line R-HepG2 was developed in our laboratory 
by incubating HepG2 cells with stepwise increase in doxorubicn concentrations as 
mentioned in the Materials and Methods. The established cell population possesses 
over-expressed P-glycoprotein and upregulated MDRl gene expression as 
demonstrated by Western and Northern blot analysis (Chan et al., 2000). This cell 
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line was found to be multidrug resistant, in addition to the resistance to doxorubicin, it 
exhibited cross-resistance to the common therapeutic agents such as vincristine and 
methotrexate (Chan et al., 2000). 
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1.4 Multidrug Resistance of Tumor Cells 
Multidrug resistance (MDR) is the protection of tumor cells against 
numerous drugs with different chemical structures and action mechanisms. MDR is 
considered to be one of the causes of chemotherapy failure in human cancers. The 
mechanisms of cellular drug resistance include a) activation of transmembrane 
proteins, such as P-glycoprotein to efflux different chemical substances from the cells, 
b) activation of enzymes of the glutathione detoxification system, c) repair of 
drug-induced damage, and d) alteration of the genes and the proteins (p53 and Bcl-2) 
involved in the control of apoptosis (Stavrovskaya, 2000). The best-studied 
mechanism of MDR is that due to overexpression of an energy-dependent multidrug 
efflux pump，known as P-glycoprotein. 
1.4.1 Multidrug Resistance Mediated by P-Glycoprotein 
1.4.1.1 Location and Structure of P-Glycoprotein 
P-glycoprotein (P-gp) is a transmembrane protein with molecular weight of 
170 kDa and functions as an ATP-driven drug efflux pump in cancer cells. A family 
of P-gp isoforms is encoded by the mdr genes, which are located on human 
chromosome 7 and mouse chromosome 5. P-gp encoded by human MDRl and 
mouse mdr la/lb genes functions as a drug efflux transporter, while the human MDR2 
(or MDR3) and the mouse mdr2 isoforms are believed to be involved in the transport 
of phospholipids (Di Pietro et al., 1999; Lin & Yamazaki, 2003). In addition to the 
expression in tumor cells, human P-gp is also highly expressed in normal tissue, such 
as on the canalicular surface of hepatocytes in liver, the apical surface of epithelial 
cells of proximal tubules in kidneys, columnar epithelial cells of intestine, epithelial 
cells of placenta, and the luminal surface of capillary endothelial cells in the brain. 
— -
I 
Chapter 1 Introduction 
Because of its localization, P-gp is believed to play a significant role in the processes 
of absorption, distribution, metabolism and excretion of drugs in humans and animals 
(Lin & Yamazaki, 2003). P-gp is composed of two homologous and symmetrical 
halves, each containing six transmembrane domains and an ATP binding domain, 
separated by a flexible linker polypeptide (Ambudkar et al, 1999; Stavrovskaya, 2000; 
Lin & Yamazaki, 2003). The structure of P-glycoprotein is shown in Fig. 1.3. 
1.4.1.2 Substrates of P-Glycoprotein 
P-gp confers resistance against a wide variety of compounds that are 
hydrophobic, amphipathic natural products drugs with different structures and 
mechanisms of action. These compounds include not only the anticancer drugs, but 
also therapeutic agents such as HIV-protease inhibitors (Ambudkar et al., 1999). 
These compounds are chemically diverse, the only common features among these 
compounds are hydrophobic, large in size and carry a positive charge at physiological 
pH (generally carried by a nitrogen atom) (Ambudkar et al., 1999; Di Pietro et aL, 
1999). The substrates for P-gp are indicated in Table 1.2. 
1.4.1.3 Mechanism of Action of P-Glycoprotein 
Several models have been proposed to describe the mechanism for the drug 
transport by P-gp. The initial model hypothesizes that the hydrophobic 
membrane-spanning regions and hydrophilic elements of P-gp form an aqueous 
transmembrane pore through which drugs are transported from the cytosol to the 
extracellular media. The second model suggests that P-gp detects and removes its 
hydrophobic substrates directly from the lipid bilayer before they enter the cytoplasm. 
Another version of this model suggests that P-gp acts as a flippase, carrying its 
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substrate from the inner leaflet of the lipid bilayer to the outer leaflet and into the 
extracellular medium. However, this model only demonstrated for the mdr2/MDR2 
transporter which uses phosphatidylcholine as a substrate (Ambudkar et al., 1999; Di 
Pietro et al, 1999; Lin & Yamazaki, 2003). It is clear now that ATP binding and 
subsequent hydrolysis are essential for drug transport and hydrolysis of 1-3 molecules 
of ATP is required for the transport of one molecule of the drug (Ambudkar et al.’ 
1997). However, the molecular mechanisms of how the multidrug transporter lowers 
intracellular accumulation of anticancer drugs are still unclear. 
1.4.2 Reversal of Multidrug Resistance by Chemosensitizers 
A number of non-cytotoxic compounds known as chemosensitizers or MDR 
modulators sensitized resistant cells for the action of cytotoxic drugs. 
Chemosensitizers include calcium channel blockers, calmodulin antagonist, 
hydrophobic peptides, steroids, protein kinase inhibitors, antibiotics, hormones and 
flavonoids (Ambudkar et al., 1999; Di Pietro et aL, 1999). Inhibition of drug 
transport could result from the blockage of specific recognition of the substrate, 
binding of ATP, ATP hydrolysis or coupling of ATP hydrolysis to translocation of the 
substrate. Most of the reversing agents block drug transport by acting as competitive 
or non-competitive inhibitors and by binding either to drug interaction sites or to other 
modulator binding sites. None of the known modulators inhibit ATP binding. 
Reversing agents such as cyclosporin A inhibit transport function by interfering with 
both substrate recognition and ATP hydrolysis. Modulators such as verapamil are 
substrates of the transporter and inhibit the transport function in a competitive manner 
without interrupting the catalytic cycle of P-gp. Therefore, they behave as 
pseudo-substrates that only lower the rate of anticancer drug efflux but not real 
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inhibitors (Ambudkar et al, 1999; Di Pietro et al., 1999). High concentrations of 
these compounds would cause unendurable side effects such as cardiotoxicity and 
hypotension for verapamil or immunosuppression for cyclosporin A (Di Pietro et al., 
1999). Thus, it would be better to look for the anti-tumor agents that can overcome 
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Fig. 1.3 Proposed structure of the multidrug resistant P-glycoprotein. Each 
cassette of P-glycoprotein contains six transmembrane domains followed by a 
nucleotide binding site (NBS). These motifs are connected by a linker region. This 
diagram is adapted from Di Pietro et al., 1999. 
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Table 1.2 Substrates of P-glycoprotein. Adapted from Ambudkar et al., 1999 
Anticancer drugs 
Vinca alkaloids (vincristine, vinblastine) 
Anthracyclines (doxorubicin, daunorubicin, epirubicin) 
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1.5 Leukemia 
Leukemia is a type of cancer caused by unregulated proliferation of a clone 
of immature blood cells derived from mutant haematopoietic stem cells. The 
immature cells infiltrate bone marrow and inhibit normal haematopoiesis. Leukemia 
is not a common disorder but is a significant cause of death from cancer. The 
incidence of leukemia is highest in the western countries and is much less frequent in 
Japan, South America and Africa. The major forms of leukemia are divided into four 
categories on the basis of their clinical course (acute or chronic) and their cell of 
origin (myeloid or lymphoid) (Howard & Hamilton，2002). Acute leukemia is a 
rapidly progressing disease that affects mostly cells that are unformed or primitive 
(not yet fully developed or differentiated). These immature cells cannot carry out 
their normal functions. Chronic leukemia progresses slowly and permits the growth 
of greater number of.more developed cells. These more mature cells can carry out 
« 
some of their normal functions. 
1.5.1 Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) arises from the malignant transformation of 
a myeloid precursor cells. Usually this occurs at a very early stage of myeloid 
development, except the acute promyelocytic leukemia, a subtype of AML, which 
involves proliferation of a more mature cell. AML is traditionally classified as eight 
subtypes (FAB M0-M7) based on the malignant cells' morphology and 
immunophenotype. Table 1.3 shows the subtypes of AML. 
1.5.2 Acute Promyelocytic Leukemia and Treatment 
Acute promyelocytic leukemia (APL) accounts for about 10% - 15% of 
— 
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cases of acute myeloid leukemia (Stone & Mayer, 1990). In patients of APL, 
leukemic cells have a characteristic reciprocal translocation of chromosomes 15 and 
17 t(15;17) which disrupts the promyeloctyic leukemia gene (PML) on chromosome 
15 and the retinoic acid receptor-a gene (RARa) on chromosome 17 and leads to the 
formation of two fusion proteins. PML/RARa and RARa/PML. PML/RARa 
expression can be found in almost all patients with the t(15;17) translocation, whereas 
RARa/PML protein is detected in only two-thirds of APL patients. PML/RARa 
inhibits myeloid differentiation, causing an accumulation of leukemic cells at the 
promyelocytic stage of development (Chen et al” 1997a; Mayorga et al, 2002; 
Bachleitner-Hofmann et al., 2002). 
Before, 1990s, patients with APL were treated with anthracyclines 
combined with cytosine arabinoside for induction, followed by additional cycles of 
chemotherapy for consolidation and/or maintenance. The complete remission (CR) 
rate is approximately 60 - 80% of patients, and 5-year survival rate is 20 - 30% of 
patients. Despite the marked sensitivity of APL cells to anthracyclines, these agents 
were not sufficient to induce long-lasting remission. In the early 1990s, all-trans 
retinoic acid (ATRA) was introduced into the treatment of APL, it has about two-fold 
improvement of overall and disease-free survival rates (Bachleitner-Hofmann et al., 
2002; Tallman & Nabhan, 2002). However, the long-term survival is short, with a 
median overall survival of less than 20 months. Besides, once patients have relapsed 
from ATRA, maintenance therapy is not as effective as the initial treatment (Mayorga 
et al., 2002). Furthermore, some patients treated with ATRA alone developed a rapid 
increase in leukocyte count. In some studies, administration of ATRA was 
associated with the development of retinoic acid syndrome (RAS). RAS is a serious 
cardiorespiratory distress syndrome. Prominent signs and symptoms of RAS include 
I 
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fever, weight gain, respiratory distress, interstitial pulmonary infiltrates, pleural and 
pericardial effusion, episodic hypotension and acute renal failure. The incidence of 
RAS is approximately 25% (Frankel et al., 1992; Tallman & Nabhan，2002). 
Recently, arsenic trioxide (AS2O3) has shown marked activity in patients with relapsed 
APL (Mayorga et al., 2002; Tallman & Nabhan, 2002). However, adverse effects 
such as leukocytosis, gastrointestinal symptoms (e.g. nausea, vomiting, diarrhea, 
abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, QT prolongation, 
rash or itching, headaches and dizziness were observed during treatment with arsenic 
trioxide. Besides, serious adverse events such as hyperleukocytosis, 
electrocardiographic abnormalities and APL differentiation syndrome (APLS) can 
occur during treatment (Mayorga et al., 2002). Although some patients do well with 
maintenance arsenic trioxide with or without additional chemotherapy, others relapse. 
The relapsed patients can be considered for either allogeneic (alloBMT) or autologous 
stem cell transplantation (ASCT) in second CR. 
1.5.3 Human Promyelocytic Leukemia Cell Lines 
1.5.3.1 HL-60 
HL-60 is a human promyelocytic leukemia cell line established from 
peripheral blood of a 36-year-old Caucasian female with acute promyelocytic 
leukemia. HL-60 cells do not carry t(15;17) but respond to treatment with retinoic 
acids by differentiation to more mature stages (Drexler et al., 1995). 
1.5.3.2 NB-4 
NB-4 is a human promyelocytic leukemia cell line established from the bone 
, marrow of a 23-year-old woman with acute promyelocytic leukemia in second 
— • 
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ATRA-resistant relapse. NB-4 cells carry t(15;17) PML/RARa fusion gene. In 
vitro treatment of NB-4 cells with ATRA leads to growth arrest and distinct 
phenotypical changes (Drexler et al, 1995). 
« 
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Table 1.3 French-American-British (FAB) classification of acute myeloid 
leukemia. 
MO Acute Myeloblastic Leukemia, Minimally Differentiated 
Ml Acute Myeloblastic Leukemia Without Maturation 
M2 Acute Myeloblastic Leukemia With Maturation 
M3 Acute Promyelocytic Leukemia 
M4 Acute Myelomonocytic Leukemia 
M5 Acute Monocytic Leukemia 
M6 Acute Erythroleukemia 
M7 Acute Megakaryocytic Leukemia 
I 
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1.6 Objectives of Study 
1.6.1 study of Biological Activities of Cordyceps militaris 
As mentioned above, Cordyceps sinensis and its cultured mycelia were 
found to have a wide variety of biological functions especially the 
immunomodulatory and anti-tumor activities. However, not much of the research 
work was conducted on its family member Cordyceps militaris. Therefore, we 
would like to investigate the biological activities of Cordyceps militaris by using the 
water extract of cultured fruiting bodies of Cordyceps militaris (WECM). In our 
study, immunomodulatory and anti-tumor activities of Cordyceps militaris would be 
investigated in vitro and in vivo. For in vitro study, several cell lines such as human 
hepatocellular carcinoma HepG2, multidrug resistant human hepatocellular carcinoma 
R-HepG2, human acute promyelocytic leukemia HL-60, NB-4 and mouse sarcoma 
SC-180 would be used to investigate the anti-tumor effect of Cordyceps militaris. 
Tumor (SC-180) bearing mice would be used to study the anti-tumor and 
immunomodulatory effects of Cordyceps militaris in vivo. 
1.6.2 Study of Anti-tumor Activity of Cordycepin 
Cordycepin is the chemical constituent firstly isolated from Cordyceps 
militaris and it was reported to have anti-tumor activity. The anti-tumor activity of 
cordycepin on different tumor cell lines like HepG2，R-HepG2, HL-60 and NB-4 cells 
would be investigated. Besides, the underlying mechanism of the anti-tumor effect 
of cordycepin on these cell lines would be investigated by examining the changes in 
levels of the apoptosis-related proteins and the cell cycle regulatory proteins after 
cordycepin treatment. 
I 
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2.1 Materials 
2.1.1 Animal 
Male BALB/c mice aged 6-8 weeks old were obtained from the University 
Laboratory Animal Services Center of The Chinese University of Hong Kong. They 
were housed under the conditions of 22-25°C and a 12-hour light-dark cycle. They 
were supplied with rodent chow (PicoLab Rodent Diet 20，PMI Nutrition 
International, Inc., U.S.A.) ad libitum with free access to tap water. 
2.1.2 Cell Culture 
2.1.2.1 Cell Lines 
1) HepG2 
HepG2 is a human hepatocellular carcinoma cell line. It was purchased 
from American Type Culture Collection (ATCC number HB-8065), which was 
derived from a 15-year-old Caucasian male. The cells were maintained in RPMI 
1640 medium supplemented with 10% (v/v) fetal bovine serum (GibcoBRL) and 1% 
(v/v) penicillin-streptomycin (GibcoBRL). They were incubated at 37�C humidified 
incubator supplied with 5% CO2. 
2) Resistant HepG2 (R-HepG2) 
R-HepG2 is a multidrug resistant human hepatocellular carcinoma cell line. 
It was developed by our group (Chan et al., 2000). To develop the R-HepG2 cells, 
HepG2 cells were first incubated with 0.1 |LIM doxorubicin (Sigma). Dead 
non-resistant cells were removed and viable cells were further incubated with 
stepwise increasing concentrations of doxorubicin up to 100 The property of 
multidrug resistance was tested by treating the HpeG2 and R-HepG2 cells with 
i 
Chapter 2 Materials and Methods 
chemotherapeutic drugs including doxorubicin, vincristine and methotrexate for 48 
hours and MTT assay was carried out to determine the percentage of survival of cells. 
The overexpression of P-glycoprotein and upregulation of MDR 1 gene was confirmed 
by Western blot analysis and Northern blot analysis (Chan et al., 2000). R-HepG2 
cells were maintained in RPMI 1640 medium supplemented with 10% (v/v) fetal 
bovine serum (GibcoBRL), 1% (v/v) penicillin-streptomycin (GibcoBRL) and 1.2 uM 
doxorubicin (Sigma). They were incubated at 3TC humidified incubator supplied 
with 5% CO2. 
3) HL-60 
HL-60 is a human promyelocytic leukemic cell line purchased from 
American Type Culture Collection (ATCC number CCL-240). It was established 
from peripheral blood of a 36-year-old Caucasian female with acute promyelocytic 
leukemia. The cells were maintained in RPMI 1640 medium supplemented with 
2O0/0 (v/v) fetal bovine "serum (GibcoBRL), 1% (v/v) penicillin-streptomycin 
(GibcoBRL) and incubated at 37°C humidified incubator supplied with 5% CO2. 
4) NB-4 
NB-4 is a human acute promyeloctyic leukemic cell line obtained from 
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (German 
Collection of Microorganisms and Cell Cultures) (DSMS number ACC 207). It was 
established from the bone marrow of a 23-year-old woman with acute promyelocytic 
leukemia in second relapse. Maintenance of NB-4 cells is the same as HL-60 cells. 
5) WRL-68 
WRL-68 is a human normal hepatic cell line purchased from American 
Type Culture Collection (ATCC number CL-48). It is a non-tumorigenic cell line 
derived from human fetal liver that preserves the activity of some characteristic or 
“ 36 “ “ 
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specific liver enzymes (Gutierrez-Ruiz et al, 1994). The cells were maintained in 
EMEM medium supplemented with 10% (v/v) fetal bovine serum (GibcoBRL), 1% 
(v/v) penicillin-streptomycin (GibcoBRL) and 1% sodium pyruvate (GibcoBRL). 
They were incubated at 2>TC humidified incubator supplied with 5% CO2. 
6) SC-180 
SC-180 is a mouse sarcoma cell line obtained from American Type Culture 
Collection (ATCC number TIB-66). The cells were maintained in RPMI 1640 
medium supplemented with 10% (v/v) fetal bovine serum (GibcoBRL) and 1% (v/v) 
penicillin-streptomycin (GibcoBRL). They were incubated at 37�C humidified 
incubator supplied with 5% CO2. 
2.1.2.2 Cell Culture Media 
RPMI 1640 medium (Roswell Park Memorial Institute tissue culture medium 
1640) was used for culturifig of HepG2, R-HepG2, HL-60, NB-4 and SC-180 cells. 
A pack of RPMI 1640 powder (GibcoBRL) with phenol red, L-glutamine and 25 mM 
HEPES was dissolved in 1 L of distilled water. Two grams of sodium bicarbonate 
(Sigma) was added and the pH was adjusted to 7.2. The medium was then sterilized 
by filtration with 0.22 |Lim bottle-top filter (Millipore). Sterilized medium was stored 
at 4°C until use. Complete medium was prepared by supplemented with 10% or 
2O0/0 (v/v) fetal bovine serum (GibcoBRL) and 1% (v/v) penicillin-streptomycin 
(10,000 units/ml) (GibcoBRL) to the sterilized RPMI 1640 medium. 
EMEM medium (Eagle's Minimal Essential medium) was used for culturing 
of WRL-68 cells. A pack of MEM powder (GibcoBRL) with Earle's salt, 
L-glutamine and non-essential amino acids was dissolved in 1 L of distilled water and 
. 2.2 gram of sodium bicarbonate (Sigma) was added. The pH was adjusted to 7.2. 
W “ 
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The medium was then sterilized by filtration with 0.22 i^m bottle-top filter (Millipore). 
Sterilized medium was stored at 4°C until use. Complete medium was prepared by 
supplemented with 10% (v/v) fetal bovine serum (GibcoBRL), 1% (v/v) 
penicillin-streptomycin (10,000 units/ml) and 1% sodium pyruvate (GibcoBRL) to the 
sterilized MEM medium. 
2.1.2.3 Buffers and Other Reagents 
1) Phosphate Buffered Saline (PBS) 
PBS was prepared by dissolving 136 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4 and 8 mM Na2HP04 in distilled water with pH 7.4. It was sterilized by 
autoclave and was stored at 4°C. 
2) Ttypsin-EDTA Solution 
Trypsin-EDTA solution containing 0.25% trypsin and 1 mM 
EDTA-tetrasodium in HBSS without Ca^ "^  and Mg2+ was purchased from GIBCO 
BRL Life Technologies Inc. 
3) Trypan Blue Solution 
Trypan blue solution was purchased from Sigma Chemical Co. It 
contained 0.4% (w/v) trypan blue dissolved in 0.817% sodium chloride and 0.06% 
dibasic potassium phosphate. 
4) 3-(4，5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
MTT was purchased from Sigma Chemical Co. as powder form and 
dissolved in PBS at a concentration of 5 mg/ml. 
5) [methyl-^H] Thymidine fH-TdR) 
^H-TdR (1000 |LiCi/ml) was purchased from Amersham Biosciences. 
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6) Hemacolor Staining Solutions 
Hemacolor staining solutions (Merck) consisted of three different solutions 
were used to stain cells after cytocentrifUgation. Hemacolor Solution 1 was 
methanol for fixing cells, Solution 2 was a buffered color reagent red and Solution 3 
was a buffered color reagent blue. All staining solutions were light-protected and 
stored at room temperature. 
7) Adenosine 
Adenosine was purchased from Sigma Chemical Co. and dissolved in 
distilled water at the concentration of 20 mM and stored at 4°C. 
8) Cordyceps militaris 
Fruiting bodies of Cordyceps militaris cultured with advanced biotechnology 
through artificial fermentation were kindly provided by GreaterChina Technology 
Group Ltd. 
9) Cordycepin 
Cordycepin was purchased from Sigma Chemical Co. and dissolved in 
distilled water at the concentration of 20 mM and stored at -20 
10) Doxorubicin 
Doxorubicin (Sigma) was prepared by dissolving in 1 ml autoclaved distilled 
water and was then diluted with PBS into a 1 mM stock. It was stored at -20°C and 
protected from light. 
11) D-mannitol 
D-mannitol was purchased from Sigma Chemical Co. and dissolved in 
distilled water at the concentration of 1 M and stored at 4 
— 
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2.1.3 Reagents and Buffers for Different Assays 
2.1.3.1 Reagents and Buffers for Flow Cytometry 
1) Annexin V-FITC Kit 
TAGS™ Annexin V-FITC Kit was purchased from Trevigen, Inc. 
2) 5-(and 6-)-carboxy-2，，7-dichlorodihydrofluorescein diacetate (DCFH-DA) 
DCFH-DA (Molecular Probes) was prepared by dissolving it in DMSO to 
give a stock concentration of 2.5 mM. The stock was stored at -20°C. The stock 
was diluted with PBS before use. 
3) 5，5，,6，6，-tetrachloro-1，1 ’，3,3 ^ -tetraethylbenzimidazolylcarbocyanine Iodide 
(JC-1) 
JC-1 (Molecular Probes) was prepared by dissolving it in DMSO to give a 
stock concentration of 2.5 mM and stored at 4°C. The stock was diluted with PBS 
before use. 
4) Propidium Iodide (PI)'for DNA Staining 
PI (Sigma) was dissolved in PBS at a concentration of 2 mg/ml and stored at 
5) Tetramethylrhodamine, ethyl ester’ perchlorate (TMRE) 
TMRE (Molecular Probes) was prepared by dissolving it in DMSO to give 
a concentration of 125 i^M stock solution and was stored at -20°C. 
2.1.3.2 Reagents and Buffers for DNA Fragmentation Assay 
1) DNA Lysis Buffer 
DNA lysis buffer composed of 50 mM Tris [hydroxylmethyl] amino 
methane (Tris)-HCl, 3% non-ionic detergent Igepal CA-630 ((Octylphenoxy) 
polyethoxyethanol) and 20 mM EDTA (Sigma), pH 7.5. It was kept at room 
— • 
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temperature. 
2) Proteinase K 
Proteinase K (Sigma) was dissolved in distilled water to prepare a stock 
concentration of 20 mg/ml and was stored at -20°C. 
3) Ribonuclease A (RNase A) 
RNase A (Sigma) was dissolved in distilled water to prepare a stock 
concentration of 10 mg/ml and was stored at -20 
4) Sodium Acetate Solution (NaOAc) 
3 M Sodium acetate solution was prepared by dissolving 24.61 g of sodium 
acetate (Sigma) in 100 ml distilled water. It was then sterilized by autoclaving at 
121°C for 20 minutes. The solution was kept at room temperature. 
5) TioEo.1 Buffer 
TioEo.i buffer was composed of 10 mM Tris-HCl (pH 7.5) and 0.1 mM 
EDTA (Sigma). The solution was kept at room temperature. 
6) 6XDNA Loading Dye 
6X DNA loading dye was prepared by mixing 0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol FF and 40% (w/v) sucrose in distilled water. 
7) 100 Base Pairs DNA Marker 
100 base pairs DNA marker was prepared by mixing 2 100 base pair 
DNA marker (Amersham Biosciences) with 4 6X DNA loading dye and 5 |xl 
distilled water. 
8) Tris-Acetate-EDTA (TAE) Buffer 
TAE buffer was first prepared as 5OX concentrated stock solution. It was 
composed of 242 g Tris base, 57.1 ml glacial acetic acid and 100 ml 0.5 M EDTA 
(pH8.0) in 1 L of distilled water. 50X concentrated stock solution was then diluted 
-
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with distilled water to IX TAE buffer before use. 
2.1.3.3 Reagents and Buffers for Western Blot Analysis 
1) Lysis Buffer for Total Protein Extraction 
Lysis buffer for total protein extraction was composed of 2% SDS, 10% 
glycerol and 0.0625 M Tris-HCl (pH 6.8). 
2) Lysis Buffer for Cytochrome c Extraction 
Lysis buffer for cytochrome c extraction was composed of 75 mM NaCl, 1 
mM NaH2P04, 8 mM Na2HP04 and 250 mM sucrose (Sigma). The buffer was 
stored at 4®C. 21 |Lig/ml aprotinin, 5 |ig/ml leupeptin, 1 mM phenylmethyl-sulphonyl 
fluoride (PMSF) (Sigma) and various concentrations of digitonin (Merck) were added 
to the buffer just prior to use. 
3) 4X Lower Gel Buffer 
4X lower gel buffer was prepared by dissolving 90.8 g of Tris base and 2 g of 
SDS in 500 ml of distilled water. The pH was adjusted to 8.8. 
4) 4X Upper Gel Buffer 
4X upper gel buffer was prepared by dissolving 30.3 g of Tris base and 2 g of 
SDS in 500 ml of distilled water. The pH was adjusted to 6.8. 
5) lOXSDS Running Buffer 
lOX SDS running buffer was prepared by dissolving 30.3 g of Tris base, 144 
g of glycine and 10 g of SDS in 1 L of distilled water. The concentrated stock 
solution was then diluted to IX SDS running buffer. 
6) 30% Acrylamide/Bis Solution 
30% (w/v) Acrylamide/Bis solution was purchased from Bio-Rad 
Laboratories. 
^ -
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7) 10% Ammonium Persulfate (APS) 
10% Ammonium persulfate (APS) was prepared by dissolving 10% (w/v) 
APS (Bio-Rad) in distilled water and was stored at -20 
8) N，N，N，，N，-Tetra-Methylethylenediamine (TEMED) 
TEMED solution was purchased from Bio-Rad Laboratories and stored at 
4�C. 
9) 2X SDS Loading Dye 
2X SDS loading dye was prepared by mixing 10% (v/v) glycerol, 0.4% (w/v) 
SDS, 0.05% (w/v) bromophenol blue, 20 mM EDTA in 0.5 M Tris-HCl (pH 7.5) and 
5% (v/v) 2-mercaptoethanol. It was stored at 4°C. 
10) Electroblotting Buffer (E-Blot Buffer) 
E-Blot buffer was prepared by mixing 66.7 ml of lOX Tris-glycine (30.3 g of 
Tris base and 144 g of glycine in 1 L of distilled water) (pH 8.3), 100 ml of methanol 
and 500 ml of distilled water. 
11) Tris-Buffered Saline-Tween-20 (TBS-T) 
lOX TBS stock solution was prepared by dissolving 12.114 g of Tris and 
87.66 g of NaCl in 1 L of distilled water. The pH was adjusted to 8. The stock 
solution was then diluted to IX TBS. For 1 L of IX TBS, 1 ml of Tween-20 was 
added to become IX TBS-T. 
12) Commassie Blue Staining Solution 
• Commassie Blue staining solution for SDS gel staining was prepared by 
mixing acetic acids, methanol and distilled water in the ratio of 1:3:10 (v/v) with 
0.05% (w/v) Commassie brilliant blue R-250. 
13) Destaining Solution 
Destaining solution was prepared by mixing acetic acid, methanol and 
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distilled water in the ratio of 4:1:5 (v/v). 
nnjiyf 
14) Rainbow coloured protein molecular weight marker 
Rainbow™ coloured protein molecular weight markers was purchased from 
Amersham Biosciences. 
15) Polyvinylidene Difluoride (PVDF) Western Blotting Membranes 
PVDF membrane with a pore size of 0.45 fj,m was purchased from Millipore 
Corporation. 
16) ECL Western Blotting Detection Reagents 
ECL Western Blotting detection reagents was obtained from Amersham 
Biosciences and stored at 4°C. 
17) FUJI Super RX Film 
FUJI Super RX film used for Western blot analysis was obtained from FUJI 
Photo Products Co. Ltd. 
18) Primary and Secondary Antibodies 
Primary and secondary antibodies for Western blot analysis are listed in 
Table 2.1. 
— 
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Table: 2.1 List of the primary and secondary antibodies used. 
•it.： 
Antibodies Source Company 
Anti- j3 -actin Mouse Sigma 
Anti-Bax Mouse Santa Cruz 
Anti-Bci-2 Mouse Santa Cruz 
Anti-Bcl-X Rabbit Santa Cruz 
Anti-Bid Goat Santa Cruz 
.Anti-caspase-3 Mouse Santa Cruz 
Anti-caspase-8 Rabbit Zymed 
s Aiili-caspise-9 Rabbit Zymed 
Anti-cdc2 Mouse Oncogene 
Anti-cyclin A Mouse PharMingen 
Anti-cyclin B Mouse PharMingen 
Anti-cytochrome c Rabbit Santa Cruz 
Anti-Fas Rabbit Santa Cruz 
Anti-c-myc ‘ Mouse PharMingen 
— Anti-PARP Rabbit Santa Cruz 
Anti-p21 Mouse PharMingen 
Anti-p53 Mouse Santa Cruz 
Anti-goat-HRP conjugate Donkey Santa Cruz 
, Anti-mouse-HRP conjugate Goat Zymed 
Anti-rabbit-HRP conjugate Goat Santa Cruz 
:   
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2.1.3.4 Reagents and Buffers for Caspases Activities 
1) Cell Lysis Buffer 
Cell lysis buffer contained 1% Igepal CA-630, 150 mM NaCl，50 mM Tris-HCl, 
1 mM EDTA and protease inhibitor (Roche) (1 tablet) in 50 ml distilled water. The 
pH was adjusted to 7.5. The buffer was kept at 4°C. 
2) Reaction Buffer 
Reaction buffer was composed of 10 mM Hepes-KOH, 40 mM -
glycerophosphate, 50 mM NaCl, 2 mM MgCl2, 5 mM EGTA, 0.1% CHAPS, 100 
)ig/ml BSA (Sigma) and 10 mM DTT was add before used. The pH .was adjusted to 
7.0. The buffer was kept at 4°C. 
3) Substrates, inhibitors，and calibrator 
Substrates, inhibitors and calibrators for caspase activities determination are 
listed in Table 2.2. 
_ 
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Table 2.2 List of caspase substrates, inhibitors and calibrators for caspase 
activities determination.  
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2.1.3.5 Reagents and Buffers for Cell Surface Marker (CD3, CD4 and CDS) 
Staining 
1) Anti-mouse CD3 Antibody 
It is a hamster monoclonal antibody (PharMingen) conjugated with FITC. 
It reacts with the s chain of the T-cell receptor-associated CD3 complex, which is 
expressed on thymocytes, mature T lymphocytes and NK-T cells of all mouse strains. 
2) Anti-mouse CD4 Antibody 
It is a rat monoclonal antibody (PharMingen) conjugated with FITC. It 
reacts with CD4 differentiation antigen expressed on most thymocytes, a • 
subpopulation of mature T lymphocytes, and a subset of NK-T cells of all mouse 
strains. 
3) Anti-mouse CDS Antibody 
It is a rat monoclonal antibody (PharMingen) conjugated with PE. It reacts 
with a and a’ chains of the CD8 differentiation antigen of all mouse strains. 
4) Mouse IgGAntibody 
IgG from murine serum was obtained from Sigma Chemical Co. 
5) Staining Buffer 
It contained PBS supplemented with 2% heat-inactivated FBS and 0.05% 
sodium azide. 
6) 1% Paraformaldehyde Solution 
‘It was prepared by dissolving 0.5 g of paraformaldehyde into 50 ml of 
normal saline (0.9% NaCl). 
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2.1.3.6 Reagents and Buffers for Cytokine Determination 
1) Coating Buffer 
0.1 M Carbonate was prepared by dissolving 8.4 g ofNaHCOs and 3.56 g of 
Na2C03 to 1 L of distilled water (pH 9.5). 
2) Assay Diluent 
It was composed of PBS supplemented with 10% heat inactivated FBS (pH 
7). 
3) Wash Buffer 
It was composed of PBS supplemented with 0.05% Tween-20. 
4) Substrate Solution 
TMB substrate reagent set (PharMingen) was made up of 
tetramethylbenzidine (TMB) and hydrogen peroxide. 
5) OptEIATMSets 
OptEIA™ sets for the detection of mouse IL-2, IL-4, IL-6, IFN-y were 
purchased form PharMingen. 
« 
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2.2 Methods 
2.2.1 Preparation of Water Extract of Cordyceps militaris (WECM) 
Fruiting bodies of cultured Cordyceps militaris (powder form) was boiled in 
distilled water (1:10 w/v) under reflux for 15 minutes. The mixture was centrifuge 
at 2,460 X g for 10 minutes and then centrifuged at 14,000 x g for 20 minutes. The 
supernatant was collected and lyophilized to become dry powder. The product was 
dissolved in distilled water to make the final concentration to 100 mg/ml and 
sterilized by filtration. The stock was stored at -20°C. 
2.2.2 MTT Assay 
MTT assay was used to assess the cytotoxicity of WECM and its active 
component cordycepin. For HepG2 and R-HepG2 cells, 100 of cells (1x10^ 
cells/ml) were seeded into each well of a flat bottom 96-well plate. The plates were 
incubated at 37°C, 5% CO2 humidified incubator overnight. The medium was then 
removed and the cells were incubated in 100 i^l of the medium in the presence or 
absence of increasing concentrations of drugs for 24 or 48 hours. For HL-60, NB-4 
and SC-180 cells, 2x10^ cells/ml were seeded into each well and drugs were added 
immediately. After treatment, the medium in each well was discarded. Thirty 
microliters of MTT solution (5 mg/ml) (Sigma) was added and incubated at 37°C, 5% 
CO2 humidified incubator for 3 hours. MTT solution was then removed and 100 \x\ 
of DMSO was added to dissolve the crystals. The absorbance at 540 nm was read by 
ELISA plate reader (Bio-Rad). The control cells without drug treatment was set as 
100% of cell survival and the concentration of drug that inhibited cell survival by 
50% (IC50) was determined from the cell survival plots. 
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2.2.3 In Vivo Anti-tumor Study 
SC-180 cells (5x106 cells) in 0.2 ml PBS were inoculated subcutaneously at 
the right inguinal region of male BALB/c mice (6-8 weeks) in groups of 7. After 
7 days of inoculation, BALB/c mice were fed with different dosages of WECM (20 
mg/kg/day, 40 mg/kg/day and 200 mg/kg/day) consecutively for 21 days. 
BALB/c mice fed with distilled water acted as control group. After treatment for 
21 days, BALB/c mice were sacrificed and tumor weight was measured. 
2.2.4 Preparation of Splenic Lymphocytes 
Spleen from 6-8 weeks BALB/c mice was removed and put in a 60-mm 
culture dish containing 10 ml of complete RPMI medium. The spleen was pressed 
through a sterile wire sieve in complete RPMI medium using the piston from a 10-ml 
plastic disposable syringe. The single cell suspension was then transferred to 
centrifuge tube and centrifuge at 200 x g for 5 minutes. The cells pellet was then 
lysed with 10 ml lysis buffer (0.8 g ammonium chloride, 0.08 g sodium carbonate and 
0.037 g EDTANa2 in 100 ml distilled water) for 10 min to lyse the red blood cells. 
Ten ml of the cell lysate was then added slowly to 10 ml of FBS and centrifUged at 
290 X g for 10 minutes. The splenic lymphocytes were then resuspended in 
complete RPMI medium to a concentration of 1x10^ cells/ml. 
2.2.5 Lymphoproliferation Test 
Splenic lymphocytes (2xl0^cells/well) were seeded in a 96-well plate and 
incubated with various concentrations of WECM at 37°C with 5% CO2 for 3 days. 
Subsequently, tritiated thymidine (0.5 |LiCi per well) was added into each well and 
incubated for 6 hours. After 6-hour incubation with tritiated thymidine, the cells 
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were harvested on glass fiber filters by cell harvester. Radioactivity in the filters was 
measured by Microplate Scintillation and Luminescence Counter (Topcount NXT™). 
2.2.6 Cell Surface Marker (CD3，CD4 and CDS) Staining 
1) CDS Staining 
Mouse splenocytes (5x10^ cells) were washed with 10 ml of cold staining 
buffer and centrifUged at 650 x g for 5 minutes at 4°C. The cells were resuspended 
in 0.3 ml of staining buffer, 6 of mouse IgG (1 mg/ml) was added and incubated for 
30 minutes on ice. After 30 minutes incubation, the cells were washed once with 10 
ml of staining buffer to remove the unbound mouse IgG. The cells were then 
resuspended in 160 of staining buffer and divided into two equal aliquots, each 
containing 80 |LI1 of cells. To one tube (negative control), 20 of mouse IgG (50 
|Lig/ml) was added, whereas to the other tube (test sample), 20 [i\ of FITC-conjugated 
anti-mouse CDS antibody (50 i^g/ml) was added and incubated for 30 minutes on ice 
in dark. After incubation, the cells were washed twice with cold staining buffer to 
remove the unbound antibodies and fixed with 0.5 ml of 1% paraformaldehyde 
solution. The cells were analyzed by FACSort flow cytometry (Becton Dickinson). 
2) CD4/CD8 Staining 
Mouse splenocytes (5x10^ cells) were washed with 10 ml of cold staining 
buffer and centrifUged at 650 x g for 5 minutes at 4°C. The cells were resuspended 
in 0.3 ml staining buffer, 6 \i\ of mouse IgG (1 mg/ml) was added and incubated for 
30 minutes on ice. After 30 minutes incubation, the cells were washed once with 10 
ml of staining buffer to remove the unbound mouse IgG. The cells were then 
resuspended in 160 |LI1 of staining buffer and divided into two equal aliquots, each 
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containing 80 of cells. To one tube (negative control), 20 |LI1 of mouse IgG (50 
l^g/ml) was added, whereas to the other tube (test sample), 20 |il of FITC-conjugated 
anti-mouse CD4 antibody (50 |ig/ml) was added and incubated for 30 minutes on ice 
in dark. After 30 minutes incubation, the cells were washed with cold staining buffer. 
After washing, 20 [i\ of mouse IgG (50|ig/ml) was added to the negative control tube 
and 20 |LI1 of PE-conjugated anti-mouse CDS antibody (50 ^ig/ml) was added to the 
test sample and incubated for 30 minutes on ice in dark. The cells were then washed 
twice with cold staining buffer and fixed with 0.5 ml of paraformaldehyde. The cells 
were analyzed by FACSort flow cytometry (Becton Dickinson) 
2.2.7 Measurement of Cytokine Production by ELISA 
Plasma from BALB/c mice treated with WECM for 21 days or cell culture 
supernatant from splenic lymphocytes of the BALB/c mice were subjected to test for 
the presence of cytokines such as IFN-y, IL-2, IL-4 and IL-6 by ELISA. It was 
carried out according to the manufacturer's protocol. Briefly, 100 [i\ of capture 
antibody diluted in coating buffer was added to each well of a 96-well ELISA plate 
arid incubated overnight at 4°C. After incubation, the wells were washed 3 times 
with wash buffer. The plate was blocked with assay diluent and incubated at room 
temperature for 1 hour. The plate was then washed with wash buffer for 3 times. 
After washing, 100 |LI1 of each standard, plasma or 200 |il of medium supernatant were 
added into the wells. The plate was sealed and incubated at room temperature for 3 
hours. The wells were then washed with wash buffer for 5 times. 100 of 
prepared working detector (detection antibody + avidin-HRP reagent) was added to 
each well and incubated for 1 hour at room temperature. After incubation, the wells 
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were washed with wash buffer for 5 times. 100 jil of substrate solution was added to 
each well and the plate was incubated for 30 minutes at room temperature in the dark. 
Finally, 50 [i\ of stop solution (2N sulphuric acid) was added to each well and the 
absorbance at 450 nm was read with ELISA plate reader (Bio-Rad). 
2.2.8 In Vivo Study of the Toxicity ofWECM 
The toxicity of WECM was examined by in vivo study. Male BALB/c 
mice aged 6 to 8 weeks were used. The mice were divided into 4 groups, each group 
contained 7 mice. One group was regarded as control group in which distilled water 
was administrated. For another 3 groups, different dosages of WECM (20, 40 and 
200 mg/kg/day) were fed consecutively for 21 days. After treatments, the mice were 
sacrificed and plasma was collected. The enzymatic activities of the plasma were 
measured by enzymatic diagnostic kits (Sigma). Four enzymes activities that are the 
indicators of heart or liver damage were examined. Increased activities of creatine 
kinase (CK) and lactate dehydrogenase (LDH) indicate heart tissue damage. While 
the increases of alanine transaminase (ALT) and aspartate transaminase (AST) 
indicate liver tissue damage. 
The procedures of measuring the enzymatic activities were according to the 
protocol of the enzymatic kits. In brief, for measuring CK and LDH activities, 20 [i\ 
and 50 of plasma was mixed with 1 ml of CK or LDH reagent, respectively. The 
mixture was then incubated at 30°C for 3 minutes and 30 seconds for CK and LDH, 
respectively. The absorbance was measured at 340 nm by spectrophotometer 
(Beckman) for 2 minutes and 1 minute for CK and LDH, respectively at 30 seconds 
interval. For measuring AST and ALT, 100 i^ il of plasma was mixed with 1 ml AST 
or ALT reagent and incubate at 37�C for 1 minute. Absorbance was measure at 340 
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nm at 30 seconds interval for 2 minutes. 
The enzymatic activities were calculated as follows: 
Enzymatic activity (U/L) = (AA per min x TV x 1000)/ (6.22 x LP x SV) 
where A A per min = change in absorbance per minute at 340 nm 
TV = total reaction volume (ml) 
LP = light path 
6.22 = millimolar absorptivity of NADPH at 340 nm 
SV = sample volume 
1000 = conversion of units per ml to per liter 
thus, CK (U/L) = AA per min x 8200 
LDH (U/L) = AA per min x 3376 
AST (U/L) = A A per min x 1768 
ALT (U/L) = A A per min x 1768 
One unit of activity is defined as the amount of enzyme, which produces 1 
|Limole ofNADH per minute under the condition of assay procedure. 
The mean value of the enzymatic activities of the same group was then 
plotted against the corresponding treatments. 
2.2.9 Cell Cycle Analysis 
HL-60, NB-4 cells (2x10^ cells/ml), HepG2 and R-HepG2 cells (1x10^ 
/ 
cells/ml) were seeded in a 6-well plate, incubated with various concentrations of 
WECM and cordycepin for 24 or 48 hours at 37°C, 5% CO2. After incubation, cells 
were collected and washed with PBS. Cells were then fixed with 1 ml of 70% 
ethanol at 4®C overnight. After fixation, cells were spun at 800 x g for 3 minutes to 
remove the ethanol. Cells were then resuspended in 0.46 ml freshly prepared 
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propidium iodide solution containing propidium iodide (43 |xg/ml) and RNase A 
(Img/ml) and incubated in dark at 37°C for 30 minutes. After incubation, the cells 
were analyzed by FACSort flow cytometry (Becton Dickinson). 
2.2.10 DNA Fragmentation Assay 
DNA fragmentation is one of the characteristics of apoptosis. HepG2 and 
R-HepG2 cells (1x10^ cells/ml) were seeded in a 100-mm culture dish and allowed to 
grow overnight at 37°C, 5% CO2 humidified incubator. The untreated cells acted as 
a control. Medium was then removed and various concentrations of cordycepin 
were added and incubated at 37°C, 5% CO2 for 24 and 48 hours. HL-60 and NB-4 
cells (2x10^ cells/ml) were incubated with various concentrations of cordycepin for 24 
and 48 hours. After treatment, cells were harvested and washed once with cold PBS 
and centrifugation at 800 x g for 3 minutes. The cell pellets were then lysed with 
200 1^1 DNA lysis buffer" for 15 minutes at ?>TC. The samples were centrifuged at 
6,000 X g for 5 minutes to collect the supematants containing the apoptotic DNA 
fragments. 50 |LI1 of 5% SDS was added and the supematants were incubated with 10 
塞）|Li l of RNase A (0.4 |ig/|il) at 56°C for 1.5 hours to remove the cellular RNA. 20 |il 
proteinase K (1.5 |Lig/|Lil) was then added and further incubate at 56�C for 1.5 hours to 
digest the protein debris. The DNA was then precipitated with 30 pi of 3 M sodium 
acetate and 750 \i\ of absolute ethanol. After centrifugation at 20,000 x g for 30 
minutes，the DNA pellets were washed with 70% ethanol and absolute ethanol, 
followed by air dry. The dried pellets were resuspended in 20 TioEo.i buffer and 
incubated at 37�C for 30 minutes. Finally the dissolved DNA was subjected to 1.5% 
agarose gel electrophoresis and DNA bands were visualized under ultraviolet 
illumination. 
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2.2.11 Cell Morphology Study 
Hepatocellular carcinoma cells and leukemia cells were evaluated for 
apoptosis by morphological assessment. Briefly, 3 ml of HepG2 and R-HepG2 cells 
(1x10^ cells/ml) or 2 ml of HL-60 and NB-4 cells (2x10^ cells/ml) were incubated 
with various concentrations of cordycepin in a 6-well plate at 37°C, 5% CO2 for 24 
hours. After treatment, HL-60 and NB-4 cells were washed with PBS and fixed onto 
a microscopic slide by cytocentrifiigation at 50 x g for 5 minutes using the Shandon 
Cytospin 3 centrifuge (Shandon Scientific Ltd.). While HepG2 and R-HepG2 cells 
were washed once with PBS. The cells were allowed to be air-dried. Then cells 
were stained with each Hemacolor staining solution for 15 seconds and destained with 
distilled water. Finally, the air-dried cells on the slides were mounted and the cell 
morphology was examined under the light microscope. 
2.2.12 Detection of Apoptotic Cells with Annexin V-FITC/PI 
TAGS™ Annexin V-FITC kit (Trevigen, Inc.) was used to examine early 
apoptosis and necrosis/late apoptosis. 10 ml of HL-60 and NB-4 cells (2x10^ 
cells/ml) were seeded in a 100 mm tissue culture dish and incubated with various 
concentrations of cordycepin at 37°C, 5% CO2 for 24 hours. After treatment, cells 
were harvested and washed twice with PBS. 5x10^ cells were used for the assay. 
100 |j.l of Annexin V incubation reagent containing 10 fj.1 of lOX binding buffer, 10 |J,1 
of PI, 1 1^1 of Annexin V-FITC conjugate and 79 |al of distilled water were added to 
the sample and incubated in the dark at room temperature for 15 minutes. After 
incubation, 400 of IX binding buffer was added to the sample and the sample was 
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analyzed by FACSort flow cytometry (Becton Dickinson). 
2.2.13 Detection of Mitochondrial Membrane Potential by JC-1 
Fluorescent Dye 
The mitochondrial membrane potential (ij/m) was examined by flow cytometry 
with fluorescent JC-1 dye. 2 ml of HL-60 or NB-4 cells (2x10^ cells/ml) were 
seeded to each well of a 6-well plate and incubated with various concentration of 
cordycepin at 37°C, 5% CO2 for 16 hours. After treatment, cells were harvested and 
washed twice with PBS. 2.5 x 10^  cells were resuspended in '500 |il of PBS 
containing 10 |j,M of JC-1. The samples were incubated in dark at 37°C for 15 
minutes and then were analyzed by FACSort flow cytometry (Becton Dickinson) 
(Yamada et al, 2003). 
2.2.14 Simultaneous Detection of Mitochondrial Membrane Potential 
and Intracellular Hydrogen Peroxide 
The intracellular hydrogen peroxide level can be examined by flow 
cytometry with fluorescent dye DCFH-DA. Mitochondrial membrane potential can 
also be examined simultaneously by the use of TMRE. 2 ml of HL-60 or NB-4 cells 
(2x10^ cells/ml) were seeded to each well of a 6-well plate and incubated with 
different concentrations of cordycepin for different periods of time. After treatment, 
cells were collected and washed twice with PBS. 2.5 x 10^  cells were resuspended 
in 500 1^1 of PBS with 500 nM TMRE and 10 |iM DCFH-DA. The samples were 
incubated at 37°C in dark for 15 minutes and then were analyzed by flow cytometry. 
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2.2.15 Western Blot Analysis 
2.2.15.1 Total Protein Extraction 
10 ml of HepG2 and R-HepG2 cells (1x10^ cells/ml) or HL-60 and NB-4 
cells (2x10^ cells/ml) were seeded in a 100-mm tissue culture dish and treated with 
various concentrations of cordycepin for 24 and 48 hours. After treatment, cells 
were collected and were washed twice with PBS. 40-100 |LI1 of lysis buffer (2% SDS, 
10% glycerol, 0.0625 M Tris-HCl, pH 6.8) was added and allowed to stand on ice for 
3 hours. Subsequently, samples were boiled for 10 minutes. The samples were then 
centrifuged at 1,5000 x g for 10 minutes at 4�C. After centrifugation, supernatant 
was collected and stored at -20°C. 
2.2.15.2 Determination of Protein Amount 
The amount of total protein extracted by SDS lysis buffer was determined by 
bicinchoninic acid (BCA) protein assay. 1 of each sample was mixed with 9 of 
distilled water in a 96-well plate. Bovine serum albumin (BSA) was used to 
establish the protein standard curve. Both protein samples and BSA standard were 
done in triplicate. BCA reaction mixture was composed of BCA (bicinchoninic acid) 
solution and CUSO4.5H2O solution in the ratio of 50:1. 200 |LI1 of BCA mixture was 
added to each well and incubated at 2>TC for 30 minutes. BCA mixture only was 
used as blank. After incubation, the absorbance at 540 nm was measured by ELISA 
plate reader (Bio-Rad). Fig 2.1 showed a standard curve of BSA. 
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Fig 2.1 BSA protein standard curve used for protein concentration 
determination. 
2.2.15.3 SDS Polyacrylamide Gel Electrophoresis 
The apparatus of 3D vertical electrophoresis system (Bio-Rad) was set « 
according to the user manual. 
According to the molecular weight of the target protein, different percentages 
of the separating gel were used. The composition was shown as follows: 
Table 2.3 The compositions of various percentage of SDS gel. 
Separating gel Stacking gel 
^ 12% 
Dialled water ~ 1 . 9 ml 1.375 ml 0.975 ml “ 1 . 2 ml 
30%Acrylamide 1.07 ml 1.6 ml 2 ml 0.3 ml 
4 X lower gel buffer 1 ml 1 ml 1 ml / 
4 X upper gel buffer / / / 0.5 ml 
TEMED 4.65 4.65 |il 4.65 }al 2.65 
10% APS ‘ ^ ^ 1 5 ^ 
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According to the BSA standard curve, equal amount of protein samples 
(25-50 i^g) were used for SDS-gel electrophoresis. Protein samples were mixed with 
equal volume of 2 x SDS loading dye and boiled for 10 minutes. Then samples were 
loaded to the well of the polyacrylamide gel with rainbow coloured protein molecular 
marker (Amersham). The gel was run under constant voltage of 110 V for about 2 
hours. 
2.2.15.4 Electroblotting of Protein 
The apparatus of Semi-Dry Electrophoretic Transfer Cell (semi-dry blotter,. 
Bio-Rad) was set referring to the steps the in manual. 
Polyvinylidene difluoride membrane (PVDF, 0.45 jam) (Immobilon, 
Millipore) was used for electroblotting. The dry PVDF membrane was first soaked 
in absolute methanol for re-hydration. Membrane was then put in the electroblotting 
buffer (E-blot buffer) for a few seconds. Three pieces of blotter paper were soaked 
in E-Blot buffer and put onto the platinum anode. The membrane was put onto the 
blotter papers followed by the acrylamide gel (the upper stacking gel was cut and 
removed). Air bubbles were excluded by rolling. Another 3 pieces of E-blot 
buffer-soaked blotter paper were put onto the gel. The proteins were transferred at 
constant current at 150 mA for 2 gels for 20-60 minutes. After blotting, the gel was 
stained with commassie blue staining solution and destaining solution to check the 
completeness of transfer. 
2.2.15.5 Probing of Proteins with Antibodies 
The membrane was blocked in 10% non-fat milk (in TBS-T) at room 
temperature for 1-2 hours. It was washed with TBS-T for 15 minutes for 3 times. 
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Then, primary antibody in 10% non-fat milk was added for probing at 4°C overnight. 
After probing, the membrane was washed with TBS-T for 15 minutes for 3 times and 
probed with secondary antibody (conjugated with horseradish peroxidase) at room 
temperature for 1 hour. The membrane was washed again with TBS-T for 3 times 
and it was ready for ECL detection. The dilution ratio of antibodies was listed at 
Table 2.4. 
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Table: 2.4 List of the antibodies used with the corresponding target protein 
molecular weights and dilution ratios.  
Molecular weight 
Antibodies of the target protein Ratio 
(kDa) 
Anti--act in 42 1 ： 5000 
Anti-Bax ^ 1 ： 300 
— A n t i - B c l - 2 ^ 1 ： 1000 
“ Anti-Bcl-X “ ^ 1 ： 1000 
Anti-Bid 
Anti-caspase-3 ^ 1 ： 1000 
Aiiti-caspase-8 ^ 1 ： 1000 
/ . - - Anti-caspase-9 48 1 : 500 
“ A n t i - c d c 2 M 1 ： 1000 
Anti-cyclin A ^ 1 ：1000 
Anti-cyclin B ^ 1:500 
Anti-cytochrome c 15 1:500 
Anti-Fas . 48 1 ： 1000 
Anti-c-myc ^ 1 ： 500 
Anti-PARP 116,85 1 ： 1000 
Anti-p21 21 1 :500 
^ A m i i ^ « 1 ： 1000 
‘ Anti-goat-HRP conjugate / 1 ： 1000 
Anti-mouse-HRP c o n j u g a t e / 1 ： 1000 
，Anti-rabbit-HRP conjugate / 1 ： 1000 
* 
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2.2.15.6 Enhanced Chemiluminescence (ECL) Assay 
After probing with antibody, the target protein can be detected by using 
ECL assay. ECL detection reagent 1 and reagent 2 (Amersham) were mixed in the 
ratio of 1:1 and the membrane was immersed in the mixture for 90 seconds. Then 
the membrane was wrapped and put into the Hypersensitive film cassette (Amersham) 
followed by a Fuji Medical x-ray film (Super Rx, Fuji) in dark with various exposure 
time. The film was then developed by a film processor (M35 X-OMAT, Kodak) and 
the band intensity was analyzed by ImageQuant software (Molecular Dynamics). 
2.2.15.7 Extraction of Cytosolic Protein 
20 ml of HL-60 or NB-4 cells (2x10^ cells/ml) were seeded into a 100 mm 
culture dish and incubated with various concentrations of cordycepin. After 
treatment, cells were harvested and washed with PBS for 2 times. 3x10^ cells of 
each sample were used for assay. 50 |il of lysis buffer (75 mM NaCl, 1 mM 
NaH2P04, 8 mM NasHPCU，250 mM sucrose, 21 |ig/ml aprotinin, 5 [ig/m\ leupeptin, 
1 mM PMSF and 25 |ig digitonin) was added to 3 x 10^  cells and vortexed vigorously 
for 30 seconds followed by centrifugation at 8,000 x g for 1 minute at room 
temperature immediately (Li et aL, 2002). The supernatant was collected and mixed 
with equal volume of 2X SDS loading dye and boiled for 10 minutes. Then, the 
samples were subjected to centrifugation at 11,000 x g for 7 minutes at 4°C. The 
supernatant collected was used to run SDS-PAGE or stored at -70°C. For running 
SDS-PAGE, the samples were boiled for 5 minutes and 20 |il of each sample was 
loaded to the well of a 12% SDS gel. The procedures of electrophoresis and western 
blotting were the same as total protein extraction mentioned above. 
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2.2.16 Determination of Caspases Enzymatic Activity 
2.2.16.1 Extraction of Proteins 
40 ml of HL-60 or NB-4 cells (2x10^ cells/ml) were seeded into a 150 cm^ 
tissue culture flask and incubated with 150 [iM of cordycepin at 37°C, 5% CO2 
humidified incubator for 18 and 24 hours. After treatment, cells were collected and 
were washed twice with PBS. Cells were counted and were centrifuge at 800 x g for 
3 minutes to collect the cell pellet. The pellet was stored at -70�C for later use. In 
order to resuspend and lyse the cell pellet, 100 |il of chilled lysis buffer (1% Igepal 
CA-630, 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, protease inhibitor, pH 7.5) • 
was added to 5 x 10^  cells. The cells were allowed to stand on ice for 10 minutes. 
Then the cell lysate was centrifuged at 20,000 x g for 10 minutes at 4°C to precipitate 
the cell debris. The supernatant was collected and the protein concentration of each 
sample was determined by BCA assay as mentioned before. 
2.2.16.2 Determination of Caspase-3 Activity 
50 i^ g of protein of each sample was used for measuring caspase-3 activity. 
90 of reaction buffer supplemented with 10 mM DTT were added to each well of a 
96-well plate. In order to confirm that the increase of substrate signal is due to 
caspase-3 activity, caspase-3 specific inhibitor z-DEVD-fmk was added before the 
addition of substrate. Lysate containing 50 of protein sample was added and 1 i^l 
of 1 mM z-DEVD-fmk was added to the wells. To ensure all samples are tested 
under similar conditions, 1 i^l of DMSO was added to the samples that without the 
addition of inhibitor. They were incubated on ice for 30 minutes. After incubation, 
2.5.^1 of 2 mM (final concentration 50 |iM) fluorescent AMC conjugated caspase-3 
specific substrate Ac-DEVD-AMC was added to each well (including the wells with 
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inhibitor) and the plate was incubated at 37°C for 1 hour in dark (Mack et a!., 2000). 
A well without cell lysate but containing reaction buffer was served as blank. A 
standard curve of AMC was set as the following concentrations 0，0.625, 1.25, 2.5 and 
5 |aM. After incubation, the fluorescent intensity was measured by a fluorescent 
microplate reader (CytoFluo™, Millipore). The excitation and emission wavelength 
are 390 nm and 460 nm, respectively. The sensitivity of the scanning was 
maximized. According to the standard AMC fluorescent curve (Fig 2.2), the amount 
of AMC released from the conjugated substrate can be calculated. 
2.2.16.3 Determination of Caspase-8 Activity 
For measuring caspase-8 activity, 100 |ig of protein was used. Similarly, 
90 1^1 of reaction buffer supplemented with 10 mM DTT were added to each well of a 
96-well plate. In order to confirm the increase of substrate signal is due to caspase-8 
activity, caspase-8 specific inhibitor z-IETD-fmk was added before the addition of 
substrate. Lysate containing 100 \ig of protein sample was added and 1 \i\ of 1 mM 
z-IETD-fmk was added to the wells and incubated on ice for 30 minute. To ensure 
all samples are tested under similar conditions, 1 |il of DMSO was added to the 
samples that without the addition of inhibitor. After incubation, 2.5 \i\ of 2 mM 
(final concentration 50 |aM) fluorescent AMC conjugated caspase-8 specific substrate 
Ac-IETD-AMC was added to each well (including the wells with inhibitor) and the 
plate was incubated at 3TC for 1 hour in dark. A well without cell lysate but 
containing reaction buffer was served as blank. A standard curve of AMC was set as 
the following concentrations: 0, 0.625, 1.25, 2.5 and 5 jiM. After incubation, the 
fluorescent intensity was measured by a fluorescent microplate reader (CytoFluo ， 
Millipore). The excitation and emission wavelength were 390 nm and 460 nm, 
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respectively. The sensitivity of the scanning was maximized. The amount of AMC 
released from the conjugated substrate was calculated. 
2.2.16.4 Determination of Caspase-9 Activity 
For measuring caspase-9 activity, 100 of protein was used. Similarly, 90 
of reaction buffer supplemented with 10 mM DTT were added to wells of a 96-well 
plate. In order to confirm the increase of substrate signal is due to caspase-9 activity, 
caspase-9 specific inhibitor z-LEHD-fmk was added before addition of substrate. 
Lysate containing 100 |Lig of protein sample was added and 1 |LI1 of 5 mM 
z-LEDH-fmk was added to the wells and incubated on ice for 30 minutes. To ensure 
all samples are tested under similar conditions, 1 |il of DMSO was added to the 
samples that without the addition of inhibitor. After incubation 5 |LX1 of 5 mM (final 
concentration 250 fluorescent AFC conjugated caspase-9 specific substrate 
Ac-IETD-AFC was added to each well (including the wells with inhibitor) and the 
plate was incubated at 2>TC for 1 hour in dark. A well without cell lysate but 
containing reaction buffer was served as blank. A standard curve of AFC was set as 
the following concentrations: 0, 0.5, 1，2 and 4 |LIM. After incubation, the 
fluorescent intensity was measured by a fluorescent microplate reader (CytoFluo™, 
Millipore). The excitation and emission wavelength were 400 nm and 505 nm 
respectively. The sensitivity of the scanning was maximized. According to the 
standard AFC fluorescent curve (Fig 2.2), the amount of AFC released from the 
conjugated substrate can be calculated. 
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Fig 2.2 Standard curves of AMC and AFC for the determination of caspases 
activities. 
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2.2.17 Hemolysis Assay 
The hemolytic activity of cordycepin was studied by red blood cell (RBC) 
hemolysis assay. Blood was collected from the heart of 6 - 8 weeks male BALB/c 
mice with 20 |j,l of heparin (50 units/ml). The blood collected was centrifuged at 
1,500 X g for 10 minutes at 4°C. The supernatant was removed. The pellet that 
contained mostly RBC was washed with 0.15 M NaCl and centrifuged at 1,500 x g for 
10 minutes at 4°C for two times. Then the pellet was washed again with 0.15 M 
NaCl and centrifuged at 1,000 x g for 10 minutes at 4°C. The pellet obtained was 
resuspended in PBS to prepare 20% RBC suspension. 50 [i\ of the 20% RBC 
suspension was then mixed with 50 \i\ of various concentrations of cordycepin. The 
reaction mixture was incubated at 3TC for 24 hours with gentle shaking. After 
incubation, 15 |j,l of each of the reaction mixture was added to 285 |j.l of distilled 
water (for total lysis) and PBS, respectively and were centrifuged at 1,500 x g for 10 
( 
minutes at 4°C. 200 )j,l of the supernatant was then transferred to a 96-well plate and 
the absorbance was measured by ELISA plate reader at 540 nm (Bio-Rad). The 
percentage of hemolysis was directly proportional to the absorbance. The 
percentage of hemolysis would be calculated as follows: 
% Hemolysis = {1- [(Abs of H2O - Abs of PBS) / Abs of H2O] } x 100% 
2.2.18 Measurement of Intracellular Doxorubicin Accumulation 
The intracellular doxorubicin accumulation in HepG2 and R-HepG2 cells 
can be measured by flow cytometry. HepG2 and R-HepG2 cells (1x10^ cells/ml) 
were seeded in a 6-well plate and incubated with various concentrations of 
doxorubicin for 3 hours at 37°C，5% CO2. Red signals generated from intracellular 
• — — 
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doxorubicin were determined by flow cytometry. To test whether WECM and 
cordycepin can increase the doxorubicin accumulation in R-HepG2 cells. 
Intracellular doxorubicin accumulation was measured after pretreatment of cells with 
WECM and cordycepin. In brief, R-HepG2 cells (1x10^ cells/ml) were seeded in a 
6-well plate and incubated with 100 )ig/ml of WECM or 100 i^M of cordycepin at 
37°C, 5% CO2 for 24 hours. After 24 hours incubation, R-HepG2 cells were further 
incubated with 4 |aM of doxorubicin for 3 hours. After incubation, flow cytometry 
was carried out to determine the intracellular doxorubicin accumulation. 
< 
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Chapter 3 Anti-tumor and Immunomodulatory Effects of Cordyceps Militaris 
3.1 In Vitro Anti-tumor Study of Water Extract of Cordyceps 
militaris (WECM) 
Cordyceps sinensis has been used as a traditional Chinese medicine for a 
long time and its biological and pharmacological functions were widely studied in the 
past (Zhu et aL, 1998a; Zhu et al., 1998b; Wang & Shiao，2000). Cordyceps sinensis 
was found to inhibit the growth of a number of tumor cells such as K562, Jurkat, 
HL-60, U937, Sarcoma 180, Ehrilich ascites carcinoma (EAC), Meth A fibrosarcoma 
(Meth A), Lewis lung carcinoma (LLC) and B16 melanoma (B16) cells in in vitro and 
in vivo studies (Du, 1986; Yoshida et aL, 1989; Kuo et aL, 1994; Chen et al” 1997b; 
Bok et al., 1999; Nakamura et al., 1999a). Cordyceps militaris belongs to the 
Cordycpes family. However, not much of research work was conducted with 
Cordycpes militaris on its biological functions. In my study, the anti-tumor effect of 
WECM was investigated by using different human tumor cell lines like HL-60, NB-4, 
HepG2，R-HepG2 and mouse Sarcoma 180 (SC-180). 
The anti-tumor effect of WECM was initially studied by the use of 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT). MTT is 
cleaved to a colored water insoluble formazan by the succinate-tetrazolium reductase 
in metabolically active cells. After it is solubilized, the formazan formed can be 
quantitated by ELISA plate reader. The percentage of survival after the treatment of 
cells with WECM can be found by comparing with the control cells. 
In my study, HL-60, NB-4, HepG2, R-HepG2 and SC-180 cells were 
incubated with various concentrations of WECM for 24 and 48 hours. The 
percentage of survival of HL-60 and NB-4 cells was decreased with increasing 
concentrations of WECM (Fig. 3.1). The IC50 values of WECM on HL-60 cells for 
24 and 48 hours treatment were found to be 65 fig/ml and 46 ^g/ml, respectively. 
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The IC50 values of WECM on NB-4 cells for 24 and 48 hours treatment were found to 
be 52 |Lig/ml and 40 |ag/ml, respectively. For HepG2 and R-HepG2 cells, WECM 
inhibited the growth of HepG2 and R-HepG2 cells in a dose- and time-dependent 
manner (Fig. 3.2). The IC50 values of WECM on HepG2 cells for 24 and 48 hours 
treatment were found to be 223 |ig/ml and 128 |ig/ml, respectively. While the IC50 
values of WECM on R-HepG2 cells for 24 and 48 hours treatment were found to be 
193 |Lig/ml and 110 ^ig/ml，respectively. WECM also inhibited the growth of SC-180 
cells in a dose- and time-dependent manner (Fig.3.3). The IC50 values of SC-180 
cells for 24 and 48 hours treatment were found to be 78 |ig/ml and 23 |Lig/ml,‘ 
respectively. Table 3.1 summarizes the IC50 values of WECM on HL-60, NB-4, 
HepG2, R-HepG2 and SC-180 cells with different incubation times. According to 
the IC50 values, it was found that HL-60, NB-4 and SC-180 cells are more sensitive to 
the WECM than HepG2 and R-HepG2 cells. Since HL-60, NB-4 and SC-180 cells 
are non-adhesive cells in suspension while HepG2 and R-HepG2 cells are adhesive 
cells, adhesive cells may be tougher and less sensitive to the drug. 
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Fig. 3.1 Anti-proliferative effect of WECM on HL-60 and NB-4 cells. HL-60 (A) 
and NB-4 (B) cells (2xl0^cells/ml) were seeded in a 96-well plate and incubated with 
various concentrations of WECM for 24 and 48 hours at 37°C，5% CO2. After 
treatment, the cell viability was determined by MTT assay. The percentage of 
survival was calculated relative to the control (100 %). Data are expressed as the 
mean 土 SD of six determinations. 
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Fig. '3.2 Anti-proliferative effect of WECM on HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (IxlO^cells/ml) were seeded in a 96-well plate and 
incubated with various concentrations of WECM for 24 and 48 hours at 37°C, 5% 
CO2. After treatment, the cell viability was determined by MTT assay. The 
percentage of survival was calculated relative to the control (100 %). Data are 
expressed as the mean 土 SD of six determinations. 
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Fig. 3.3 Anti-proliferative effect of WECM on SC-180 cells. SC-180 cells 
(2xl0^cells/ml) were seeded in a 96-well plate and incubated with various 
concentrations of WECM for 24 and 48 hours at 37°C, 5% CO2. After treatment, the 
cell viability was determined by MTT assay. The percentage of survival was 
calculated relative to the control (100 %)• Data are expressed as the mean 土 SD of 
six determinations. 
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Table 3.1 List of the IC50 values of WECM on HL-60, NB-4, HepG2, R-HepG2 
and SC-180 cells for 24 and 48 hours treatment.  
V:, 令域f 24 hr n 48 hr 
> 、；、》、 / ‘ 、、、\、 ‘ s 、；^ ：$ 
i t 書 卜 。 。 ： � � “ 65 I^g/ml 46 lag/ml 
‘ 52 i^g/ml 40 [ig/m\ 
始iV。:、： .： - . ’ 
~ “ 223 ^ig/ml 128 ^g/ml 
I ^ w n ^  
::？ I , .H；^；,,, I ,：, 二 “ . f e i i �乂 ；’广专K  
SC-180 ^ 八、>、‘ ':、、r ： � \ 78 |ig/ml 23 |ag/ml 
. � ” • �： - f 狄：] 
HL-60, NB-4，SC-180 (2xl0^cells/ml), HepG2 and R-HepG2 (IxlO^cells/ml) cells 
were seeded in a 96-well plate and incubated with various concentrations of WECM 
for 24 and 48 hours, respectively at 37°C, 5% CO2. After treatment, the cell 
viability was determined by MTT assay. IC50 was then calculated. Data are 
representative of three independent experiments. 
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3.2 In Vitro Study of Immunomodulatoy Effect of WECM 
Cordyceps sinensis has been found to have immunostimulatory functions 
such as increase in the number of phagocytes in spleen, stimulation of splenocytes 
proliferation and increase in natural killer cells (NK cells) activity (Chen, 1985; 
Zhang, 1990; Xu et aL, 1992; Liu et al., 1992). However, the immunomodulatory 
effect of Cordyceps militaris is not clear. In order to investigate the effect of 
Cordyceps militaris on splenic lymphocytes proliferation, lymphocytes were isolated 
from the spleen of BALB/c mice and incubated with various concentrations of 
WECM for 3 days. Cell proliferation was determined by tritiated thymidine uptake.‘ 
As shown in Fig. 3.4，WECM could stimulate the proliferation of splenic lymphocytes. 
At 0.4 and 0.5 |ig/ml of WECM, a 3-fold increase in splenic lymphocytes 
proliferation was observed. Concanavalin A, (Con A) a mitogen that activates T cell, 
0.5 i^g/ml of Con A was served as a positive control which caused about 5-fold 
increase in proliferation of splenic lymphocytes. 
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Fig. 3.4 The effect of WECM on splenic lymphocytes proliferation. Splenic 
lymphocytes (2x10^ cells/well) were seeded in a 96-well plate and treated with 
various concentrations of WECM or Con A (0.5 |ig/ml) for 3 days at 37°C, 5 % CO2. 
The proliferation of cells was detected by tritiated thymidine uptake. After 6 hours 
incubation with [^H]-thymidine, cells were harvested by cell harvester and 
radioactivity was measured by scintillation counter. Values represent the mean 土 SD 
of six determinations. 
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3.3 In Vivo Anti-tumor Study of WECM 
It has been reported that Cordyceps sinensis and Cordyceps militaris can 
inhibit the growth of tumor and prolong the survival period of mice with inoculated 
Sarcoma 180 (Liu et al., 1997). In order to investigate whether WECM can inhibit 
the growth of SC-180 in vivo, BALB/c mice were inoculated with SC-180 (5x10^ 
cells) subcutaneously. After 7 days of inoculation, BALB/c mice were fed with 
different dosages (20 mg/kg/day, 40 mg/kg/day and 200 mg/kg/day) of WECM for 
further 21 days, while the control group was fed with distilled water. After 21-day 
treatment, the BALB/c mice were sacrificed and tumor weight was measured. 
At the end of experiment, all groups of BALB/c mice were surviving. For 
the group of 20 mg/kg/day, no significant decrease of tumor weight was observed. 
While the group of 40 mg/kg/day, WECM inhibited the growth of tumor by 92 %. 
For the 200 mg/kg/day treatment group, the growth of tumor was inhibited by 60 % 
(Fig. 3.5). The relative size of tumor for different groups was shown in Fig. 3.6. 
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Fig. 3.5 Tumor weight of SC-180 isolated from BALB/c mice treated with 
WECM for 21 一 days. BALB/c mice in groups of 7 were inoculated with 5x10^ 
SC-180 cells subcutaneously for 7 days. After 7 days of inoculation, BALB/c mice 
were fed with distilled water, 20 mg/kg/day, 40 mg/kg/day or 200 mg/kg/day of 
WECM for further 21 days consecutively. At the end of experiment, mice were 
sacrificed and tumor weight was measured. Values are mean 土 SD of seven 
determinations. *p<0.05, **p<0.01 compared with the control. 
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Fig. 3.6 I^mor size of SC-180 isolated from BALB/c mice treated with WECM 
for 21 days. BALB/c mice in groups of 7 were inoculated with 5x10^ SC-180 cells 
subcutaneously for 7 days. After 7 days of inoculation, BALB/c mice were fed with 
distilled water, 20 mg/kg/day, 40 mg/kg/day or 200 mg/kg/day of WECM for further 
21 days consecutively. At the end of experiment, mice were sacrificed and tumors 
were removed and weighted. 
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3.4 Anti-tumor Effect of WECM Mediated by Stimulating 
T-cell Proliferation 
Although we have found that WECM can inhibit the growth of tumor in vivo, 
the action mechanism is unclear. Since T lymphocytes play an important role in cell 
mediated immunity against tumor cells, and Cordyceps sinensis has been found to 
increase the number of T helper cells and increase the ratio of T helper to T suppressor 
cell (Chen et al., 1991), the mechanism of WECM to inhibit tumor growth in vivo 
may involve stimulation of T cells proliferation. 
Large numbers of lymphocytes are produced in the primary lymphoid 
organs such as bone marrow and thymus. The secondary lymphoid organs such as 
spleen and lymph nodes are responsible for lymphocyte interaction with antigen, other 
immune cells and accessory cells. In our experiment, lymphocytes were isolated 
from the spleen of BALB/c mice that treated with WECM for 21 days. As CD3 is a 
molecular marker unique to T lymphocytes, the proportion of T lymphocytes in the 
spleen was investigated by flow cytometric analysis after staining the cells with 
FITC-conjugated anti-CD3 antibody. As shown in Fig. 3.7B-C, the proportion of T 
•  lymphocytes in control group was 19.95 %, while the proportion of T lymphocytes in 
20 mg/kg/day treatment group was 21.24 %. Treatment of BALB/c mice with 40 
mg/kg/day and 200 mg/kg/day of WECM caused the proportion of T lymphocytes 
increased from 19.95 % of the control to 35.82 % and 29.86 %, respectively (Fig. 
3.7D-E). This indicated that the anti-tumor effect of WECM may be mediated by a 
stimulation of the proliferation of T lymphocytes. 
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Fig. 3.7 Increase of T cells in splenic lymphocytes of BALB/c mice after 21 days 
treatment. Splenic lymphocytes (2.5 x 10^  cells) isolated from BALB/c mice 
treated with various dosages of WECM or distilled water alone for 21 days were 
stained with anti-CD3 antibody and flow cytometric analysis was carried out. (A) 
Control cells incubated without anti-CD3 antibody, (B) control, (C) 20 mg/kg/day, (D) 
40 mg/kg/day and (E) 200 mg/kg/day of WECM. 
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T cells can be subdivided into cytotoxic T (Tc) cells and helper T (Th) cells 
based upon the cell surface markers and functions. T cells that bear the CD4 surface 
marker are known as helper T cells and respond to antigen complexed with the MHC 
class II molecule. T cells that bear CDS surface marker are cytotoxic T cells and 
respond to antigen complexed with the MHC class I molecule (Wise & Carter，2002). 
In order to investigate whether WECM can stimulate Th or Tc cells, the splenic 
lymphocytes were stained with FITC-conjugated anti-CD4 and PE-conjugated 
anti-CD8 antibody and flow cytometry was carried out. 
The results are indicated in Fig. 3.8 where R1 represents the double negative 
non-T cells, R2 represents the CDS positive Tc cells and R3 represents CD4 positive 
Th cells. It was found that treatment of BALB/c mice with 20 mg/kg/day of WECM 
did not cause a significant increase in Tc and Th cells (Fig. 3.8C). However, a 
significant increase in Tc and Th cells was observed in the groups of 40 mg/kg/day and 
200 mg/kg/day of WECM (Fig. 3.8 D-E). This indicated that the anti-tumor effect of 
WECM might associate with the increase of Tc and Th cells. 
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Fig. 3.8 Increase of CD4+ and CD8+ T cells in splenic lymphocytes of BALB/c 
mice after 21 days treatment. Splenic lymphocytes (2.5x10^ cells) isolated from 
BALB/c mice that treated with various dosages of WECM for 21 days were stained 
with anti-CD4 and anti-CD8 antibody. Flow cytometric analysis was carried out. 
(A) Negative control without anti-CD4 nor -CDS antibody, (B) control, (C) 20 
mg/kg/day, (D) 40 mg/kg/day and (E) 200 mg/kg/day of WECM. 
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Cytokines play an important role in the induction of cell differentiation into 
a specific lineage. A single Th cell precursor is able to differentiate into either Thl or 
Th2 subsets and two subsets of CD4+ T cells can be identified by the distinct spectrum 
of cytokine they secrete. The Thl subset has been shown to produce IL-2 and IFN-y, 
while the Th2 subset has been shown to produce IL-4, IL-5, IL-6, IL-10 and IL-13. 
CD8+T cells also have distinct cytokine secretion profiles. Tel subsets were shown 
to produce IL-2, IFN-y and TNF-a, while Tc2 subsets were shown to produce IL-4, 
IL-5 and IL-10 (Groux & Yssel, 1999; Marini & Cohen，2000). In order to 
investigate which subsets of CD4+ and CD8+ T cell were activated in response to 
WECM treatment, the level of IL-2, IFN-y, IL-4, IL-6 released by the splenic 
lymphocytes isolated from BALB/c mice were determined by ELISA. 
As shown in Fig. 3.9，there was a 1.5-fold and 2-fold increase in IL-2 
secretion by the splenic lymphocytes of 40 mg/kg/day and 200 mg/kg/day treatment 
group，respectively. There was no significant difference in the plasma IFN-y level 
among different groups of BALB/c mice (Fig. 3.10A). However, the IFN-y released 
by splenic lymphocytes was significantly increased in the group of 40 mg/kg/day and 
200 mg/kg/day (Fig. 3.1 OB). 
For IL-4, no increase in IL-4 secretion by the splenic lymphocytes was 
observed in all groups of treatment (Fig. 3.11). There was a significant increase in 
IL-6 released by splenic lymphocytes of 200 mg/kg/day treatment group but not 
increase in the other groups (Fig. 3.12). The increase of IL-2 and IFN-y secretion 
and no increase in IL-4 secretion by the splenic lymphocytes suggested that the CD4+ 
and CD8+ T cells activated by WECM are Thl and Tel subsets, respectively. 
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Fig. 3.9 IL-2 released by splenic lymphocytes of BALB/c mice treated with 
WECM for 21 days. Lymphocytes isolated from the spleen of BALB/c mice that 
treated with various dosages of WECM for 21 days were seeded in a 6-well plate 
(IxlO^cells/ml) and incubated at 37°C, 5 % CO2 for 24 hours. After 24 hours 
incubation, cell culture supernatant was collected and subjected to determination of 
IL-2 by ELISA. Values are mean 士 SD of three determinations. *p<0.01 compared 
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Fig. 3.10 Plasma IFN-y level and IFN-y secreted by splenic lymphocytes of 
• BALB/c mice treated with WECM for 21 days. (A) IFN-y level in plasma of 
BALB/c mice that treated with various dosages of WECM for 21 days. Values are 
mean 土 SD of seven determinations. (B) Lymphocytes isolated from the spleen of 
BALB/c mice that treated with various dosages of WECM for 21 days were seeded in 
a 6-well plate (IxlO^cells/ml) and incubated at 37°C, 5 % CO2 for 48 hours. After 
48 • hours incubation, cell culture supernatant was collected and subjected to 
determination of IFN-y by ELISA. Values are mean 土 SD of three determinations. 
* p<0.01 compared with the control. 
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Fig. 3.11 IL-4 released by splenic lymphocytes of BALB/c mice treated with 
WECM for 21 days. Lymphocytes isolated from the spleen of BALB/c mice that 
treated with various dosages of WECM for 21 days were seeded in a 6-well plate 
(IxlO^cells/ml) and incubated at 37°C, 5 % CO2 for 48 hours. After 48 hours 
incubation, cell culture supernatant was collected and subjected to determination of 
IL-4 by ELISA. Values are mean 土 SD of three determinations. 
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Fig. 3.12 IL-6 released by splenic lymphocytes of BALB/c mice treated with 
WECM for 21 days. Lymphocytes isolated from the spleen of BALB/c mice that 
treated with various dosages of WECM for 21 days were seeded in a 6-well plate 
(IxlO^cells/ml) and incubated at 37°C, 5 % CO2 for 72 hours. After 72 hours 
incubation, cell culture supernatant was collected and subjected to determination of 
IL-6 by ELISA. Values are mean 土 SD of three determinations. *p<0.05 compared 
with the control. 
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3.5 Toxicity Studies of WECM 
Apart from studying the anti-tumor effect and immunomodulatory effect of 
WECM, toxicity study was also conducted. At the end of the 21-day treatment with 
different dosages of WECM, the BALB/c mice were sacrificed and plasma was 
collected. Plasma enzyme activity of creatine kinase (CK), lactate dehydrogenase 
(LDH), aspartate transaminase (AST) and alanine transaminase (ALT) were measured. 
CK, LDH and AST are predominantly found in the heart. When the heart is 
damaged, CK, LDH and AST will be released into the blood. Therefore, any 
increase in plasma CK and LDH activity indicated the damage of heart tissue. AST, 
ALT and LDH are predominantly found in the liver. Damage of liver will cause the 
release of AST, ALT and LDH into the blood. As a result, increase in plasma AST 
and ALT activity indicated the damage of liver tissue. 
From our results, there was no significant increase in CK, LDH, AST and 
ALT activity in the plasma of BALB/c mice that were treated with different dosages 
of WECM (Fig. 3.13. and Fig. 3.14). This indicated that WECM is not toxic to the 
heart and liver. 
In order to study the cytotoxicity of WECM in vitro, human normal hepatic 
cell line WRL-68 was used. WRL-68 is a non-tumorigenie cell line derived from 
fetal liver. Some morphological and functional characteristics of WRL-68 are 
similar to hepatoctyes and hepatic primary cultures (Gutierrez-Ruiz et al., 1994; 
Ramirez et aL, 2000). In the study, WRL-68 cells were treated with various 
concentrations of WECM for 24 and 48 hours, MTT assay was then carried out. It 
was found that at the concentration of 50 to 200 |ig/ml of WECM which inhibited the 
growth of tumor cells by over 50%, only showed a slight cytotoxic effect on normal 
liver cells WRL-68 (Fig. 3.15). Therefore, WECM is relatively less toxic to the 
. -
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normal liver cells. 
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Fig. .3.13 In vivo study of the toxicity of WECM by measuring the plasma 
enzymes CK and LDH. BALB/c mice were fed with various dosages of WECM as 
indicated for 21 days. After treatment, mice were sacrificed and plasma was 
collected. Plasma CK (A) and LDH (B) activity was measured. Values are mean 土 
SD of seven determinations. 
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Fig. 3.14 In vivo study of the toxicity of WECM by measuring the plasma 
enzymes AST and ALT. BALB/c mice were fed with various dosages of WECM as 
indicated for 21 days. After treatment, mice were sacrificed and plasma was 
collected. Plasma AST (A) and ALT (B) activity was measured. Values are mean 士 
SD of seven determinations. *p<0.05 compared with the control. 
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Fig. 3.15 Cytotoxicity of WECM on WRL-68 cells. WRL-68 cells (2x10^ 
cells/ml) were seed in a 96-well plate and incubated with various concentrations of 
WECM for 24 and 48 hours, respectively at 37°C, 5% CO2. After treatment, the cell 
viability was determined by MTT assay. The percentage of survival was calculated 
relative to the control that is expressed as 100 %. Data are expressed as the mean 土 
SD of six determinations. 
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4.1 Anti-proliferative Study of D-mannitol, Adenosine and 
Cordycepin (3'-deoxyadenosine) 
From the previous Chapter, it was found that WECM inhibited the growth of 
human tumor cells HepG2, R-HepG2, HL-60, NB-4 and mouse tumor cells SC-180. 
However, we have no idea about the components in the WECM that caused the 
growth inhibition of tumor cells. Chemical constituents of Cordyceps sinensis 
include polysaccharides, sugar derivatives (e.g. D-mannitol), proteins, sterols, fatty 
acids, vitamins, trace elements, nucleosides and nitrogen bases such as uracil, guanine, 
uridine, guanosine and adenosine (Shiao et al., 1989; Shiao et aL’ 1994; Zhu et al., 
1998a). Several constituents such as p-sitosterol, ergosterol, D-mannitol, uracil, 
guanine, uridine, guanosine, adenine, adenosine and cordycepin were found in 
Cordycpes militaris (Kaczka et al., 1964; Shiao et al., 1989; Liu et al, 1989; Shiao et 
al., 1994; Guo'et al, 1998). Among these chemical constituents of Cordyceps 
militaris, D-mannitol, adenosine and cordycepin that are commercially available as 
pure compounds were chosen to investigate their anti-proliferative effect on human 
tumor cells such as HL-60, NB-4, HepG2 and R-HepG2 cells. 
“ The anti-proliferative effect of D-mannitol, adenosine and cordycepin on 
these human tumor cells was studied by MTT assay. As showed in Fig. 4.1，there 
was no significant growth inhibition in the HepG2, R-HepG2, HL-60 and NB-4 cells 
after the treatment of cells with D-mannitol for 48 hours. While adenosine inhibited 
the growth of these tumor cells slightly in the 48 hours treatment (Fig 4.2). However, 
cordycepin inhibited the growth of HL-60, NB-4, HepG2 and R-HepG2 cells 
significantly in a dose-dependent manner in both 24 and 48 hours treatment (Fig. 4.3 
and Fig. 4.4). The IC50 values of cordycepin on different cell lines are summarized 
in Table 4.1. Since cordycepin could inhibit the growth of human tumor cells, it 
- — -
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Fig. 4.1 Anti-proliferative effect of D-mannitol on HepG2, R-HepG2, HL-60 and 
NB-4 cells. HepG2, R-HepG (IxlO^cells/ml), HL-60 and NB-4 cells (2xl0^cells/ml) 
were seeded in a 96-well plate and incubated with various concentrations of 
D-mannitol for 48 hours at 37°C, 5% CO2. After treatment, the cell viability was 
determined by MTT assay. The percentage of survival was calculated relative to the 
control (100%). Data are expressed as the mean 士 SD of six determinations. 
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Fig. 4.2 Anti-proliferative effect of adenosine on HepG2, R-HepG2, HL-60 and 
NB-4 cells. HepG2, R-HepG2 (IxlO^cells/ml), HL-60 and NB-4 cells 
(2xl0^cells/ml) were seeded in a 96-well plate and incubated with various 
concentrations of adenosine for 48 hours at 37°C, 5% CO2. After treatment, the cell 
viability was determined by MTT assay. The percentage of survival was calculated 
relative to the control (100%). Data are expressed as the mean 土 SD of six 
_ determinations. 
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Fig 4.3 Anti-proliferative effect of cordycepin on HL-60 and NB-4 cells. HL-60 
(A) and NB-4 (B) cells (2xl0^cells/ml) were seeded in a 96-well plate and incubated 
with various concentrations of cordycepin for 24 and 48 hours at 37°C, 5% CO2. 
After treatment, the cell viability was determined by MTT assay. The percentage of 
survival was calculated relative to the control (100%). Data are expressed as the 
mean 士 SD of six determinations. 
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Fig. 4.4 Anti-proliferative effect of cordycepin on HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (IxlO^cells/ml) were seeded in a 96-well plate and 
incubated with various concentrations of cordycepin for 24 and 48 hours at 37°C, 5% 
CO2. After treatment, the cell viability was determined by MTT assay. The 
percentage of survival was calculated relative to the control (100%). Data are 
expressed as the mean 士 SD of six determinations. 
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Table 4.1 Summary of the IC50 values of cordycepin on HL-60, NB-4, HepG2 and 
R-HepG2 cells for 24 and 48 hours treatment. 
HL-60 NB-4 HepG2 R-HepG2 
24 hours 149 |aM 144 i^M 163 |iM 148 |iM 
48 hours 127 |aM 123 [xM 113 |nM 118 |aM 
HL-60, NB-4 (2xl0^cells/ml), HepG2 and R-HepG2 (IxlO^cells/ml) cells were 
seeded in a 96-well plate and incubated with various concentrations of cordycepin for 
24 and 48 hours, respectively at 37°C, 5% CO2. After treatment, the cell viability 
was determined by MTT assay. IC50 was then calculated. Data are representative 
of three independent experiments. 
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Chapter 4 Anti-proliferative Effect of the Active Component of Cordyceps militaris 
4.2 Anti-proliferative Study of Doxorubicin 
Doxorubicin is a common anti-cancer drug. In order to compare the 
efficacy of cordycepin and doxorubicin on human tumor cells, the anti-proliferative 
effect of doxorubicin on HL-60, NB-4, HepG2 and R-HepG2 cells was also studied. 
As indicated in Fig. 4.5, doxorubicin inhibited the growth of HL-60 and 
NB-4 in a dose- and time-dependent manner. Doxorubicin also inhibited the growth 
of HepG2 and R-HepG2 in a dose- and time-dependent manner (Fig 4.6). However, 
the IC50 value of R-HepG2 was found to be much higher than that of other tumor cells. 
It was because R-HepG2 is a multidrug resistant cell line. P-glycoprotein inside the 
R-HepG2 cells can pump the doxorubicin out of the cells and thus much higher 
concentration of doxorubicin was required to inhibit the growth of R-HepG2 cells 
(Chan et al, 2000). Table 4.2 shows the IC50 values of doxorubicin on HL-60, NB-4, 
HepG2 and R-HepG2 cells. 
Chapter 4 Anti-pwliferative Effect of the Active Component of Cordyceps militaris 
A 
广 \ 24 hours 
1 W — O — 48 hours 
i 6�人 \ 
0 H 1 1 1 1 1  
0 2 4 6 8 10 
Concentrat ion o f doxorubic in ( j iM ) 
B 
100 <x 
- f U . — • — 24 hours 
80 1 ^ ‘ — O — 48 hours 
,4。乂乂 
0 H 1 1 1 1 1  
0 2 4 6 8 10 
Concentrat ion o f doxorubic in (|iM) 
Fig. 4.5 Anti-proliferative effect of doxorubicin on HL-60 and NB-4 cells. 
HL-60 (A) and NB-4 (B) cells (2xl0^cells/ml) were seeded in a 96-well plate and 
incubated with various concentrations of doxorubicin for 24 and 48 hours at 37°C, 5% 
CO2. After treatment, the cell viability was determined by MTT assay. The 
percentage of survival was calculated relative to the control (100%). Data are 
expressed as the mean 土 SD of six determinations. 
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Fig. 4.6 Anti-proliferative effect of doxorubicin on HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (IxlO^cells/ml) were seeded in a 96-well plate and 
incubated with various concentrations of doxorubicin for 24 and 48 hours at 37°C, 5% 
CO2. After treatment, the cell viability was determined by MTT assay. The 
percentage of survival was calculated relative to the control (100%). Data are 
expressed as the mean 士 SD of six determinations. 
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Table 4.2 Summary of the IC50 values of doxorubicin on HL-60, NB-4, HepG2 
and R-HepG2 cells for 24 and 48 hours treatment. 
HL-60 NB-4 HepG2 R-HepG2 
24 hours 1.8 i^M 0.9 |aM 7.7 |iM >250 [lM 
48 hours 0.4 |UM 0.3 |liM 0.9 |IM 40 [IU 
HL-60, NB-4 cells (2xl0^cells/ml), HepG2 and R-HepG2 (IxlO^cells/ml) were 
seeded in a 96-well plate and incubated with various concentrations of doxorubicin 
for 24 and 48 hours, respectively at 37°C, 5% CO2. After treatment, the cell 
viability was determined by MTT assay. IC50 was then calculated. Data are 
representative of three independent experiments. 
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4.3 Accumulation of Doxorubicin in HepG2 and R-HepG2 Cells 
As we found that the sensitivity of R-HepG2 cells to doxorubicin is much 
lower than that of the parental HepG2 cells, in order to investigate whether the 
decreased sensitivity is due to the increased efflux of drugs from the R-HepG2 cells, 
drug accumulation studies were performed. Since doxorubicin is a substrate of P-gp 
and is a fluorescent substance, the doxorubicin content in HepG2 and R-HepG2 cells 
can be measured by flow cytometry (Li et al, 2002). In my study, HepG2 and 
R-HepG2 cells were treated with various concentrations of doxorubicin for 3 hours. 
Then the accumulation of doxorubicin inside the cells was measured by flow 
cytometry. As shown in Fig. 4.7, the doxorubicin accumulation in HepG2 cells 
increased in a great extent and in a dose-dependent manner. However, there was 
only a slight shift in red fluorescence in R-HepG2 cells when incubated with 
increasing doxorubicin concentrations. This indicated that the accumulation of 
doxorubicin in R-Hep"G2 cells was less than that of HepG2 cells. Therefore, the low 
sensitivity of R-HepG2 cells to doxorubicin can be explained by the increased efflux 
of doxorubicin in R-HepG2 cells. 
Multidrug resistance mediated by P-gp can be reversed by reversing agents. 
In order to investigate whether WECM and cordycepin can increase the accumulation 
of doxorubicin in R-HepG2 cells, R-HepG2 cells were pretreated with WECM or 
cordycepin for 24 hours and then incubated with doxorubicin for 3 hours. The 
calcium channel blocker verapamil which inhibits active drug efflux by P-gp (Tsuruo 
et al, 2003), was used as a positive control. It was found that pretreatment of cells 
with 100 |jM of verapamil decreased the efflux of doxorubin in R-HepG2 cells and 
caused an increase in doxorubicin accumulation (Fig. 4.8A and 4.9A). However, 
pretreatment of cells with 100 |Lig/ml of WECM and 100 jiM of cordycepin could not 
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increase the doxorubicin accumulation (Fig. 4.8B and 4.9B). Therefore, the WECM 
and cordycepin may not be a reversing agent for the multidrug resistance in R-HepG2 
cells. Although cordycepin is not as potent as doxorubicin in inhibiting tumor 
growth, cordycepin can inhibit the growth of multidrug resistant R-HepG2 cells at a 
concentration similar to that of HepG2 cells. Thus, cordycepin can be used as an 
alternative to treat the multidrug resistant cells. 
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Fig. 4.7 Doxorubicin accumulation in HepG2 and R-HepG2. cells. HepG2 (A) 
and R-HepG2 (B) cells (IxlO^cells/ml) were seeded in a 6-well plate and incubated 
with various concentrations of doxorubicin (Dox) for 3 hours at 37°C, 5% CO2. 
After 3 hours incubation, cells were harvested and washed with PBS. Flow 
cytometry was then carried out. 
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Fig. 4.8 Doxorubicin accumulation in R-HepG2 after pretreatment of cells with 
WECM. R-HepG2 cells (IxlO^cells/ml) were seeded in a 6-well plate and 
incubated with 100 [M of verapamil or 100 i^g/ml of WECM for 24 hours at 37°C, 
5% CO2. After 24 hours incubation, cells were fiirther incubated with 4 i^M of 
doxorubicin (Dox) for 3 hours at 37°C, 5% CO2. Then R-HepG2 cells were 
harvested and washed with PBS. Flow cytometry was then carried out. 
Chapter 4 Anti-proliferative Effect of the Active Component of Cordyceps militaris 
A B 
湾1 h 
f : 八 f : 八 
/ \ Control ^ / \ Control 
V 10- 10- 1 巧 , 食 、 V o - i_o ‘ 
I \ FL3-H / \ F L 3 - H 
懲 . M • 作 M D � x p ： I 4MMDox 
I / V I \ 100 ^ iM Verapamil | / ^ 100 ^ M Cordycepin 
> 0 . / I I > 0 . I   
UJ ID� 10' J10^ 10' 10* 山 10^ 10， 10* 
100 i^M Verapamil + / �L3-H 100 ^ iM Cordycepin 
j L 4^MDox j +4mMDox 
O • J • I ^ I I I o • ‘ ‘ “•_•• ； I V I • 
10* 10^ 10' 10* 1 0。 1 0 ' 10^ 1 0， 1 0 * 
FL3-H FL3-H 
Fig. 4.9 Doxorubicin accumulation in R-HepG2 after pretreatment of cells with 
cordycepin. R-HepG2 cells (IxlO^cells/ml) were seeded in a 6-well plate and 
incubated with 100 mM of verapamil or 100 ^M of cordycepin for 24 hours at 37°C, 
5% CO2. After 24 hours incubation, cells were further incubated with 4 i^M of 
doxorubicin (Dox) for 3 hours at 37�C, 5% CO2. Then R-HepG2 cells were 
harvested and washed with PBS. Flow cytometry was then carried out. 
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4.4 Cytotoxicity Study of Cordycepin and Doxorubicin on 
Normal Liver Cells 
In order to study the cytotoxicity of cordycepin and doxorubicin, human 
normal hepatic cell line WRL-68 was used. WRL-68 is a non-tumorigenic cell line 
derived from fetal liver. Some morphological and functional characteristics of 
WRL-68 are similar to hepatoctyes and hepatic primary cultures (Gutierrez-Ruiz et al, 
1994; Ramirez et al, 2000). It provides a good in vitro model to study the toxic 
effects of drug. In the study, WRL-68 was incubated with various concentrations of 
cordycepin or doxorubicin for 24 and 48 hours, respectively. MTT assay was then 
carried out. 
It was found that the IC50 values of cordycepin on normal liver cells 
WRL-68 for 24 and 48 hours were found to be 523 |aM and 441 \xM, respectively (Fig. 
4.1 OA). While the IC50 values of doxorubicin on WRL-68 cells for 24 and 48 hours 
were found to be 25 )iM and 9 |j,M, respectively (Fig. 4.1 OB). The results indicated 
that doxorubicin is more toxic than cordycepin towards the normal liver cells. 
Besides, for the effective dose (120 - 150 i^M) of cordycepin which inhibited 50% of 
the growth of R-HepG2 cells, only exerted a slight cytototoxic effect on normal liver 
cells WRL-68 (Fig. 4.10A). While the dose of doxorubicin (40|iM for 48 hours 
treatment), which inhibited 50% of the growth of R-HepG2 cells, killed almost all the 
normal liver cells (Fig. 4.1 OB). Therefore, cordycepin may be the new target for the 
treatment of multidrug resistant cells. 
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Fig. 4.10 Cytotoxicity of cordycepin and doxorubicin on WRL-68 cells. 
WRL-68 cells (2xl0^cell/ml) were seeded in a 96-well plate and incubated with 
various concentrations of cordycepin (A) or doxorubicin (B) for 24 and 48 hours, 
respectively at 37°C, 5% CO2. After treatment, the cell viability was determined by 
MTT assay. The percentage of survival was calculated relative to the control (100%). 
Data are expressed as the mean 士 SD of six determinations. 
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4.5 Hemolytic Study of Cordycepin 
As mentioned above, cordycepin inhibited the growth of acute 
promyelocytic leukemia HL-60 and NB-4 cells. In order to investigate whether 
cordycepin would cause adverse effect on the red blood cells, hemolytic activity of 
cordycepin was studied. In the study, various concentrations of cordycepin were 
incubated with the red blood cells obtained from the BALB/c mice for 24 hours at 
37°C and hemolysis assay was performed. As shown in Table 4.3, there was no 
significant increase in the percentage of hemolysis in all concentrations of cordycepin 
being tested as compared to the control. This indicated that cordycepin did not cause 
hemolysis. 
. — 
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Table 4.3 Hemolytic activity of cordycepin  
Cordycepin Concentration % Hemolysis 
OfiM 20.7 士 8.9 
12.5 \xM 21.1 ±5.5 
25 laM 18.45 ±5.4 
50 nM 20.4 ± 7.4 
100 [iU 18.7 ±6.1 
200 laM 15.5±3.1 
400 laM 16.7 ±4.3 
800 i^ M 16.8 ±4.5 
Red blood cells from BALB/c mice were incubated at 37°C for 24 hours. Hemolysis 
assay was carried out as mentioned in Materials and Methods. Values are mean 士 
SD of five determinations. 
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5.1 Cell Cycle Analysis of Leukemia Cells 
Cell populations are tightly regulated by their proliferation, differentiation 
and death. Tumors growth is due to the imbalance between cell proliferation and 
cell death and an expansion of the cell population (Slingerland & Tannock, 1998). 
It was found that cordycepin could inhibit the growth of human acute 
promyelocytic leukemia HL-60 and NB-4 cells. However, the action mechanisms 
of growth inhibition are not very clear. Basically, there are three ways of 
inhibiting tumors growth by anti-cancer drugs. They are the induction of cell 
cycle arrest, differentiation and apoptosis. Changes in DNA histogram are 
commonly used to study the action mechanism of cytotoxic drugs as they will 
generally disrupt the cell cycle. Measurement of DNA contents in the cells can 
give a picture of the cell cycle. 
Typically, cells start the cycle in Gi-phase in which cells have a diploid 
DNA content. Cells then enter the S-phase during which the DNA content 
increases until it has doubled, upon which the cells are in G2-phase. Eventually, 
cells enter mitosis (M-Phase) and divide to re-enter their cycle. Propidium iodide 
(PI) was used to study the cell cycle of tumor cells. PI is only weakly fluorescent 
in aqueous solution but is fluorescent strongly when bound to DNA. It 
intercalates into double-stranded nucleic acids of permeabilized cells (Ormerod, 
, 1 9 9 9 a ) . HL-60 and NB-4 cells were stained with PI after treated with 50，100 and 
200 i^ M of cordycepin for 24 hours. Sub Gi peak was observed in HL-60 and 
NB-4 cells treated with 100 and 200 |aM of cordycepin (Fig. 5.1 C-D and Fig. 5.2 
C-D). The sub Gi peak represents apoptotic cells as at the late stage of apoptosis, 
endonucleases attack at the linker between the nucleosomes and breaks the DNA 
into large numbers of small fragments whose sizes are oligomers of about 180 base 
. — -~-
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pairs. Cell permeabilization or alcohol fixation does not fully preserve the 
degraded DNA within apoptotic cells. Some of the lower molecular weight DNA 
leak out and subsequently lower the DNA content. The apoptotic cells can be 
observed as a hypodiploid or sub Gi peak in a DNA histogram (Ormerod, 1999b). 
From the results (Fig. 5.1 and 5.2), after 24-hour cordycepin treatment, the number 
of apoptotic cells was increased in a dose-dependent manner. However, no arrest 
in any phase of the cell cycle was observed (Fig, 5.1 and 5.2). It was suggested 
that the growth inhibition of HL-60 and NB-4 cells induced by cordycepin was 
correlated with apoptosis but not cell cycle arrest. 
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Fig. 5.1 Cell cycle distribution of HDL-60 cells treated with cordycepin for 24 hr. 
HL-60 cells (2xl0^cells/ml) were seeded in a 6-well plate and incubated with medium 
alone (A) or cordycepin at 50 |liM (B), 100/zM (C) and 200 " M (D) for 24 hours at 
‘37°C, 5% CO2. The cells were stained with propidium iodide and analyzed by flow 
cytometry. Results are representative of three independent experiments. 
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Fig. 5.2 Cell cycle distribution of NB-4 cells treated with cordycepin for 24 hr. 
NB-4 cells (2xl0^cells/ml) were seeded in a 6-well plate and incubated with medium 
alone (A) or cordycepin at 50 pM (B), 100 "M (C) and 200/zM (D) for 24 hours at 
‘ 3 7 ° C , 5% CO2. The cells were stained with propidium iodide and analyzed by flow 
cytometry. Results are representative of three independent experiments. 
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5.2 Hallmarks of Apoptosis 
Apoptosis is a highly regulated process of cell death. The biochemical 
changes that characterize apoptosis include the loss of mitochondrial membrane 
potential, loss of plasma membrane asymmetry and eventual fragmentation of cellular 
DNA. Morphological changes include cell shrinkage, membrane blebbing, 
chromatin condensation and nuclear fragmentation (Saraste & Pulkki’ 2000). 
5.2.1 Induction of Phosphatidylserine Extemalization in Leukemia 
Cells by Cordycepin 
In viable cells, phosphatidylserine (PS) is located on the cytoplasmic surface 
of the cell membrane. When cells undergo apoptosis, PS is translocated to the outer 
leaflet of the plasma membrane and exposed to the extracellular environment (van 
Engeland et aL; 1998). 
Annexin V is a 35-36 kDa Ca^^ dependent phospholipid-binding protein that 
has a high affinity for PS. Annexin V conjugated with a fluorophore such as FITC 
can identify apoptotic cells by binding to PS when it is exposed to the outer leaflet. 
-Since Annexin V can also detect necrotic cells as a result of the loss of membrane 
integrity, PI was used to differentiate the apoptotic cells from necrotic cells. Intact 
cell membrane of viable and early apoptotic cells can exclude PL Viable cells are 
Annexin V-FITC and PI negative. Early apoptotic cells are Annexin V-FITC 
positive and PI negative. The late apoptotic or necrotic cells are Annexin V-FITC 
positive and PI positive. These subpopulations can be measured by flow cytometry. 
PS extemalization of cordycepin-treated HL-60 and NB-4 cells was 
investigated by Annexin V-FITC and PI staining. HL-60 and NB-4 cells were 
treated with 100 and 200 |iM of cordycepin for 8 and 16 hours, respectively. From 
• — -
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the results, most of the HL-60 and NB-4 cells were viable without cordycepin 
treatment. For the 8-hour treatment of HL-60 and NB-4 cells with cordycepin, some 
of the cells shifted from lower left quadrant to lower right quadrant (Fig. 5.3 A-C and 
Fig. 5.4 A-C). This indicated that HL-60 and NB-4 cells underwent apoptosis. 
Treatment of HL-60 and NB-4 cells with cordycepin for 16 hours resulted in an 
increase of cell population in the upper right quadrant (Fig. 5.3 D-F and Fig. 5.4 D-F). 
The Annexin V-FITC and PI stained cells are late apoptotic cells. This indicated that 
some of the HL-60 and NB-4 cells became late apoptotic when treated with 
cordycepin for 16 hours. The proportion of apoptotic cells was higher in NB-4 cells 
than in HL-60 cells suggested that NB-4 cells are more sensitive to cordycepin than 
HL-60 cells. 
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Fig. 5.3 Phosphatidylserine externalization of HL-60 cells induced by cordycepin. 
HL-60 cells (2 x 10^  cells/ml) were seeded into a 100 mm culture dish and incubated 
with the absence (A,D) or presence of 100 i^M (B,E) and 200 i^M (C,F) of cordycepin 
for 8 (A,B,C) and 16 hours (D,E,F), respectively at 37�C’ 5% CO2. After treatment, 
cells were collected and stained with Annexin V-FITC and PI, followed by flow 
cytometric analysis. Results are representative of two independent experiments. 
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Fig. 5.4 Phosphatidylserine externalization of NB-4 cells induced by cordycepin. 
NB-4 cells (2 x 10^  cells/ml) were seeded into a 100 mm culture dish and incubated 
with the absence (A,D) or presence of 100 i^M (B,E) and 200 i^M (C’F) of cordycepin 
for 8 (A,B,C) and 16 hours (D,E,F), respectively at 37�C，5% CO2. After treatment, 
cells were collected and stained with Annexin V-FITC and PI, followed by flow 
cytometric analysis. Results are representative of three independent experiments. 
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5.2.2 Induction of DNA Fragmentation in Leukemia Cells by 
Cordycepin 
Another biochemical hallmark of apoptosis is the degradation of DNA by 
endogenous DNase, which cuts the intemucleosomal regions into double-strand DNA 
fragments of 180-200 base pairs. The DNA fragments are detectable as a ladder 
pattern in the electrophoresis of isolated DNA (Saraste & Pulkki，2000). 
The ability of cordycepin to induce DNA fragmentation in leukemia cells 
was studied. HL-60 and NB-4 cells were incubated with 50，100 and 200 [iM of 
cordycepin for 24 and 48 hours. As shown in Fig. 5.5A- and Fig. 5.6A, a 
characteristic ladder pattern of DNA fragments was observed at the concentration of 
100 and 200 of cordycepin for 24 hours treatment. This further confirmed that 
cordycepin could induce apoptosis in HL-60 and NB-4 cells. For 48 hours treatment, 
DNA ladder was observed at 50 |liM of cordycepin (Fig. 5.5B and Fig. 5.6B). 
Therefore, cordycepin could induce apoptosis in HL-60 and NB-4 cells in a dose- and 
time-dependent manner. 
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Fig. 5.5 Induction of DNA fragmentation in cordycepin-treated HL-60 cells. 
HL-60 cells (2 x 10^  cells/ml) were seeded into a 100 mm culture dish and incubated 
with various concentrations of cordycepin for 24 or 48 hours at 37°C，5% CO2. 
After treatments, cells were collected and DNA was extracted. DNA fragmentation 
was analyzed by 1.5% agarose gel electrophoresis. (A) 24 hr treatment. (B) 48 hr 
treatment. Lane 1: 100 base pairs DNA marker. Lane 2: control. Lane 3: 50 /xM 
cordycepin. Lane 4: 100 /xM cordycepin. Lane 5: 200 juM cordycepin. Results 
are representative of three independent experiments. 
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Fig. 5.6 Induction of DNA fragmentation in cordycepin-treated NB-4 cells. 
NB-4 cells (2 x 10^  cells/ml) were seeded into a 100-mm culture dish and incubated 
with various concentrations of cordycepin for 24 or 48 hours 37°C, 5% CO2. After 
treatments, cells were collected and DNA was extracted. DNA fragmentation was 
analyzed by 1.5% agarose gel electrophoresis. (A) 24 hr treatment. Lane 1: 
Control. Lane 2: 50 jiiM cordycepin. Lane 3: 100 juM cordycepin. Lane 4: 200 
juM cordycepin. Lane 5: 100 base pairs marker. (B) 48 hr treatment. Lane 1: 
100 base pairs marker. Lane 2: control. Lane 3: 50 fxM cordycepin. Lane 4: 100 
liM cordycepin. Lane 5: 200 /xM cordycepin. Results are representative of three 
“ separate experiments. 
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5.2.3 Morphological Changes in Leukemia Cells Induced by 
Cordycepin 
Apart from intemucleosomal DNA degradation, apoptotic cells have distinct 
morphological features such as shrinkage of cell, nucleus condensation and formation 
of apoptotic bodies. In order to investigate whether cordycepin could induce 
morphological changes in leukemia cells, cell morphology was evaluated by staining 
the cells with Hemacolor staining solution when cells were treated with cordycepin 
for 24 hours. 
From the results, treatment of HL-60 and NB-4 cells with 50 [iM of 
cordycepin for 24 hours did not induce any morphological changes (Fig. 5.7 B and 5.8 
B). However, characteristic morphological changes such as cell shrinkage and 
apoptotic bodies formation were observed in both HL-60 and NB-4 cells treated for 
24 hours with J 00 and 200 |iM of cordycepin, respectively (Fig. 5.7 C-D and Fig. 5.8 
C-D). The proportion of apoptotic cells was higher in the cells treated with 200 |aM 
of cordycepin. 
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Fig. 5.7 Morphological changes of HL-60 cells induced by cordycepin. HL-60 
cells (2 X 105 cells/ml) were exposed to (A) 0 mH (B) 50 |iM, (C) 100 |iM and (D) 
200 |iM of cordycepin for 24 hr at 37°C, 5% CO2. Cytospin preparation and 
Hemacolor staining were carried out as described in Materials and Methods. 
Apoptotic cells are indicated by arrows. Results are representative of two 
independent experiments. 
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Fig. 5.8 Morphological changes of NB-4 cells induced by cordycepin. NB-4 cells 
(2 X 10^  cells/ml) were exposed to (A) 0 jiM, (B) 50 i^M, (C) 100 i^M and (D) 200 
(iM of cordycepin for 24 hr at 37°C, 5% CO2. Cytospin preparation and Hemacolor 
staining were carried out as described in Materials and Methods. Apoptotic cells are 
indicated by arrows. Results are representative of two independent experiments. 
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5.2.4 Caspase-3 Activation in Leukemia Cells Induced by Cordycepin 
Caspases are cysteine proteases that cleave their substrate proteins 
specifically behind an aspartate residue. They are formed constitutively and are 
normally present as inactive proenzymes. For the induction of full enzymatic 
activity, cleavage at specific internal aspartate residues is required. Caspase 
activation is essential for the occurrence of apoptotic phenotype of cell death. 
Activation of upstream caspases such as caspases-2, -8, -9 and -10，by pro-apoptotic 
signals leads to proteolytic activation of the downstream or effector caspases-3, -6 and 
-7. The effector caspases cleave a set of vital proteins and thus, initiate and execute 
the apoptotic degradation phase including DNA degradation and the typical 
morphological features (Saraste & Pulkki，2000). 
Since caspase-3 is one of the effector caspases that execute the biochemical 
and morphological changes in apoptosis, the level of procaspase-3 in leukemia cells 
was examined by Western blot analysis. From the results, the level of procaspase-3 
was decreased in cordycepin treated HL-60 and NB-4 cells in a concentration- and 
time-dependent manner (Fig. 5.9). This suggested that the inactive procaspase-3 was 
cleaved and became active caspase-3. 
Activation of caspase-3 leads to the cleavage of a number of proteins, one of 
which is poly(ADP-ribose) polymerase (PARP) (Zhivotovsky et al., 1997). PARP is 
required for DNA repair and the activated caspase-3 cleaves PARP to 85 kDa and 24 
kDa'fragments (Soldani et al” 2001; Soldani & Scovassi, 2002). In order to test 
whether the decrease of procaspase-3 was due to the cleavage of procaspase-3 to 
active caspase-3 or not, the levels of PARP in HL-60 and NB-4 cells were measured. 
It was found that the intact 116 kDa PARP was cleaved to 85 kDa fragment in HL-60 
and NB-4 cells treated with cordycepin (Fig. 5.10). The level of cleaved 85 kDa 
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Fig. 5.9 Cleavage of procaspase-3 in HL-60 and NB-4 cells treated with 
cordycepin. HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with 
various concentrations of cordycepin as indicated for 24 and 48 hours at 37°C, 5% 
CO2. Proteins were extracted and 25 |ig of protein was loaded into each well and 
run in a 12% SDS gel. Western blot analysis was carried out as described in 
Materials and Methods, p-actin was used as internal control. The value at the 
bottom of each band represents the relative intensity after normalization with respect 
to p-actin and comparison was made with the corresponding control. Results are 
representative of four independent experiments. 
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Fig. 5.10 Cleavage of PARP in HL-60 and NB-4 cells treated with cordycepin. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various 
concentrations of cordycepin as indicated for 24 hours at 37°C, 5% CO2. Proteins 
were extracted and 25 |ag of protein was loaded into each well and subjected to 8% 
SDS-PAGE. Western blot analysis was carried out as described in Materials and 
Methods. P-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to P-actin and 
comparison was made with the corresponding control. The results are representative 
of three independent experiments. 
. — 
Chapter 5 Mechanistic Study of Cordycepin in the Induction of Apoptosis in Leukemia Cells 
Apart from studying the protein levels of procaspase-3 and PARP by 
Western blot analysis, the enzymatic activity of caspase-3 was also studied. 150 |iM 
of cordycepin was used to treat HL-60 and NB-4 cells for 18 and 24 hours. The 
protein extract was incubated with caspase-3 specific fluorescent AMC conjugated 
substrate Ac-DEVD-AMC for 1 hour. Ac-DEVD-AMC was cleaved by active 
caspase-3. The amount of fluorescent AMC (|iM) released from the substrate by the 
action of caspase-3 is directly proportional to its enzymatic activity. To confirm the 
correlation between the fluorescence signal and caspase-3 activity, caspase-3 specific 
inhibitor z-DEVD-fmk was added to the protein extract before the addition of 
substrate. As shown in Fig. 5.11 and Fig. 5.12, caspase-3 activity in HL-60 and 
NB-4 cells was increased after treated with cordycepin. In the presence of inhibitor, 
the caspase activity induced by cordycepin was suppressed. This further supported 
the idea that caspase-3 was activated in cordycepin-treated HL-60 and NB-4 cells. 
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Fig. 5.11 Inhibition of cordycepin-induced caspase-3 activation in HL-60 cells. 
HL-60 cells (2x10^ cells/ml) were treated with 150 [iM cordycepin for 18 and 24 
hours at 37°C, 5% CO2. Cytosolic extracts were prepared and assayed for caspase-3 
activity with caspase-3 specific substrate Ac-DEVD-AMC (50^M) in the absence or 
presence of caspase-3 inhibitor z-DEVD-fmk (10 }iM). Values represent means 士 
SD of there independent experiments. * p < 0.05 compared with the control. 
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Fig. 5.12 Inhibition of cordycepin-induced caspase-3 activation in NB-4 cells. 
NB-4 cells (2x10^ cells/ml) were treated with 150 i^M cordycepin for 18 and 24 hours 
at 37°C, 5% CO2. Cytosolic extracts were prepared and assayed for caspase-3 
activity with caspase-3 specific substrate Ac-DEVD-AMC (50 )j,M) in the absence or 
presence of caspase-3 inhibitor z-DEVD-fmk (10 jjM). Values represent means 士 
SD of there independent experiments. * p < 0.05 compared with the control. 
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5.3 Study of the Underlying Mechanisms of 
Cordycepin-induced Apoptosis in Leukemia Cells 
Generally, apoptotic pathways are classified into mitochondrial pathway (Type 
II) and death receptor pathway (Type I). The mitochondrial pathway involves a 
number of Bcl-2 family members, cytochrome c, and caspase-9. The death receptor 
pathway involves death receptors such as Fas and tumor necrosis factor-a receptor 1 
(TNFRl), caspase-8. However, there is a cross talk between the death receptor and 
mitochondrial pathway involving the Bcl-2 family member Bid. Bid facilitates 
cytochrome c release from mitochondria, thereby activating caspase-9 and the 
downstream caspases (Kaufmann & Eamshaw，2000). The underlying mechanisms 
of apoptosis induced by cordycepin in leukemia cells were investigated. 
5.3.1 Induction of Mitochondrial Membrane Depolarization in 
Leukemia Cells 
Decrease in mitochondrial transmembrane potential (A\|/m) is one of the early 
events of apoptosis. The cell permeant fluorescent probe 
5,5' ,6,6'-tetrachloro-1,1' ,3,3' -tetraethyl-benzimidazolyIcarbocyanine iodide (JC-1) 
can be employed to monitor changes in Av|/m in cells, by flow cytometry. In the 
presence of a high Axj/m, JC-1 forms J-aggregates which fluoresce strongly at 590 nm. 
Reduced A\|/m results in an increased green signal and /or in a reduced red signal in 
JC-1 stained cells (Costa-Pereira & Cotter, 1999). 
The effect of cordycepin on mitochondrial membrane potential of 
leukemia cells was studied by JC-1. The x-axis of the contour plot represents the 
green fluorescence of monomeric JC-1 while the y-axis represents the red 
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fluorescence of dimeric JC-1. The region R1 indicated the cell population with 
higher green to red fluorescence ratio which reflects A\|/m dissipation. As shown in 
Fig. 5.13 and Fig. 5.14, the proportion of HL-60 and NB-4 cells with higher green to 
red fluorescence ratio was increased, after treated with increasing concentration of 
cordycepin for 16 hours. This indicated that cordycepin induced the mitochondrial 
membrane depolarization in HL-60 and NB-4 cells. 
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Fig. 5.13 Induction of mitochondrial membrane potential depolarization in 
“cordycepin-treated HL-60 cells. HL-60 cells (2 x 10^  cells/ml) were seeded into a 
6-well plate and incubated in the absence (A) or presence of 50 i^M (B), 100 |iM (C) 
and 200 fjM cordycepin, respectively for 16 hours at 37°C, 5% CO2. After treatment, 
cells were stained with JC-1 for 15 minutes and analyzed by flow cytometry. 
,Results are representative of two independent experiments. 
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Fig. 5.14 Induction of mitochondrial membrane potential depolarization in 
cordycepin-treated NB-4 cells. NB-4 cells (2 x 10^  cells/ml) were seeded into a 
6-well plate and incubated in the absence (A) or presence of 50 |iM (B), 100 ^M (C) 
and 200 ^M cordycepin, respectively for 16 hours at 37°C, 5% CO2. After treatment, 
cells were stained with JC-1 for 15 minutes and analyzed by flow cytometry. 
,Results are representative of three independent experiments. 
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5.3.2 Elevation of Intracellular Hydrogen Peroxide Level in 
Cordycepin-treated Leukemia Cells 
Oxidative stress has been suggested as a possible common mediator of 
apoptosis in response to a number of stimuli. The fluorescent probes 
2' ,7'-dichlorofluorescin diacetate (DCFH-DA) can be used for the measurement of 
intracellular hydrogen peroxide (Costa-Pereira & Cotter, 1999). DCFH-DA is a cell 
permeant and non-fluorescent indicator. When it enters the cell, it is cleaved by 
nonspecific esterases forming DCFH and oxidized to a fluorescent compound 
2' ,7' -dichlorofluorescein (DCF) in the presence of H2O2. Hydrolyzed, oxidized 
DCFH-DA fluoresces at 529 nm (FL-1) and is unable to leave the cell, thus allowing 
the measurement of intracellular hydrogen peroxides by flow cytometry 
(Costa-Pereira & Cotter, 1999; Jing et al, 1999). 
Since the increase of intracellular reactive oxygen species (ROS) may impair 
a variety of intra- and extra-mitochondrial membrane transport system such as 
decrease of mitochondrial membrane potential (Arimura et aL’ 2003), the changes of 
both H2O2 and A\\fm were measured simultaneously by flow cytometry with two 
compatible fluorescent dyes tetramethylrhodamine, ethyl ester, perchlorate (TMRE) 
for A\|/n, and 5-(and 6-)-carboxy-2',7-dichlorodihydrofluorescein diacetate 
(DCFH-DA) for H2O2. TMRE is a positively charged fluorescence dye and is 
‘uptaken by the negatively charged \|/m. The fluorescence intensity would decrease 
when the cells become depolarized. 
HL-60 and NB-4 cells were analyzed for intracellular H2O2 production and 
change in A\|/m after 8 and 16 hours cordycepin treatment. The x-axis of the density 
plot (Fig. 5.15 and 5.16) represents the green fluorescence of DCF while the y-axis 
represents the red fluorescence of TMRE. The region R1 indicates the percentage of 
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cells having higher DCF but lower TMRE fluorescence (i.e. higher H2O2 level but 
lower mitochondrial membrane potential). From the results, treatment of HL-60 
with 100 i^ M and 200 \iM of cordycepin for 8 hours caused the percentage of cells in 
R1 increased from 2.09% of the control to 8.24% and 16.29% of 100 [xM and 200 |iM 
of cordycepin, respectively (Fig. 5.15 A-C). Sixteen hours treatment caused the 
percentage of HL-60 cells in R1 increased from 2.23% of the control to 11.92 % and 
16% of 100 |liM and 200 of cordycepin, respectively (Fig. 5.15 D-F). For NB-4 
cells, treatment with cordycepin for 8 hours increased the percentage of cells in R1 
from 3.21% of the control to 22.05% and 23.61% of 100 |iM and 200 [xM of 
cordycepin, respectively (Fig. 5.16 A-C). While 16 hours treatment increased the 
percentage of NB-4 cell in R1 from 5.97 % of the control to 35.32% and 40.62% of 
100 )iM and 200 [iM of cordycepin, respectively (Fig. 5.16 D-F). Therefore, 
cordycepin is able to induce intracellular H2O2 level accumulation and decrease the 
mitochondrial membrane potential simultaneously in a dose- and time-dependent 
manner. The extent of intracellular H2O2 production and mitochondrial membrane 
depolarization in NB-4 cells induced by cordycepin is larger than HL-60 cells. 
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Fig. 5.15 Induction of the intracellular H2O2 production and mitochondrial 
membrane depolarization in cordycepin-treated HL-60 cells. HL-60 cells (2 x 
10^  cells/ml) were seeded into a 6-well plate and incubated with or without 100 |iM 
and 200 |iM of cordycepin for 8 and 16 hours, respectively at 37°C, 5% CO2. After 
treatment, cells were stained with both DCFH-DA and TMRE for 15 minutes. 
Results are representative of two independent experiments. 
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Fig. 5.16 Induction of the intracellular H2O2 production and mitochondrial 
membrane depolarization in cordycepin-treated NB-4 cells. NB-4 cells (2 x 10 
cells/ml) were seeded into a 6-well plate and incubated with or without 100 jaM and 
200 i^M of cordycepin for 8 and 16 hours, respectively at 37°C, 5% CO2. After 
treatment, cells were stained with both DCFH-DA and TMRE for 15 minutes. 
Results are representative of two independent experiments. 
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5.3.3 Induction of Cytochrome c Release from Mitochondria of 
Leukemia Cells 
Mitochondria act as central regulator of cell death. Changes in the 
mitochondrial inner membrane function are accompanied by an increase in outer 
membrane permeability, leading to the release of soluble intermembrane proteins 
(SIMPs) such as cytochrome c and apoptosis inducing factor (AIF). The activation 
of protease (caspases) and nucleases by SIMPs is necessary for the acquisition of 
apoptotic morphology (Costantini et al, 2000). Detection of the release of SIMPs 
into the cytosol is a complementary indication of the mitochondrial involvement in 
different cell death pathways. 
The cytochrome c released from mitochondria was examined in HL-60 and 
NB-4 cells treated with cordycepin. As shown in Fig. 5.17, cytochrome c was 
released from mitochondria to cytosol after treated with cordycepin for 18 hours. 
The amount of cytochrome c released in HL-60 and NB-4 cells was increased with 
increasing cordycepin concentrations. 
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Fig. 5.17 Release of cytochrome c in HL-60 and NB-4 cells treated with 
cordycepin. HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with 
various concentrations of cordycepin as indicated for 18 hours at 37°C, 5% CO2. 
After treatment, cells were collected and cytosolic fraction was extracted as 
mentioned in Materials and Methods. The cytosolic proteins were then subjected to 
Western blot analysis. p-actin was served as internal control. Results are 
representative of two independent experiments. 
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5.3.4 Caspase-9 Activation in Leukemia Cells Induced by Cordycepin 
The release of cytochrome c from mitochondria to cytosol was regarded as a 
key regulatory event in apoptosis. Caspase-9 is the most upstream caspase in 
mitochondrial apoptotic pathway. It is activated via the release of cytochrome c 
from the mitochondria to the cytosol. Activated caspase-9 then cleaves and activates 
the downstream effectors such as caspase-3, -6 and -7 (Von Ahsen et al” 2000). In 
order to investigate whether caspase-9 was activated in cordycepin treated leukemia 
cells, the levels of procaspase-9 and caspase-9 activities in HL-60 and NB-4 cells 
were measured after treated with cordycpein. 
Western blot analysis showed that the level of procaspase-9 in HL-60 and 
NB-4 cells was decreased after treating with 100 and 200 |liM of cordycepin for 24 
hours (Fig. 5.18). The decrease of procaspase-9 suggested the cleavage of 
procaspase-9 to active caspase-9. The decrease of procaspase-9 was in a dose- and 
time-dependent manner (Fig. 5.18). 
Caspase-9 activity was measured by the use of caspase-9 specific substrate 
Ac-LEHD-AFC. Ac-LEHD-AFC is a fluorescence conjugated substrate. Once 
caspase-9 is activated, the substrate is cleaved and released the fluorescent AFC. 
The caspase-9 activity is proportional to the amount of AFC released. To verify the 
caspase activity, caspase-9 inhibitor z-LEHD-fmk was added before adding the 
substrate. As indicated in Fig. 5.19, the caspase-9 activity of HL-60 and NB-4 cells 
was increased after the treatment of cells with 150 |aM of cordycepin for 18 and 24 
hours. The caspase-9 activity was suppressed in the presence of caspase-9 inhibitor 
further support the induction of caspase-9 activation by cordycepin. 
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Fig. 5.18 Cleavage of procaspase-9 in HL-60 and NB-4 cells treated with 
cordycepin. HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with 
various concentrations of cordycepin for 24 and 48 hours at 37°C, 5% CO2, 
respectively. Proteins were extracted and 25 |ag of protein was loaded into each well 
and subjected to 12% SDS-PAGE. Western blot analysis was carried out as 
mentioned in Materials and Methods. P-actin was used as internal control. The 
value at the bottom of each band represents the relative intensity after normalization 
with respect to P-actin and comparison was made with the corresponding control. 
Results are representative of two independent experiments. 
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Fig. 5.19 Inhibition of cordycepin-induced caspase-9 activation in leukemia cells. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with 150 i^M cordycepin 
for 18 and 24 hours, respectively at 37°C，5% CO2. Cytosolic extracts were 
prepared and assayed for caspase-9 activity with caspase-9 specific substrate 
Ac-LEHD-AFC (250 i^M) in the absence or presence of caspase-9 inhibitor 
z-LEHD-fmk (50 |iM). Values represent means 士 SD of there independent 
experiments. *p < 0.05 compared with the control. 
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5.3.5 Involvement of Bcl-2 Family Members in Cordycepin-induced 
Apoptosis 
The release of cytochrome c and other apoptogenic proteins from 
mitochondria is known to be regulated by the Bcl-2 family of proteins. These 
proteins can be found in the outer mitochondrial membrane, endoplasmic reticulum 
and the nuclear envelope. Once translocated to the mitochondria, they cause 
mitochondrial membrane permeabilization and release of apoptogenic proteins by 
interacting with other members of the Bcl-2 family. The Bcl-2 family members can 
be subdivided into two groups according to their function. Pro-apoptotic Bcl-2 
family members include Bax, Bak, Bcl-Xs, Bad, Bid, Bok, Bik, Bim, Krk and Mtd. 
Anti-apoptotic Bcl-2 family members include Bcl-2, BC1-XL, Bcl-w, Mcl-l and Al 
(Wang, 2001; Antonsson & Martinou, 2000). 
Overexpression of Bcl-2 has been reported in a wide variety of cancers 
(Reed, 1999). Increase in Bcl-2 expression induces resistance to chemotherapeutic 
drugs, while decrease in Bcl-2 expression promote apoptotic responses to anticancer 
drugs (Reed, 1997). Therefore, the level of Bcl-2 in HL-60 and NB-4 cells was 
investigated after treated with cordycepin. From the results, there was no decrease 
in Bcl-2 expression in HL-60 cells treated with cordycepin for 24 hours. However, 
there was a slight decrease in Bcl-2 expression in HL-60 cells after 48 hours treatment 
, (F ig . 5.20A). The level of Bcl-2 in cordycepin-treated NB-4 cells was decreased in a 
dose- and time-dependent manner (Fig. 5.20B). 
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Fig. 5.20 Expression of Bcl-2 in cordycepin-treated HL-60 and NB-4 cells. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various 
concentrations^ of cordycepin as indicated for 24 and 48 hours at 37°C, 5% CO2. 
Proteins were extracted and 25 |ig of protein was loaded into each well and subjected 
to 12% SDS-PAGE. Western blot analysis was carried out as mentioned in Materials 
and Methods, p-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to P-actin and 
comparison was made with the corresponding control. Results are representative of 
three independent experiments. 
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Anti-apoptotic Bcl-2 family members inhibit cytochromc c release by 
inhibiting the ability of pro-apoptotic family members to facilitate the opening of 
voltage dependent ion channel in the outer mitochondrial membrane. The balance 
between levels of pro- and anti-apoptotic family members expression is important for 
the initiation of apoptosis (Kaufmann & Eamshaw，2000; Coultas & Strasser, 2003). 
Therefore, apart from measuring the level of anti-apoptotic Bcl-2 level, the level of 
pro-apoptotic family members such as Bax, Bcl-Xs and Bid in HL-60 and NB-4 cells 
treated with cordycepin was also investigated. 
As indicated in Fig. 5.21, there was a slight increase in the level of Bax in 
HL-60 and NB-4 cells treated with cordycepin for 24 hours. For Bcl-Xs, the level 
Bcl-Xs in HL-60 cells increased dose-dependently in both 24 and 48 hours treatment 
and there was more than two-fold induction of Bcl-Xs when treated with 100 |aM and 
200 |iM of cordycpein (Fig. 5.22A). The level of Bcl-Xs in untreated NB-4 cells 
was nearly undetectable and there was a marked increase of Bcl-Xs in NB-4 cells 
induced by cordycepin (Fig. 5.22B). Therefore, the release of cytochrome c induced 
by cordycepin was contributed partly by the increase of Bax and Bcl-Xs. 
Bid is another member of pro-apoptotic proteins. The action of Bid was 
believed to involve the mitochondrial re-location of its truncated form tBid, to 
facilitate the release of apoptogenic proteins such as cytochrome c (Esposti, 2002). 
From the results, the level of Bid was decreased and the level of tBid was increased in 
HL-60 and NB-4 cells after treated with cordycepin for 24 hours (Fig. 5.23). This 
indicated that the release of cytochrome c induced by cordycepin was contributed by 
the cleavage of Bid to its active form tBid. 
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Fig. 5.21 Expression of Bax in cordycepin-treated HL-60 and NB-4 cells. HL-60 
(A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various concentrations of 
cordycepin as indicated for 24 hours at 37°C，5% CO2. Proteins were extracted and 
25 |Lig of protein was loaded into each well and subjected to 12% SDS-PAGE. 
Western blot analysis was carried out as mentioned in Materials and Methods. 
P-actin was used as internal control. The value at the bottom of each band represents 
the relative intensity after normalization with respect to P-actin and comparison was 
made with the corresponding control. Results are representative of at least two 
independent experiments. 
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Fig. 5.22 Expression of Bcl-Xs in cordycepin-treated HL-60 and NB-4 cells. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various 
concentrations of cordycepin as indicated for 24 and 48 hours, at 37°C, 5% CO2. 
Proteins were extracted and 25 |Lig of protein was loaded into each well and subjected 
to 12% SDS-PAGE. Western blot analysis was carried out as mentioned in Materials 
and Methods, p-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to P-actin and 
comparison was made with the corresponding control. Results are representative of 
at least two independent experiments. 
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Fig. 5.23 Cleavage of Bid in HL-60 and NB-4 cells treated with cordycepin. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various 
concentrations of cordycepin as indicated for 24 hours at 37°C, 5% CO2. 25 pg of 
protein was loaded into each well and subjected to 12% SDS-PAGE. Western blot 
analysis of Bid was carried out. P-actin was used as internal control. The value at 
the bottom of each band represents the relative intensity after normalization with 
respect to P-actin and comparison was made with the corresponding control. Results 
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5.3.6 Involvement of Death Receptor Pathway in Cordycepin-induced 
Apoptosis in Leukemia Cells 
There is cross-talk between mitochondrial pathway (intrinsic pathway) and 
death receptor pathway (extrinsic pathway). Receptor-mediated activation of 
caspase-8 can cleave and activate Bid that can facilitate cytochrome c release from the 
mitochondria and as a result, activate downstream caspases (Kaufmann & Eamshaw， 
2000). As described in the previous section, Bid was cleaved to tBid in HL-60 and 
NB-4 cells after treated with cordycepin. This suggested that the death receptor 
pathway is involved in cordycepin-induced apoptosis. To test this hypothesis, the 
level of procaspase-8 and caspase-8 activity in HL-60 and NB-4 was evaluated after 
cordycepin treatment. 
As shown in Fig. 5.24A, the level of procaspase-8 in HL-60 was decreased 
after the treatment of cells with 100 and 200 [xM of cordycepin for 24 hours. For 
NB-4 cells, the level of procaspase-8 was also decreased after treated with 200 ^M of 
cordycepin for 24 hours (Fig. 5.24B). This indicated that activation of caspase-8 
occurred after cordycepin treatment. To verify the cleavage of procaspase-8 was 
correlated to caspase-8 activation, caspase-8 activity was determined after the 
treatment of cells with 150 |aM of cordycepin, by using the caspase-8 substrate 
Ac-IETD-AMC in the absence or presence of caspase-8 inhibitor z-IETD-fmk. 
‘ F r o m the results, the caspase-8 activity of HL-60 and NB-4 cells was increased after 
cordycepin treatment and suppressed in the presence of caspase-8 inhibitor (Fig. 5.25). 
This indicated the caspase-8 activation induced by cordycepin in HL-60 and NB-4 
cells. 
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Fig. 5.24 Cleavage of procaspase-8 in HL-60 and NB-4 cells treated with 
cordycepin. HL-60 (A) and NB-4 (B) cells (2x1 O�cells/ml) were treated with 
various concentrations of cordycepin as indicated for 24 hours at 37°C, 5% CO2. 25 
|ig of protein was loaded into each well and subjected to 12% SDS-PAGE. Western 
blot analysis of procaspase-8 was carried out. p-actin was used as internal control. 
The value at the bottom of each band represents the relative intensity after 
normalization with respect to P-actin and comparison was made with the 
corresponding control. Results are representative of three independent experiments. 
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‘Fig . 5.25 Inhibition of cordycepin-induced caspase-8 activation in leukemia cells. 
HL-60 (A) and NB-4 (B) cells (2x10^ cells/ml) were treated with 150 [iU cordycepin 
for 18 and 24 hours, respectively at 37°C, 5% CO2. Cytosolic extracts were 
prepared and assayed for caspase-8 activity with caspase-8 specific substrate 
Ac-IETD-AMC (50|LIM) in the absence or presence of caspase-8 inhibitor 
z-IETD-fmk (10 |aM). Values represent means 土 SD of there independent 
experiments. *p < 0.05 compared with the control. 
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Events leading to caspase-8 activation start with ligation of one of the death 
receptors such as Fas (CD95). Ligation of Fas by FasL results in receptor 
trimerization followed by binding of adaptor molecule known as Fas-associated death 
domain (FADD) to the cytoplasmic domain of the receptor. FADD in turn recruits 
procaspase-8 and cleave it into proteolytically active form (Kaufmann & Eamshaw, 
2000). In order to investigate whether cordycepin induces Fas expression in HL-60 
and NB-4 cells, the level of Fas was measured after treated with cordycepin. As 
shown in Fig. 5.26A, the expression of Fas in HL-60 cells was increased 
dose-dependently after the treatment of cells with cordycepin for 24 hours. While 
the expression of Fas in NB-4 cells was increased after the treatment with 100 and 
200 [iM of cordycepin for 24 hours (Fig. 5.26B). Therefore, the activation of 
caspase-8 was associated with the induction of Fas expression by cordycepin. 
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Fig. 5.26 Expression of Fas in cordycepin-treated HL-60 and NB-4 cells. HL-60 
(A) and NB-4 (B) cells (2x10^ cells/ml) were treated with various concentrations of 
cordycepin for 24 hours at 37°C, 5% CO2. Proteins were extracted and 50 jig of 
protein was loaded into each well and subjected to 12% SDS-PAGE. Western blot 
analysis was carried out as mentioned in Materials and Methods, p-actin was used 
as internal control. The value at the bottom of each band represents the relative 
intensity after normalization with respect to p-actin and comparison was made with 
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6.1 Cell Cycle Analysis of Hepatocellular Carcinoma Cells 
Cancer cells exhibit a diverse set of phenotypic abnormalities, including the 
increase of motility or invasiveness, loss of differentiation and decrease of drug 
sensitivity. The growth abnormality in cancer cells appears to be a result of the lack 
of appropriate responses to the signals that normally cause the cell to stop go through 
the cell cycle and lack of a cellular death program in response to appropriate stimuli 
or stresses (Kastan & Skapek, 2001). Some therapeutic agents take advantage of the 
disruption in normal cell cycle regulation to target checkpoint control and ultimately 
induce growth arrest or apoptosis in cancer cells (Villamarin et al., 2002; Park et al., 
2002). Cordycepin can inhibit the proliferation of human hepatoma HepG2 and 
multidrug resistant human hepatoma R-HepG2 cells. However, the mechanism of 
growth inhibition by condycepin is unclear. 
In order to investigate whether cordycepin induces cell cycle arrest in 
HepG2 and R-HepG2 cells, cell cycle analysis was carried out. HepG2 and 
R-HepG2 cells were treated with various concentrations of cordycepin for 24 and 48 
hours. After treatment, the cells were harvested and stained with PI. Flow 
cytometry analysis was carried out. As shown in Fig. 6.1 and Fig. 6.2, the number of 
HepG2 cells in G2/M phase of the cell cycle was increased after treating with 
cordycepin for 24 and 48 hours, respectively. For R-HepG2 cells, the number of 
,ce l l s in G2/M phase was also increased after cordycepin treatment (Fig. 6.3 and Fig. 
6.4). These results indicated that cordycepin inhibited the proliferation of HepG2 
and R-HepG2 cells via G2/M phase arrest of the cell cycle. 
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Fig. 6.1 Cell cycle distribution of HepG2 cells treated with cordycepin for 24 hr. 
HepG2 cells (1x10^ cells/ml) were seeded in a 6-well plate and incubated with 
medium atone (A) or cordycepin at 50 i^M (B), 100 pM (C) and 200 [M (D) for 24 
hours at 37�C, 5% CO2. The cells were stained with propidium iodide and analyzed 
by flow cytometry. Results are representative of three independent experiments. 
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Fig. 6.2 Cell cycle distribution of HepG2 cells treated with cordycepin for 48 hr. 
HepG2 cells (1x10^ cells/ml) were seeded in a 6-well plate and incubated with 
medium alone (A) or cordycepin at 50 i^M (B), 100 ^M (C) and 200 ^M (D) for 48 
hours at 37�C，5% CO2. The cells were stained with propidium iodide and analyzed 
by flow cytometry. Results are representative of three independent experiments. 
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Fig. 6.3 Cell cycle distribution of R-HepG2 cells treated with cordycepin for 24 
hr. R-HepG2 cells (1x10^ cells/ml) were seeded in a 6-well plate and incubated with 
medium alone (A) or cordycepin at 50 i^M (B), 100 i^M (C) and 200 ^M (D) for 24 
hours at 37°C, 5% CO2. The cells were stained with propidium iodide and analyzed 
by flow cytometry. Results are representative of three independent experiments. 
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Fig. 6.4 Cell cycle distribution of R-HcpG2 cells treated with cordycepin for 48 
hr. R-HepG2 cells (1x1 O，cells/ml) were seeded in a 6-well plate and incubated with 
medium alone (A) or cordycepin at 50 i^M (B), 100 |iM (C) and 200 |iM (D) for 48 
hours at 37°C, 5% CO2. The cells were stained with propidium iodide and analyzed 
by flow cytometry. Results are representative of three independent experiments. 
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6.2 Expression of Cell Cycle Regulatory Proteins in 
Cordycepin-treated Hepatocellular Carcinoma Cells 
Cell cycle is controlled by a family of cyclin depependent kinases (Cdks), 
whose activity is regulated by the binding of cyclins (Slingerland & Tannock, 1998). 
The cyclins activate specific Cdks, which are present constitutively in the nucleus: the 
resulting phosphorylation of a variety of target proteins on serine and threonine 
residues propels the cell through the cell cycle. Passage through Gi into S phase is 
regulated by the activities of cyclin D- and cyclin E-associated kinases. Cyclin D in 
Gi phase forms complexes with Cdk4 and Cdk6, thereby enabling the kinases to 
phosphorylate retinoblastoma protein (pRb) and release the repression of E2F that 
induces cyclin E expression. Cyclin E/Cdk2, together with cyclin D/Cdk(4，6)， 
propels the cell through the restriction point into S phase. Cyclin A/Cdk2 
accumulates during S phase and promotes passage through S and G2 phase. Cdkl 
also known as cdc2, activated by cyclin A and subsequently by cyclin B is responsible 
for driving the cell through the G2 and M phases (Slingerland & Tannock, 1998; 
Denhardt, 1999). Fig 6.5 showed the series of cyclin and Cdks involved in each 
phase of the cell cycle. 
To examine the mechanism of cordycepin in the induction of cell cycle 
arrest in HepG2 and R-HepG2 cells, the expression of cell cycle regulatory proteins in 
cordycepin-treated HepG2 and R-HepG2 cells were determined. Since cyclin A, 
cyclin B and cdc2 are required for the progression through the G2/M phase, the level 
of cyclin A, cyclin B and cdc2 were determined by Western blot analysis. As 
indicated in Fig. 6.6, the level of cyclin A was decreased dose-dependently in 
cordycpin-treated HepG2 and R-HepG2 cells. Treatment of HepG2 and R-HepG2 
cells with 50, 100 and 200 of cordycepin for 24 and 48 hours caused a decrease in 
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cyclin B1 expression (Fig. 6.7). Cdc2, the catalytic regulator of cyclin B was also 
decreased in HepG2 and R-HepG2 cells after treated with cordycepin for 24 and 48 
hours. The results suggested that the induction of cell cycle arrest in G2/M phase by 
cordycepin is mediated by the reduced expression of cyclin A, cyclin B1 and cdc2. 
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Fig 6.5 Progression through the cell cycle is governed by a series of cyclin 
dependent kinases (Cdks) whose activities are positively regulated by cyclins. In 
early G1 phase, pRb binds the transcription factor E2F and pRb/E2F complex inhibits 
transcription of genes whose products are essential for S phase entrance. Cyclin D 
dependent kinase relay proliferative signal by initiating phosphorylation of pRb, 
which leads to the relief of E2F repression. E2F then induces cyclin E expression. 
Cyclin E expression is maximal around the Gi/S border, and both cyclin E/Cdk2 and 
cyclin A/Cdk2 are necessary to initiate DNA replication. Cyclin A/Cdk2 
accumulates during S phase and promotes passage through S and G2 phase. Cyclin 
B/Cdkl complexes accumulate in G2 phase and induce mitosis. Cyclin A also plays 
a role in mitosis. 
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Fig. 6.6 Expression of cyclin A in cordycepin-treated HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (1x10^ cells/ml) were treated with various 
concentrations of cordycepin for 24 and 48 hours at 37°C, 5% CO2. Proteins were 
extracted and 25 |ig of protein was loaded into each well and subjected to 12% 
SDS-PAGE. Western blot analysis was carried out as mentioned in Materials and 
Methods, p-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to P-actin and 
comparison was made with the corresponding control. Results are representative of 
two independent experiments. 
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Fig. 6.7 Expression of cyclin Bl in cordycepin-treated HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (1x10^ cells/ml) were treated with various 
concentrations of cordycepin for 24 and 48 hours at 37°C, 5% CCh. Proteins were 
extracted and 25 i^g of protein was loaded into each well and subjected to 12% 
SDS-PAGE. Western blot analysis was carried out as mentioned in Materials and 
Methods, p-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to P-actin and 
comparison was made with the corresponding control. Results are representative of 
two independent experiments. 
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Fig. 6.8 Expression of cdc2 in cordycepin-treated HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (1x10^ cells/ml) were treated with various 
concentrations of cordycepin for 24 and 48 hours at 37°C, 5% CO2. Proteins were 
extracted and 25 |Lig of protein was loaded into each well and subjected to 12% 
SDS-PAGE. Western blot analysis was carried out as mentioned in Materials and 
Methods. P-actin was used as internal control. The value at the bottom of each 
band represents the relative intensity after normalization with respect to p-actin and 
comparison was made with the corresponding control. Results are representative of 
two independent experiments. 
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6.3 Increased Expression of p21 in Cordycepin-treated 
Hepatocellular Cellular Carcinoma Cells 
Cyclin dependent kinase inhibitors (CDKIs) bind and inhibit the activity of 
cyclin/Cdk complexes and negatively regulate cell cycle progression. There are two 
classes of mammalian CDKIs. One group is the CIP/KIP family, including 
p2iCip/wAFi，P27KIP1 and pSV'^ ^ l^ CIP/KIP inhibitors target a broad spectrum ofCdks, 
including Cdk2, Cdk4, Cdk6 and possibly, Cdkl. The other group is the INK4 
family, including pl5腿 'b, pi6狐4a，pig腿4C ^ d pl9狐'd，which inhibit specifically 
Cdk4 and Cdk6 (Harper et al., 1995; Slingerland & Tannock, 1998; Sherr, 2000). 
Increases in the levels of CDKIs, which bind to cyclin/Cdk complexes render the 
inactivation of these complexes. 
Since cordycepin caused the induction of G2/M phase arrest in the cell cycle 
of HepG2 and R-HepG2 cells and p21 was shown to play an important role in G2 
phase arrest (Niculescu, III et al, 1998)，the level ofp21 in HepG2 and R-HepG2 was 
determined by Western blot analysis. It was found that treatment of HepG2 and 
R-HepG2 cells with cordycepin for 24 hours caused an increase in p21 expression 
(Fig. 6.9). This implied that the induction of G2/M phase arrest in HepG2 and 
R-HepG2 cells is partly mediated by the induction of p21, which inactivate the 
cyclin/Cdk complexes in G2/M phase of the cell cycle. 
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Fig. 6.9 Expression of p21 in cordycepin-treated HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (1x10^ cells/ml) were treated with various 
concentrations of cordycepin for 24 hours at 37�C’ 5% CO2. Proteins were extracted 
and 25 of protein was loaded into each well and subjected to 12% SDS-PAGE. 
Western blot analysis was carried out as mentioned in Materials and Methods. 
P-actin was used as internal control. The value at the bottom of each band represents 
the relative intensity after normalization with respect to p-actin and comparison was 
made with the corresponding control. Results are representative of two independent 
experiments. 
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6.4 Involvement of p53 in G2/M Phase Arrest of the Cell 
Cycle in Hepatocellular Carcinoma Cells 
p53 protein is known to play a key role in growth arrest and apoptosis after 
cell stress. A recent study showed that p53 and p21 are necessary to maintain a G2 
arrest after DNA damage (Bunz et aL, 1998). Other studies found that p53 prevent 
the G2/M transition by repressing the transcription ofcdc2 and cyclin Bi (Innocente et 
al, 1999; Taylor et al., 1999). As we found that treatment ofHepG2 and R-HepG2 
cells with cordycepin resulted in an increase in p21 and a decrease in cdc2 and cyclin 
Bi expression, it was hypothesized that the induction of G2/M phase arrest in HepG2 
and R-HepG2 cells was mediated by p53. 
In order to examine whether p53 is involved in the induction of G2/M phase 
arrest by cordycepin, the level of p53 in HepG2 and R-HepG2 was determined after 
treated with cordycepin for 24 hours. As indicated in Fig. 6.10, there was a slight 
increase in p53 expression in HepG2 cells treated with 100 and 200 |iM of cordycepin 
and in R-HepG2 cells treated with 100 |aM of cordycepin. The results suggested that 
the induction of G2/M phase arrest in the cell cycle of HepG2 and R-HepG2 cells may 
involve p53. 
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Fig. 6.10 Expression of p53 in cordycepin-treated HepG2 and R-HepG2 cells. 
HepG2 (A) and R-HepG2 (B) cells (1x10^ cells/ml) were treated with various 
concentrations of cordycepin for 24 hours at 37°C, 5% CO2. Proteins were extracted 
and 25 |ig of protein was loaded into each well and subjected to 12% SDS-PAGE. 
Western blot analysis was carried out as mentioned in Materials and Methods, 
p-actin was used as internal control. The value at the bottom of each band represents 
the relative intensity after normalization with respect to p-actin and comparison was 
made with the corresponding control. Results are representative of two independent 
experiments. 
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6.5 Induction of Apoptosis in Cordycepin-treated R-HepG2 
cells 
As described in Chapter 5, cordycepin could induce apoptosis in leukemia 
cells. It was queried about whether cordycepin can induce apoptosis in 
hepatocellular carcinoma cells. Since apoptosis can be characterized by the 
morphological and biochemical changes, the morphology and genomic integrity of 
cordycepin-treated HepG2 and R-HepG2 cells were assessed. 
As indicated in Fig. 6.11，no morphological change was observed in HepG2 
cells that treated with various concentrations of cordycepin for 24 hours. Besides, 
no DNA fragmentation was detected in HepG2 cells after the treatment of HepG2 
cells with cordycpein for 24 and 48 hours (Fig. 6.13). For R-HepG2 cells, no 
morphological changes were observed in 24-hour cordycepin treatment (Fig 6.12). 
However, DNA fragmentation was observed in R-HepG2 cells that treated with 
cordycepin for 48 hours (Fig 6.14B). The results indicated that cordycepin can 
induce apoptosis in R-HepG2 cells in addition to the G2/M arrest in the cell cycle. 
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Fig. 6.11 Morphological study of HepG2 cells treated with cordycepin for 24 hr. 
HepG2 cells (1 x 10^  cells/ml) incubated with medium alone (A) or cordycepin at 50 
|iM (B), 100 mM (C) and 200 i^M (D) for 24 hours at 37�C，5% CO2. Hemacolor 
staining was carried out. Results are representative of two independent experiments. 
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Fig. 6.12 Morphological study of R-HepG2 cells treated with cordycepin for 24 hr. 
R-HepG2 cells (1 x 10^  cells/ml) were incubated with medium alone (A) or 
cordycepin at 50 (B), 100 ^M (C) and 200 ^M (D) for 24 hours at 37°C, 5% CO2. 
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Fig. 6.13 No induction of DNA fragmentation in cordycepin-treated HepG2 cells. 
HepG2 cells (1 x 10^  cells/ml) were seeded into a 100 mm culture dish, various 
concentrations of cordycepin were added and incubated for 24 or 48 hours at 37°C, 
5% CO2. After treatment, cells were collected, DNA was extracted, and subjected to 
1.5% agarose gel electrophoresis. (A) 24 hr treatment. Lane 1: control. Lane 2: 
50 jiiM cordycepin. Lane 3: 100 fxM cordycepin. Lane 4: 200 fiM cordycepin. 
Lane 5: 100 base pairs marker. (B) 48 hr treatment. Lane 1: 100 base pairs 
marker. Lane 2: control. Lane 3: 50 /xM cordycepin. Lane 4: 100 jLiM cordycepin. 
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Fig 6.14 Induction of DNA fragmentation in cordycepin-treated R-HepG2 cells 
for 48 hr. R-HepG2 (1 x 10^  cells/ml) cells were seeded into a 100 mm culture dish, 
various concentrations of cordycepin were added and incubated for 24 or 48 hours at 
37°C, 5% CO2. After treatment, cells were collected, DNA was extracted, and 
subjected to 1.5% 'agarose gel electrophoresis. (A) 24 hr treatment. (B) 48 hr 
treatment. Lane 1: 100 base pairs marker. Lane 2: control. Lane 3: 50 /xM 
cordycepin. Lane 4: 100 juM cordycepin. Lane 5: 200 fiM cordycepin. Results 
are representative of three independent experiments. 
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7.1 In Vitro and In Vivo Studies in the Biological Activities of 
WECM 
In my study, it was found that WECM possesses both direct and host 
mediated effects against various tumor cells. In the in vitro study, WECM inhibited 
the growth of human and murine tumor cells such as HepG2, R-HepG2, HL-60, NB-4 
and SC-180 after 24 and 48 hours treatment (Fig. 3.1 - Fig. 3.3). The sensitivity of 
HepG2 and R-HepG2 cells to WECM is lower than that of HL-60, NB-4 and SC-180 
cells. Since HepG2 and R-HepG2 cells are adhesive cells while HL-60, NB-4 and 
SC-180 cells are non-adherent cells in suspension, the adhesive cells may be tougher 
and affect the sensitivity to WECM. 
Although WECM could inhibit the growth of different tumor cells, little 
information is known about the active components of WECM. Several constituents 
such as P-silosterol, ergosterol, D-mannitol, uracil, guanine, uridine, guanosine, 
adenine, adenosine and cordycepin were found in Cordycpes militaris (Kaczka et al.’ 
1964; Shiao et al., 1989; Liu et al., 1989; Shiao et al, 1994; Guo et al, 1998). 
Among these chemical constituents of Cordyceps militaris, D-mannitol, adenosine 
and cordycepin that are commercially available as pure compounds were chosen to 
investigate their anti-proliferative effect on tumor cells such as HL-60, NB-4, HepG2 
and R-HepG2 cells. It was found that D-mannitol showed no anti-proliferative 
effect and adenosine only showed a slight anti-proliferative effect on the tumor cells 
being tested. Our results therefore suggested that D-mannitol and adenosine are not 
the major active components of WECM. In 1964, cordycepin was identified as a 
metabolite of Cordyceps militaris by Kaczka et al. (1964). The biological activities 
of cordycepin include: (a) inhibition of RNA synthesis (Glazer, 1976), (b) disruption 
of microtubule network (Deitch & Sawicki，1979; Zieve et cd., 1987)，(c) inhibition of 
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nucleic acid methylation (Kredich, 1980), (d) enhancement of cell differentiation 
(Mathew et aL, 1989)，(e) inhibition of eukaryotic DNA primase (Izuta et al.’ 1996), (f) 
anti-tumor activity (Koc et al., 1996; Kodama et al., 2000) and (g) anti-fungal activity 
(Sugar & McCaffrey，1998). From my study, cordycepin could inhibit the growth of 
HepG2, R-HepG2, HL-60 and NB-4 cells. Cordycepin might be one of the active 
components of WECM in inhibiting tumor growth. By HPLC analysis, it was found 
that WECM contained about 1.23% of cordycepin (data not shown). 100 |ag/ml of 
WECM contained 1.23 of cordycepin. By converting it into level, 100 }ag/ml 
of WECM contained 5 i^M of cordycepin. This value is not equal to the IC50 value 
of cordycepin. This implied that components other than cordycepin played a role in 
inhibiting the tumor growth. Study of Kuo et al. (1994) showed that growth 
inhibitors present in fruiting bodies of Cordyceps sinensis inhibited the growth of 
tumor cells such as K562, Vero, Wish, Calu-1 and Raji cells. Besides, sterols from 
the mycelia of Cordyceps sinensis also inhibited the proliferation of K562, Jurkat, 
WM-1341, HL-60 and RPMI-8226 cells (Bok et al； 1999). Therefore, other 
components present in WECM may play a role in inhibiting the tumor growth. 
However, further investigation is required to find out other active ingredients or the 
synergistic action, if any, among the active ingredients. 
Study of Du et al. (1986) demonstrated that subcutaneous and peritoneal 
injection of water extract of Cordyceps sinensis into C57BL mice inhibited the growth 
of Sarcoma 180. Liu et al (1997) also found that Cordyceps militaris inhibited the 
growth of Sarcoma 180 and prolonged the survival period of Swiss mice bearing the 
tumor. In order to investigate whether WECM can inhibit the growth of tumor in 
vivo, in vivo study was also conducted. In my study, BALB/c mice were inoculated 
with Sarcoma 180 subcutaneously. After 7 days of inoculation, oral administration 
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of various dosages of WECM (20 mg/kg/day, 40 mg/kg/day and 200 mg/kg/day) were 
applied to BALB/c mice for 21 days consecutively. It was found that the group with 
treatment protocol 20 mg/kg/day did not inhibit the growth of tumor. While the 
group of 40 mg/kg/day and 200 mg/kg/day inhibited the growth of tumor by 92% and 
60%, respectively (Fig. 3.5). Since the standard deviation of tumor weight in the 
group of 200 mg/kg/day was very large, the inhibition of tumor growth in this group 
may be underestimated. The large standard deviation in tumor weight may be due to 
the individual variation among the BALB/c mice. 
In addition to the direct cytotoxic effect of WECM, WECM was found to 
have immunostimulatory effect. WECM stimulated the proliferation of splenic 
lymphocytes in vitro. However, WECM only stimulated the splenic lymphocytes 
proliferation at low concentrations (Fig 3.4). At high concentrations of WECM, it 
inhibited the growth of tumor cells directly. The effects of Cordyceps sinensis on 
murine T lymphocyte subsets have been reported. Chen et al (1991) noted that 
Cordyceps sinensis increased the number of T helper cells and the T helper to T 
suppressor cells ratio in peripheral blood and spleen of mice. In our in vivo study, it 
was found that WECM stimulated the proliferation of T helper (CD4+) cells and 
cytotoxic T (CD8+) cells after 21 days treatment (Fig. 3.8). 
CD4+ T cells have been subdivided into two subsets, Thl and Th2, on the 
basis of the patterns of cytokines that they secrete after being stimulated. The 
secreted cytokines determine the function of the T cell. One group promotes 
primarily cellular immune responses and the other group promotes humoral immune 
response. In mouse models, Thl cells secrete primarily IL-2, IFN-y, and TNF-(3 
(lymphotoxin), and they promote delayed-type hypersensitivity responses, cytotoxic 
cell responses, and macrophage activation (Restifo & Wunderlich，2001). On the 
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Other hand, Th2 cells secrete IL-4, IL-5, IL-6 and IL-10, and promote B-lymphocyte 
responses and the synthesis of IgG, IgE, and IgA antibodies (Restifo & Wunderlich, 
2001). Cytotoxic T cells have also been classified into two groups. CD8+ T cells 
that secrete Thl-like cytokine are referred to as Tel, while CD8+ T cells that secrete 
Th2-like cytokines are referred to as Tc2 cells (Restifo & Wunderlich，2001). The 
cytokine pattern released by splenic lymphocytes was investigated too. From our 
results, a significant increase in the release of IL-2 and IFN-y was observed in the 
splenic lymphocytes of 40 mg/kg/day and 200 mg/kg/day treatment groups (Fig 3.9 
and Fig. 3.10). On the contrary, no increase in IL-4 release was observed in the 
splenic lymphocytes of all groups of treatment. Our results therefore demonstrated 
that the CD4+ and CD8+ T cells stimulated by WECM were Thl and Tel subtype. 
We speculated that the activation of CD4+ T cells by WECM caused the 
release of IL-2 and IFN-y. IL-2 subsequently induced the proliferation of CD8+ T 
cells. Cytotoxic T cells can kill the tumor cells after cross-linking of the T cell 
receptors (ICRs) with the target cell MHC class I antigen. There are two 
mechanisms of cytotoxicity that are characterized among CD8+ T cells: (1) secretory 
granule exocytosis and (2) triggering of programmed cell death by surface Fas 
receptor (APO-1, CD95) (Apasov & Sitkovsky, 1999; Restifo & Wunderlich，2001). 
With respect to the secretory granule exocytosis, activated CD8+ T cells are able to 
form conjugates with potential target cells and upon TCR stimulation, to secrete the 
‘ contents of the cytolytic granules into the extrcellular synapse-like junctional cleft 
formed between the CD8+ T cells and the target cells. Perforin forms pores in the 
outer membrane of the target cell, thereby permeabilizing them for ions and 
granzymes that diffuse into the target cell cytoplasm. Granzymes enter the target 
cells and induce apoptosis of the target cells. Another way of killing the tumor cells 
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involves the cross-linking of Fas molecules. Activated CD8+ T cells upregulate 
surface expression of Fas ligands that cross-link Fas molecules on target cells and 
induce apoptosis of target cells (Apasov & Sitkovsky，1999; Restifo & Wunderlich, 
2001). Therefore, the anti-tumor activity of WECM may be mediated by cytotoxic T 
cells that directly kill the tumor cells. 
IFN-y is a specific cytokine produced by activated Thl, Tel and NK cells. 
IFN-y stimulates innate cell-mediated immunity through NK cells, specific cytotoxic 
immunity based on the recognition of cell surface-bound antigen expressed in 
association with MHC molecules and activation of macrophages (Boehm et al, 1997). 
NK cells and activated macrophages are the host's major sources of cell-mediated 
cytotoxic activity that are not triggered by antigen-specific recognition of foreign cells 
(Restifo & Wunderlich，2001). NK cells are lymphocytes with cytotoxic potential 
against certain tumor cells. Studies from Liu et al. (1992) and Xu et al (1992) 
showed that Cordyceps sinensis activated the activity of NK cells in vitro and in vivo. 
The increase of NK cell activity inhibited the colony formation of Bie melanoma in 
mouse lungs (Xu et aL, 1992). Therefore, increase in NK cell activity may also 
contribute to the anti-tumor activity. Several studies demonstrated that Cordyceps 
sinensis caused the activation of macrophage (Zhang, 1985; Chen, 1985; Koh et al, 
2002). In my study, there was a slight increase in plasma IL-ip level in BALB/c 
mice that treated with WECM for 21 days (data not shown). Since activated 
macrophage may release IL-ip, the increase in IL-lp release indicated the activation 
of macrophage. Therefore, the anti-tumor effect of WECM may be partly mediated 
by the T cell proliferation and the activation of macrophage. 
From the toxicity study, 21 days treatment of BALB/c mice with WECM did 
not cause the increase of plasma CK, LDH, AST and ALT levels. This indicated that 
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WECM is not toxic to the heart and liver. In the in vitro cytotoxicity study, WECM 
at the concentration of 50 - 200 |ag/ml exerted a slight cytotoxic effect on the normal 
liver cells WRL-68, whereas it inhibited the growth of tumor cells for over 50% 
(Table 3.1 and Fig. 3.15). Therefore, WECM exerted less cytotoxic effect on the 
normal liver cells. Cordycepin is one of the active components in Cordyceps 
militaris. At the concentration of 120 - 150 i^M, it showed a significant growth 
inhibition in tumor cells. However, it only exerted a slight cytotoxic effect on the 
normal liver cells. This indicated that cordycepin is relatively less toxic to the 
normal liver cells. Furthermore, we found that cordycepin did not induce hemolysis. 
Therefore, the adverse effect of cordycepin is mild. 
：• ‘ 
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12 Induction ofApoptosis in Leukemia Cells by Cordycepin 
Cordycepin is one of the active components in the WECM. In my study, 
cordycepin was found to inhibit the growth of human acute promyelocytic leukemia 
HL-60 and NB-4 cells. Since anti-proliferation can be mediated by the induction of 
cell cycle arrest, cell differentiation and apoptosis, the way of growth inhibition 
induced by cordycepin in HL-60 and NB-4 cells was investigated. Changes in DNA 
histogram are commonly used to study the action mechanism of cytotoxic drugs, as 
they will generally disrupt the cell cycle. Therefore, we first looked into the cell 
cycle by staining the cells with PI after cordycepin treatment and fixation. It was 
found that no cell cycle arrest was observed in both HL-60 and NB-4 cells (Fig 5.1 
and Fig 5.2). However, sub Gi peaks which represent the apoptotic cells were 
observed after treatment of cells with 100 and 200 of cordycepin for 24 hours 
(Fig. 5.1 and Fig. 5.2). These results suggested that the anti-proliferative effect of 
« 
cordycepin on HL-60 and NB-4 cells was due to the induction of apoptosis. In order 
to confirm this hypothesis, PS extemalization analysis and DNA fragmentation assay 
were carried out. When cells undergo apoptosis, PS is translocated from the inner to 
outer leaflet of the plasma membrane (van Engeland et al, 1998), and the apoptotic 
cells can be detected by the use of Annexin V-FITC and PI. In my study, the number 
of apoptotic HL-60 and NB-4 cells was increased in a dose- and time-dependent 
manner (Fig. 5.3 and Fig. 5.4). DNA fragmentation, which is the hallmark of 
apoptosis, was also observed in HL-60 and NB-4 cells that treated with cordycepin for 
24 and 48 hours (Fig. 5.5 and Fig 5.6). Besides, apoptosis is characterized by a 
series of morphological features such as shrinkage of cell, condensation of nuclear 
chromatin and fragmentation into membrane-bound apoptotic bodies (Saraste & 
Pulkki, 2000; Yamada et al, 2003). By the morphological study, it was found that 
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morphological changes such as cell shrinkage, nuclear condensation and formation of 
apoptotic bodies were observed in HL-60 and NB-4 cells (Fig. 5.7 and Fig. 5.8). 
These results further support the idea that the anti-proliferative effect of cordycepin 
on HL-60 and NB-4 cells was due to the induction of apoptosis. 
At molecular level, apoptosis is tightly regulated by the activation of the 
caspase cascade. There are two main pathways leading to the activation of caspases. 
One of the pathways is mitochondrial pathway (intrinsic pathway), involving the 
participation of mitochondria. Another pathway is death receptor pathway (extrinsic 
pathway), involving the interaction of a death receptor with its ligand (Kaufmann & 
Eamshaw, 2000; Herr & Debatin, 2001; Zimmermarm et al.，2001). Pro- and 
anti-apoptotic members of the Bcl-2 family regulate the mitochondrial pathway. 
Cellular stress induces pro-apoptotic Bcl-2 family members to translocate from the 
cytosol to the mitochondria and induce the release of cytochrome c, while the 
anti-apoptotic Bcl-2 proteins prevent the cytochrome c release from mitochondria 
(Coultas & Strasser, 2003). Cytochrome c released from mitochondria catalyzes the 
oligomerization of apoptotic protease activating factor-1 (Apaf-1) and promoting the 
activation of procaspase-9, which then activates the procaspase-3 (Li et al” 1997; 
Srinivasula et aL, 1998; Hu et aL, 1999). For the death receptor pathway, ligation of 
death receptors such as tumor necrosis factor receptor-1 and Fas receptor causes the 
activation of caspase-8. Caspase-8 may either directly activate caspase-3 or cleave 
the pro-apoptotic protein Bid, which then subsequently induces cytochrome c release 
(Zimmermann et al., 2001; Esposti, 2002). The consequence of either pathway is 
caspase activation and cleavage of specific cellular substrates and resulting in the 
morphological and biochemical changes associated with the apoptotic phenotype. 
With the evidence from our results that cordycepin induced apoptosis in 
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HL-60 and NB-4 cells, we next focused on the apoptotic pathway which cordycepin 
induces. Mitochondria play a central role in apoptosis. Dysfunction of 
mitochondria may lead to apoptosis. In order to investigate whether mitochondria 
are involved in the cordycepin-induced apoptosis, mitochondrial membrane potential 
was measured. It was found that treatment of HL-60 and NB-4 cells with 
cordycepin caused the loss mitochondrial membrane potential (Fig. 5.13 and Fig.5.14). 
This implicated that cordycepin exposure caused mitochondrial dysfunction. 
In some experimental situations, induction of apoptosis is accompanied by 
an increase in intracellular reactive oxygen species (ROS) level. Recent studies have 
suggested that hydrogen peroxide mediated the induction of apoptosis in response to 
external stimuli in HL-60 and NB-4 cells (Jing et al., 1999; Mizutani et aL, 2002). 
Therefore, the H2O2 levels in HL-60 and NB-4 cells were also examined. In my 
study, treatment of HL-60 and NB-4 cells with cordycepin caused an increase in 
intracellular H2O2 in a dose- and time-dependent manner (Fig. 5.15 and Fig. 5.16). 
The increase of intracellular H2O2 was observed as early as at 8 hours after treatment 
and the H2O2 was released with a collapse in the mitochondrial membrane potential in 
HL-60 and NB-4 cells. This can be explained by the fact that ROS takes a role in 
triggering the mitochondrial permeability transition and thereby lowering the A\\！m in 
the cells. Our results also showed that the level of H2O2 generated in NB-4 cells was 
higher than that of HL-60 cells after codycepin treatment (Fig 5.15 and Fig 5.16). 
This may be due to the relatively low levels of glutathione peroxidase and catalase in 
NB-4 cells as reported by Jing et al. (1999). The higher H2O2 level generated in 
NB-4 cells may contribute to the higher sensitivity of NB-4 cells to cordycepin. 
Increase in permeability of the outer mitochondrial membrane leads to the 
release of several apoptogenic factors, such as cytochromec c, AIF, Smac/Diablo, 
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endonuclease G which activate downstream death programs (Wang, 2001; Tsujimoto, 
2003). From our results, cytochrome c was released in HL-60 and NB-4 cells in a 
dose-dependent manner after the treatment of cells with cordycepin (Fig. 5.17). The 
mechanism of mitochondrial membrane permeabilizatoin is not completely 
understood. Normally, the outer membrane is not permeable to proteins that reside 
in the intermembrane space, such as cytochrome c. One mechanism through which 
mitochondrial outer membranes can become permeabilized is through the 
mitochondrial permeability transition (MPT). Permeability transition involves the 
opening of a proteinaceous channel, known as the permeability transition (PT) pore, 
in the inner membrane. PT pore was thought to be comprised of complexes between 
cyclophilin D and the adenine nucleotide translocator (ANT) in the inner membrane, 
associated with voltage-dependent anion channel (VDAC) and the peripheral 
benzodiazepine receptor in the outer membrane (Kroemer & Reed, 2000; Newmeyer 
& Ferguson-Miller, 2003). PT pore opening is regulated by voltage, matrix pH, 
oxidative stress, electron flow, and by two of the pore constituents, cyclophilin D and 
ANT (Gottlieb, 2000). Sustained opening of the PT pore allows the equilibration of 
ions between the matrix and cytoplasm and renders a dissipation of the inner 
membrane potential, A\i/m. The ionic redistribution also leads to an osmotic swelling 
of the matrix and a consequent rupture of the outer membrane (Newmeyer & 
Ferguson-Miller, 2003). Rupture of the outer mitochondrial membrane results in the 
release of cytochrome c. 
Mitochondrial membrane permeability is directly controlled by the 
apoptosis regulators, such as Bcl-2 family proteins. Bcl-2 family proteins have been 
classified into three subfamilies based on various structural and functional 
characteristics. The anti-apoptotic subfamily comprises Bcl-2, BCI-XL, Bcl-w, Mcl-l 
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and Al. These proteins share sequence homology within some of the four Bcl-2 
homology (BH) regions, BHl through BH4. Pro-apoptotic subfamily members such 
as Bax, Bak, Bok and Bcl-rambo share sequence homology within their BHl, BH2 
and BH3, but not BH4 region. Another Bcl-2 subfamily is the BH3-only subfamily, 
members such as Bik, Bad, Bid, Bim and Noxa are pro-apoptotic and only share 
sequence homology at the BH3 region (Tsujimoto, 2002; Tsujimoto, 2003). Cellular 
response to the death signals depends on the ratio of pro- and anti-apoptotic molecules. 
Recent studies showed that Bcl-2 maintains the translocase activity of ANT and 
prevents the pore formation, while Bax inhibit the translocase activity of ANT and 
favor the pore forming (Belzacq et al., 2003; Brenner et al., 2000). Other studies 
found that Bax interacts with VDAC and form large pore, while Bcl-2 is able to close 
the VDAC and prevent pore formation (Shimizu et al., 2000a; Shimizu et al., 2000b). 
Another hypothesis about pore formation is that the pro-apoptotic Bcl-2 family 
members are inserted in the outer membrane where they oligomerize and form 
cytochrome c permeant pores and do not require the interaction with other 
mitochondrial membrane proteins (Costantini et al., 2000; Tsujimoto & Shimizu, 
2000). However, Bcl-2 family members may have to undergo a change in 
conformation before undertaking membrane insertion. Taken together, the major 
function of the Bcl-2 family is to directly modulate mitochondrial membrane 
permeability and thereby regulating the release of apoptogenic factors from the 
intermembrane space into the cytoplasm. 
In order to investigate the cause of cytochrome c release, the levels of pro-
and anti-apoptotic Bcl-2 family members in HL-60 and NB-4 cells were examined 
after cordycepin treatment. It was found that the levels of Bcl-2 in HL-60 and NB-4 
cells were decreased (Fig. 5.20), while the level of Bax was increased after treated 
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with cordycepin (Fig. 5.21). The increase in the Bax to Bcl-2 ratio after treatment of 
cells with cordycepin may contribute to the opening of mitochondrial permeability 
transition pore and the release of cytochrome c. Besides, the level of Bcl-Xs in 
HL-60 and NB-4 cells was also increased dose-dependently after cordycepin 
treatment (Fig. 5.22). The increase in the Bcl-Xs may counteract the activity of 
anti-apoptotic Bcl-2 and induce cytochrome c release. 
The release of cytochrome c is usually accompanied with the activation of 
caspase-9 by cleaving the procaspase-9. Therefore, the levels of procaspase-9 in 
HL-60 and NB-4 cells were determined by Western blot analysis after cordycepin 
treatment. From our results, the levels of procaspase-9 in HL-60 and NB-4 cells 
decreased in a dose- and time-dependent manner after cordycepin treatment (Fig. 
5.18). This indicated that procaspase-9 was cleaved to active caspase-9. To 
confirm this hypothesis, the activities of caspase-9 in HL-60 and NB-4 cells were also 
determined. It was found that the caspase-9 activities in HL-60 and NB-4 cells were 
increased after treating with cordycepin for 18 and 24 hours (Fig. 5.19). The 
caspase-9 activities were suppressed after treating the cytosolic extract with caspase-9 
specific inhibitor z-LEHD-fmk. These results indicated that caspase-9 was activated 
in the cordycepin-induced apoptosis. 
Caspase-3 is one of the effector caspases that actively participates in the 
caspase-dependent apoptotic pathway. As shown from our results, cordycepin 
decreased the levels of procaspase-3 in HL-60 and NB-4 cells (Fig. 5.9) while the 
caspase-3 activities in HL-60 and NB-4 cells were increased after codycepin 
treatment (Fig. 5.11). These results suggested the occurrence of caspase-3 activation. 
PARP is a zinc-finger DNA-binding enzyme, which detects and signals DNA strand 
breaks generated directly during base excision repair or indirectly by genotoxic agents. 
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PARP is activated at an intermediate stage of apoptosis and is then cleaved and 
inactivated at a late stage by caspase-3 (Decker & Muller, 2002). The levels of 
PARP in HL-60 and NB-4 were also determined after cordycepin treatment. It was 
found that PARP in HL-60 and NB-4 cells was cleaved into a 85 kDa fragment after 
the treatment of cells with cordycepin for 24 hours (Fig. 5.10). This further 
confirmed that the decrease of procaspase-3 level in HL-60 and NB-4 cells after 
cordycepin treatment was due to the activation of caspase-3. In non-apoptotic cells, 
caspase-activated deoxyribonuclease (CAD) is present as an inactive complex with its 
inhibitor (ICAD). Caspase-3 activated by apoptotic stimuli then cleaves the ICAD, 
allowing CAD to enter the nucleus and degrade chromosomal DNA (Enari et al.’ 
1998). 
There is a cross-talk between mitochondrial and death receptor pathway 
through the action of Bid. The action of Bid was believed to involve the 
mitochondrial re-location of its truncated form (tBid), to facilitate the release of 
apoptogenic proteins such as cytochrome c (Esposti, 2002). Desagher et al. (1999) 
reported that during certain types of apoptosis, Bid translocates to mitochondria and 
binds to Bax, leading to a change in conformation of Bax and the release of 
cytochrome c release form mitochondria. While Eskes et al. (2000) found that 
binding of Bid to Bax triggered the oligomerization and integration of Bax in the 
outer mitochondrial membrane, thereby releasing cytochrome c. Besides, Bid 
cleaved by caspase-8 is at least 10-fold more efficient in triggering Bax insertion into 
the mitochondrial membrane and cytochrome c efflux from mitochondria. Study of 
Grinberg et al. (2002) indicated that tBid itself could oligomerize and form pores in 
the mitochondrial membrane. The above evidence suggested that tBid is an 
important protein that triggers the release of cytochrome c. In order to investigate 
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whether Bid is involved in the cordycepin-induced apoptosis, the levels of Bid and its 
truncated form tBid were determined by Western Blot analysis. According to our 
results, treatment of HL-60 and NB-4 cells with cordycepin resulted in the cleavage of 
Bid to tBid (Fig. 5.23). Taken together, tBid translocated to mitochondria may assist 
in the pore formation and trigger the release of cytochrome c from mitochondria to 
cytosol and the subsequent activation of caspase-3 in response to cordycepin 
treatment. 
Since we have found that tBid participated in the apoptotic pathway 
induced by cordycepin, we further investigate whether caspase-8 which cleaves the 
Bid to tBid was activated. It was found that the levels of procaspase-8 in HL-60 and 
NB-4 cells were decreased after treated with cordycepin (Fig. 5.24). This is due to 
the cleavage of procaspase-8 to active caspase-8. The activation of caspase-8 was 
further confirmed by measuring the caspase-8 activity. Our results showed that the 
caspase-8 activity of HL-60 and NB-4 cells was increased after treating with 150 [xM 
of cordycepin for 18 and 24 hours (Fig. 5.25). The caspase-8 activity at 18 hours 
treatment was higher than that of 24 hours treatment. It was because caspase-8 is an 
initiator caspase and it is activated at early time point in response to the apoptotic 
stimulus. Our results therefore demonstrated that the apoptosis induced by 
cordycepin involves the activation of caspase-8. 
Since activation of death receptor pathway involves members of the TNF 
receptor superfamily such as Fas. In order to investigate whether cordycepin affects 
the expression of Fas, the levels of Fas in HL-60 and NB-4 cells were determined 
after cordycepin treatment. It was found that the expression of Fas was increased in 
HL-60 and NB-4 cells after treated with cordycepin for 24 hours. Fas acts upstream 
of the caspase-8. The binding of Fas with its trimeric ligand (FasL) induces the 
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trimerization of the receptor itself. Upon Fas activation, it recruits the adaptor 
protein, Fas-associated death domain (FADD) through an interaction between the 
C-terminal domain of Fas and the death domain of FADD. This interaction is 
followed by the recruitment of FADD-like ICE (FLICE), which contains procaspase-8 
on its C-terminus, via an interaction of the death effector domain in FADD with the 
N-terminal domain in FLICE. These four proteins assemble in a complex called 
death-inducible signal complex (DISC). A high proximal concentration of 
procaspase-8 within this complex was thought to induce its autoproteolytic cleavage 
to yield active caspase-8 (Zhivotovsky & Orrenius，2003; Ozoren & El Deiry, 2003). 
Caspase-8 is then initiates the down stream pathway of apoptosis as mentioned above. 
Our results demonstrated that the activation of death receptor pathway was initiated 
by the increased expression of Fas and the activation of caspase-8. The increased 
expression of Fas in the tumor cells induced by cordycepin also allows the cytotoxic T 
cells and NK cells to kill the tumor cells by triggering apoptosis. The proposed 
apoptotic pathway induced by cordycepin was shown in Fig. 7.1. 
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Fig. 7.1 Proposed apoptotic pathway in HL-60 and NB-4 cells induced by 
cordycepin. Cordycepin can induce apoptosis through the death receptor pathway 
or mitochondrial pathway. Cordycepin induces cellular stress and causes an increase 
in expression of death receptor (Fas), triggering the activation of caspase-8. Active 
caspase-8 directly activates caspase-3 or cleaves the Bid to tBid. tBid in the cytosol 
is translocated to mitochondrial membrane and leading to the disruption of outer 
mitochondrial membrane and the release of cytochrome c. On the other hand, 
cordycepin increases the expression of Bax and Bcl-Xs, and decreases the expression 
of Bcl-2, leading to the permeabilization of outer mitochondrial membrane and the 
release of cytochrome c. Cytochrome c associates with Apaf-1 and procaspase-9 in 
the presence of dATP/ATP to form apoptosome and leads to activation of caspase-9. 
Active caspase-9 cleaves the procaspase-3 to active caspase-3 and resulting in 
apoptosis. 
_ — ~ 
Chapter 7 Discussion 
7.3 Induction of Cell Cycle Arrest in Hepatocellular 
Carcinoma Cells by Cordycepin 
In my study, cordycepin was also found to inhibit the growth of human 
hepatocellular carcinoma HepG2 and multidrug resistant human hepatocellular 
carcinoma R-HepG2 cells. Flow cytometric analysis revealed that 
cordycepin-treated HepG2 and R-HepG2 cells were arrested in the G2/M phase of the 
cell cycle (Fig. 6.1- Fig. 6.4). However, the mechanism of the induction of cell cycle 
arrest in HepG2 and R-HepG2 cells is unclear. In order to investigate the 
mechanism of cell cycle arrest by cordycepin, we further looked into the proteins that 
regulate the G2/M phase transition. Progression through the cell cycle is controlled 
by the action of cyclin dependent kinases (Cdks) whose activity is governed by the 
binding of cyclins. Cdc2 interacts with cyclin B has been found to play an important 
role in the regulation of the cell cycle. Activation of the cdc2/cyclin B complex is « 
required for transition from the G2 to the M phase of the cell cycle (Nurse, 1990). 
Therefore, we tried to find out whether the expression of cyclin BI and cdc2 in 
HepG2 and R-HepG2 cells was affected by the cordycepin treatment. Western blot 
analysis showed that the levels of cyclin BI and cdc2 in HepG2 and R-HepG2 cells 
were decreased after cordycepin treatment (Fig. 6.7 and Fig. 6.8). These results 
suggested that the cell cycle arrest is mediated by the limited supply of cyclin B1 and 
cdc2 for the formation of cyclin B/cdc2 complex, which is an essential step in 
regulating the passage into mitosis. Since cyclin A also plays a role in the G2/M 
phase transition, the levels of cyclin A in HepG2 and R-HepG2 cells were also 
evaluated. It was found that the expression of cyclin A in HepG2 and R-HepG2 cells 
was decreased after treated with cordycepin. This suggested that the decrease in 
cyclin A expression was mediated in part in the cordycepin-induced cell cycle arrest. 
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During G2 phase, the cdc2/cyclin B complex is kept inactive by 
phosphorylation on tyrosine 15 and threonine 14 of cdc2 by the kinases Weel and 
Mytl，respectively. At the onset of mitosis, both of these residues are 
dephosphorylated by the phosphatase cdc25. However, the activity of cdc2 can be 
inhibited by a number of events. For example, DNA damage stimulates the kinases 
ATM and ATR, which activate the Chkl and Chk2 kinases, which then phosphorylate 
cdc25, causing cdc25 to bind to 14-3-3 proteins and thereby inhibiting cdc25 to 
activate cdc2 (Taylor & Stark, 2001). Jin et al (2000) reported that Gadd45 
contained a cdc2-binding domain and directly dissociated the cdc2/cyclin Bl protein 
complex. p21 is a Cdk inhibitor and it inhibits Cdk activity by binding directly to 
Cdk/cyclin complexes (Harper et al., 1995). In order to investigate whether p21 was 
involved in the cordycepin-induced cell cycle arrest, p21 levels in HepG2 and 
R-HepG2 cells were determined by Western blot analysis. It was found that the 
levels of p21 in HepG2 and R-HepG2 were increased after treated with cordycepin for 
24 hours (Fig. 6.9). Our results therefore suggested that the G2/M phase arrested 
induced by cordycepin was partly mediated by the increase in p21 that inhibits the 
activity of cdc2. 
As increasing number of studies reported that G2 arrest involved the 
overexpression ofp53 (Bunz et al., 1998; Taylor et al., 1999; Innocente et al, 1999), 
the levels of p53 in HepG2 and R-HepG2 cells were also investigated after 
cordycepin treatment. A slight increase in p53 level was observed in HepG2 cells 
treated with 100 and 200 |liM of cordycepin and in R-HepG2 cells treated with 100 
|iM of cordycepin (Fig. 6.10). Therefore, the cordyepin-induced cell cycle arrest 
may involve p53. 
A number of p53-regulated, cell cycle-related genes have been identified. 
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Cyclin A, cyclin B and cdc25 that activates the cdc2 were found to be 
transcriptionally downregulated by p53 (Desdouets et al., 1996; Innocente et al.，1999; 
Krause et al., 2000; Krause et aL, 2001). Taylor et al. (1999) demonstrated that 
overexpression of p53 caused the loss of cyclin B1 followed by the loss of cdc2 by 
transcriptional repression. In addition, p21, a potent inhibitor of Cdk, was found to 
be induced in wild-type p53 containing cells by exposure to DNA damaging agents, 
but not in mutant p53-containing cells (El Deiry et aL, 1994). Therefore, p21 is 
upregulated by p53. In my study, the levels of cyclin A, cyclin B and cdc2 in HepG2 
and R-HepG2 cells were decreased while the levels of p21 and p53 were increased 
after cordycepin treatment. These results suggested that the cell cycle arrest induced 
by cordycepin was due to the increase of p53. Since the regulation of p53 stability 
and its response are very complicated, further investigation is required to investigate 
the mechanism by which cordycepin induces the p53-mediated cell cycle arrest. The 
proposed pathway for the cordycepin-induced G2/M arrest was shown in Fig. 7.2. 
Cordycepin was found to arrest HeLa cells, Vero cells and Nil 8 hamster 
fibroblasts at the onset of mitosis by other investigators (Deitch & Sawicki，1979; 
Zieve et al.，1987). Study of Deitch and Sawicki (1979) showed that the arrest in 
mitosis was due to the effect of cordycepin in the polymerization of microtubules. 
Similar results were observed in the study of Zieve et al. (1987). Zieve et al. (1987) 
found that 15 minutes after the addition of cordycepin to the culture medium cells 
begin to arrest at the onset of mitosis with the depolymerization of the spindle 
microtubules to small aster. By 45 minutes, the number of microtubules begins to 
decline and only a few microtubules remain in the cytoplasm after 4 hours. Since 
the HPLC analysis demonstrated that cordycepin taken up by the cells was 
phosphorylated to 3'-dATP, while the ATP level was declined, Zieve et al (1987) 
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proposed that 3，-dATP directly inhibited an ATP-dependent process necessary for the 
normal maintenance of the fiber networks. This alternative mechanism for the 
mitosis arrest suggested by other investigators may also occur in the G2/M arrest in 
HepG2 and R-HepG2 cells. However, further investigations are required. 
It is interesting to note that cordycepin induces apoptosis in acute 
promyelocytic leukemia cells but induces cell cycle arrest in hepatocellular carcinoma 
cells. By looking at the p53 status, p53 gene in both HL-60 and NB-4 cells was 
mutated (Wolf & Rotter, 1985; Fleckenstein et al., 2002), while HepG2 and R-HepG2 
cells have wild type p53. Since p53 expressed in HL-60 and NB-4 cells are inactive, 
apoptosis induced by cordycepin is p53-independent. However, p53-independent 
mechanisms of cell death remain unclear. Cellular level of p53 can affect the choice 
of responses, such as induction of cell cycle arrest or apoptosis (Chen et al., 1996). 
The increase in p53 level in HepG2 and R-HepG2 cells induced by cordycepin caused 
the induction of G2/M phase arrest in the cell cycle. The anti-tumor effect induced 
by cordycepin in leukemia and hepatocellular carcinoma cells may through distinct 
mechanisms. 
p21 is believed to be a negative regulator of apoptosis (Cartel & Tyner， 
2002). Suzuki et al. (1998) revealed that p21 in HepG2 cells form complex with 
procaspase-3 and prevented Fas-mediated apoptosis. Our results showed that 
cordycepin increased the levels of p21 in HepG2 and R-HepG2 cells. The increase 
of'p21 may bind to procaspase-3 and inhibited the activation of caspase-3, and 
thereby preventing apoptosis. Therefore, the inhibitory effect of p21 on 
procaspase-3 is another explanation for the absence of apoptosis observed in HepG2 
cells. Although no apoptosis was observed in R-HepG2 cells after treatment of cells 
with cordycepin for 24 hours, DNA fragmentation, the hallmark of apoptosis was 
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observed in R-HepG2 cells after treated with cordycepin for 48 hours (Fig. 6.14). 
This may be due to the R-HepG2 cells were unable to repair the DNA damage and 
underwent apoptosis after cell cycle arrest. However, the molecular mechanism for 
the induction of apoptosis in R-HepG2 cells remains further investigation. Defects 
or dysregulation of different steps within the apoptotic machinery contributed to the 
cells resistant to apoptosis (Zhivotovsky & Orrenius, 2003). Therefore, by looking 
into the proteins that regulate the apoptotic pathway in tumor cells may give us some 
cues about the cause of resistance. 
R-HepG2 cells used in our experiments have been demonstrated to have 
P-gp overexpression (Chan et al., 2000). Overexpression of P-gp renders the 
exclusion of drugs from the cells as mentioned in Chapter 1 • From our results, the 
IC50 value of doxorubicin on R-HepG2 cells is much greater than that of HepG2 cells 
(Table 4.2). We also demonstrated that doxorubicin accumulation in R-HepG2 cells 
is much lower than, that of HepG2 cells. Thus, higher concentration of doxorubicin 
is required to inhibit the R-HepG2 cells. However, both WECM and cordycepin can 
inhibit the growth of R-HepG2 cells at the dose comparable to that of parental HepG2 
cells. Therefore, WECM and cordycepin can overcome the multidrug resistant effect 
exerting by P-gp that is overexpressed in R-HepG2 cells. Substrates of P-gp are 
usually hydrophobic, amphipathic and some of them may carry a positive charge at 
physiological pH (Ambudkar et al., 1999). According to the chemical structure of 
cordycepin (Fig. 1.2), it possesses amine group which can easily be protonated to 
become positively charged. Molecular conformation of cordycepin was found by 
Karthe et al (1997). Based on the data of Karthe et al (1997) and calculations, the 
molecular size of cordycepin was found to be 5 - 9 人（Fig. 7.3). The pore size of 
human P-gp has been found to be about 9 - 25 A (Loo & Clarke, 2001). Therefore, 
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it can be bound by the P-gp. However, P-gp is an ATP-dependent transporter 
(Ambudkar et aL, 1997), the availability of ATP is important for the action of P-gp. 
Zieve et al (1997) demonstrated that cordycepin taken up by the cells was 
phosphorylated to 3'-dATP, while the ATP level was declined. Therefore, we 
speculated that the multidrug resistance in R-HepG2 cells overcame by cordycepin is 
due to the depletion of ATP that is required for the drug transport. However, further 
investigations are required to confirm. 
Resistance to chemotherapeutic drugs is a big obstacle in the treatment of 
cancer. Nevertheless, WECM and cordycepin were demonstrated to inhibit the 
growth of R-HepG2 cells at the concentration comparable to that of the parental 
HepG2 cells, they can be the new target for the treatment of multidrug resistant cells. 
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Fig. 7.2 Proposed pathway of cordycepin-induced cell cycle arrest in HepG2 and 
R-HepGl cells. That cyclin B associates with cdc2 (cdkl), controls the entry into 
and exit from mitosis. Phosphorylation of the inhibitory Thr 14 and Tyr 15 sites on 
cdc2 keeps the kinase inactive until the G2/M transition. Dephosphorylation of these 
moieties by cdc25 phosphatase and CAK activation, triggers cdc2 activation which is 
essential for mitosis to occur. Increase of p53 level induced by cordycepin, inhibited 
the transcription of cyclin A, cyclin B and cdc2 which are required for the G2/M phase 
transition. Besides, p21 induced by p53, combined with cdc2/cyclin B complex and 
inhibited the activity of cdc2 and thereby inhibited the G2/M phase transition. 
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Our results demonstrated that Cordyceps militaris possesses both anti-tumor 
and immunostimulatory activities. The results of in vitro and in vivo study suggested 
that WECM could directly inhibit the growth of tumor cells or indirectly through 
stimulating the proliferation of T helper and cytotoxic T cells in the host. 
Cordycepin in WECM was found to have direct anti-proliferative effect on the tumor 
cells such as HL-60, NB-4, HepG2 and R-HepG2 cells. However, the amount of 
cordycepin in WECM is minute, it seems unlikely that the anti-tumor effect of 
WECM is due to the sole effect of cordycepin. Therefore, other chemical 
ingredients other than cordycepin in Cordyceps militaris may also take part in 
inhibiting the tumor growth. The anti-tumor effect may be mediated by the 
combined action of many active ingredients found in the Cordyceps militaris. 
Therefore, further investigations such as purification and characterization of the 
ingredients in the WECM are required to found out other active ingredients in 
Cordyceps militaris. After the purification and identification of other active 
ingredients, combined treatment of these active ingredients could also be conducted to 
see if there is any synergistic effect between these components. Besides, quality 
control such as monitoring the percentage yield and the purity should be conducted to 
make sure that WECM obtained in each extraction is standardized. 
The anti-tumor effect of cordycepin on acute promyelocytic leukemia HL-60 
and NB-4 cells is mediated by the induction of apoptosis. Both mitochondrial and 
, death receptor pathway are involved in the cordycepin-induced apoptosis in HL-60 
and NB-4 cells. Cordycepin caused an increase in the expression of death receptor 
(Fas) and triggered the activation of caspase-8. Activated caspase-8 cleaved the Bid 
to tBid. tBid translocated to the mitochondria and caused the collapse of 
mitochondrial membrane potential and the release of cytochrome c. The release of 
“ m 
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cytochrome c was contributed by the decrease of anti-apoptotic protein Bcl-2 and the 
increase of pro-apoptotic protein Bax and Bcl-Xs. Cytochrome c released from the 
mitochondria complexed with Apaf-1 and procaspase-9 in the presence of ATP/dATP, 
leading to the activation of caspase-9. Activated caspase-9 then cleaved the 
procaspase-3 to active caspase-3 and rendering downstream apoptosis events. 
Because of the mutation of p53 in HL-60 and NB-4 cells, the cordycepin-induced 
apoptosis is p53-independent. Therefore, cordycepin has therapeutic advantage in 
treating p53-deficient tumor cells. However, the mechanism of p53-independent 
apoptosis induced by cordycepin awaits further investigation. 
The anti-tumor effect of cordycepin on HepG2 and R-HepG2 cells is 
mediated by G2/M phase arrest of the cell cycle. The mechanism of G2/M phase 
arrest by cordycepin is through the decreased expression of cell cycle regulatory 
protein cyclin A, cyclin B and cdc2. The increase of cyclin dependent kinase 
inhibitor p21, which inhibits the activity of cdc2 also contributed to the G2/M phase 
arrest in HepG2 and R-HepG2 cells. The slight increase in p53 levels induced by 
cordycepin suggested that p53 may mediate the G2/M phase arrest in HepG2 and 
R-HepG2 cells. Interestingly, DNA fragmentation was observed in R-HepG2 cells 
after 48 hours treatment with cordycepin. This suggested that cordycepin could also 
induce apoptosis in R-HepG2 cells. The molecular mechanism by which cordycepin 
induces the apoptosis in R-HepG2 cells remains further investigation. It is also 
, interesting to investigate the differential response of different cell lines to the 
cordycepin treatment. 
Nowadays, drug resistance and side effects seem to be an important clinical 
problem. Therefore, new drugs that specifically target tumor cells but without 
adverse side effects should be explored. Our results showed that both WECM and 
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cordycepin significantly inhibit the growth of tumor cells such as HL-60, NB-4, 
HepG2 and the multidrug resistant R-HepG2 cells but with only little cytotoxic effects 
on normal liver cells WRL-68. Therefore, Cordyceps militaris and cordycepin could 
be used as therapeutic agents to treat cancer. However, clinical trials should be 
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